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Abstract
The clinical introduction of proton therapy requires an extensive analysis of its benefits compared
to conventional radiotherapy and a detailed analysis of possible uncertainties which might have
serious consequences for patient treatment. In the first part of the presented thesis, the expected
toxicities were evaluated for a treatment of head and neck cancer patients using a biologically
adapted dose escalation schedule with photon and proton therapy. The feasibility of the dose
escalation schedule could be demonstrated for both photon and proton therapy, since only a small
increase in toxicity risk occurred for most toxicities. However, the expected toxicity risks were in
most cases smaller with proton therapy. Furthermore, a higher benefit was found for patients
with primary tumour locations in the upper head and neck area, who thus might be preferably
referred to proton therapy. In the second part of this thesis, an extensive analysis of the impact
of tumour motion in lung cancer treatment with active-scanning proton therapy was conducted. It
could be shown, that dose degradations were small for tumour motion amplitudes below 5 mm.
Parameters like the target volume concept, the optimisation approach, changes in the motion
pattern and application sequence times had additional impact on the dose degradation. However,
their magnitude was patient specific. Since not all parameters can be assessed before treatment,
e.g. the motion pattern during treatment, prospective estimations should be supplemented by
retrospective analyses.
Kurzfassung
Die Einführung der Protonentherapie in die klinische Praxis erfordert umfassende Analysen ihrer
Vor- und Nachteile im Vergleich zur konventionellen Photonentherapie sowie detaillierte Unter-
suchungen der Auswirkungen von Unsicherheiten in der Therapieapplikation. Im ersten Teil
der vorliegenden Arbeit wurden die zu erwartenden Nebenwirkungen bei der Behandlung von
Patienten mit Kopf-Hals-Tumoren mit einem biologisch-adaptierten Fraktionierungsschema inklu-
sive Dosiseskalation mit Photonen- und Protonentherapie evaluiert. Dabei konnte gezeigt wer-
den, dass die Dosiseskalation sowohl mit Photonen- als auch Protonentherapie angewandt wer-
den kann, da die Wahrscheinlichkeit für das Auftreten von Nebenwirkungen in den meisten
Fällen kaum erhöht wurde. Weiterhin wurden die Nebenwirkungswahrscheinlichkeiten mit der
Protonentherapie im Vergleich zur Photonentherapie reduziert. Dies war vor allem für Patien-
ten mit Tumoren im oberen Kopf-Hals-Bereich der Fall. Diese könnten daher bevorzugt zur
Protonentherapie überwiesen werden. Darüber hinaus wurde im zweiten Teil der Arbeit eine
umfassende Analyse des Einflusses der Tumorbewegung auf die Dosisverteilung bei Behand-
lung von Lungentumoren mit aktiver Protonenstrahlformierung durchgeführt. Dabei zeigte sich,
dass Dosisdegradierungen bei Bewegungsamplituden unter 5 mm gering sind. Parameter wie
das Zielvolumenkonzept, Veränderungen des Bewegungsmusters oder der Applikationszeiten
nehmen zusätzlich Einfluss auf die Dosisdegradierung, allerdings in unterschiedlichem Maß für
individuelle Patienten. Da nicht alle Parameter vor Behandlung bekannt sein können, sollten
prospektive Dosisabschätzungen durch retrospektive Analysen ergänzt werden.
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1 Introduction
The introduction of new therapy options into the clinical practice requires a detailed analysis of
their benefits and disadvantages compared to the standard of care. In cancer treatment with ra-
diotherapy (RT), the efficiency of new techniques for radiation application needs to be analysed
in studies, in which their advantage compared to the conventional technique has to be proven.
The design of such studies comprehend a chain of tasks starting with comparisons on a simpli-
fied scale which evaluate probable difficulties and expected benefits (e.g. virtual studies or cell
experiments), leading to patient case studies and finally up to large phase III clinical trials. In RT,
one such new therapy option is the use of proton therapy (PT) for cancer treatment. Although PT
was already suggested by Wilson (1946) in 1946 for deep-seated tumours, the immense financial
investment of such a facility prevented a quick spread of this technology in the last decades. The
installation of PT centres was expedited in the last few years with a near doubling of operating
facilities from 2010 (27) to 2015 (50) (PTCOG 2015). The advantages of PT in comparison to
photon therapy (XT), the current standard of care, lie in their inverse depth dose profile which, in
theory, allows for the application of dose focused on the tumour volume while sparing the healthy
tissue better which surrounds the tumour. However, disadvantages of PT are based on the same
physical property: the pristine dose distribution generated by protons is more sensitive to uncer-
tainties than the shallow dose distribution of a photon beam.
Currently, the therapeutic benefit of PT over the conventionally used XT is only proven for a
small number of diseases. These include mainly rare diseases like eye tumours, chordoma and
chondrosarcoma of the spine and the skull base. Furthermore, the reduced dose to healthy tissue
decreases the probability of secondary malignancies caused by RT. This renders the technique
highly relevant for paediatric cases (Jarosek et al. 2012). For other more common diseases,
there is still a lack of clinical evidence for the benefit of PT. The superiority of PT would be com-
monly accepted if its benefit could be proven in randomised prospective clinical phase III trials,
which are rated as the highest level of evidence (Burns et al. 2011). However, for PT compared
to XT such studies are lacking: first, they require a large number of patients treated with identi-
cal treatment approaches and schedules as well as a sufficient follow-up, which was difficult to
achieve with the few existent PT facilities in the last decades. Second, the theoretical superi-
ority of PT renders such studies ethically disputable, since, in theory, the patients receiving XT
would be treated with an inferior technique (Johnstone et al. 2013). Therefore, the necessity of
randomised clinical trials to prove the superiority of PT over XT is a topic of controversial dis-
cussion (Suit et al. 2008; Sakurai et al. 2012). Another option to show the superiority of PT is
given by clinical trials comparing PT to historic data of XT treatment. This approach is hindered
by the advances in XT, reducing the historic data basis for comparisons to modern XT treatments.
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Before implementing PT for patients, virtual treatment planning studies, comparing PT to XT
in silico, can be used to estimate the probable benefit of PT and identify difficulties in its use.
With such studies, patient outcome can be simulated, transferring the results into biometric esti-
mations, e.g. calculating the patient number which is required to achieve significant results in a
prospective clinical trial. Furthermore, these virtual studies can be used to asses uncertainties
of the new therapy option by systematically introducing these uncertainties in the virtual study
and evaluating their impact on the simulated treatment outcome. For PT, such evaluations are
especially important considering its increased sensitivity to uncertainties in the patient anatomy,
e.g. caused by tumour location changes due to breathing motion. How severe such changes
might actually be for the patient outcome in a realistic treatment, requires a careful evaluation.
Based on the results, adequate treatment approaches and mitigation techniques can be devel-
oped where necessary and included into treatment protocols. In addition to knowledge transfer
from existing centres, for new PT facilities and their specific equipment virtual studies are impor-
tant. These serve in particular for the preparation of patient treatments for which no commonly
accepted treatment approaches exist. Furthermore, it is reasonable to include all patients treated
with PT in clinical trials to evaluate their outcome with high quality. The University Proton Therapy
Dresden (UPTD) at the University Hospital Carl Gustav Carus Dresden (UKD) started operation
in late 2014 and since was used to treat mainly patients with cancer in the scull base or brain,
prostate cancer and paediatric cases. The treatment options should be extended to other tumour
entities in the framework of clinical trials. For such trials, protocols need to be developed. Rele-
vant entities are head and neck squamous cell carcinoma (HNSCC), where reduced toxicities are
aimed for, and lung cancer, which is a frequently occurring cancer type with poor patient outcome.
The presented thesis focuses on evaluating the benefit of PT for HNSCC and on the appli-
cability of PT treatment approaches for lung cancer, based on treatment planning studies. For
patients with locally advanced HNSCC, the reduction of toxicity risks using PT instead of XT
is studied. Outcome evaluations are based on modern normal tissue complication probability
(NTCP) models and physical dose parameters for a multitude of toxicities. These data are fur-
ther analysed to determine whether a subpopulation of HNSCC patients could be identified that
would gain substantial benefit from PT in order to optimally use the limited PT resources. The
treatment schedule includes a treatment intensification with dose escalation to the tumour vol-
ume with high risk of recurrence. The feasibility of the dose escalation with either XT or PT is
investigated. For PT of lung cancer, the thesis focuses on the applicability of pencil beam scan-
ning (PBS) PT, which is highly sensitive to the tumour motion caused by breathing. A treatment
planning study is conducted assessing the impact of the breathing motion on the applied dose for
lung cancer patients by the generation of four-dimensional, time-resolved (4D) dose distributions.
Furthermore, several treatment- and patient-related parameters which might influence the dose
degradation, e.g. the target configuration or variations in the motion patterns, and two motion
mitigation techniques, gating and rescanning, are evaluated.
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In the following chapter the theoretical background is described which is important for the
treatment planning studies presented in this thesis. More detailed information can be found in
Steel GG (Ed.) (2002), Herrmann et al. (2006), Krieger (2007) and Paganetti H (Ed.) (2012).
2.1 Radiotherapy with photons and protons
RT treatment aims at the transfer of energy into a tumour cell resulting in the destruction of the
ability of the cell to proliferate. A quantity to describe this energy deposition is the energy dose D
in Gray (Gy), which is defined as the mean absorbed energy per mass unit. Important physical
characteristics of the used radiation in RT are the dose distribution in depth, the so-called depth
dose distribution, and the lateral dose spread, the so-called penumbra. For the use of photon
and proton beams in RT, different techniques for the field formation exist.
2.1.1 Energy deposition due to interaction of radiation with matter
The energy deposition of ionising radiation is caused by the transfer of energy to irradiated matter
resulting in the ionisation of molecules. Depending on the electrical charge, the radiation type
is classified as indirectly ionising radiation characterising particles without electric charge, e.g.
photons, or directly ionising radiation describing particles with electric charge, e.g. protons.
Photons for RT are generated as bremsstrahlung with an electron linear accelerator. The
therapeutically used energy spectra of modern systems range between 4 MV and 18 MV. The
dominant interaction process for photons at these energies is incoherent scattering: the photon
transfers a part of its energy to an electron in the atomic shell, thereupon changing its direction.
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The thereby generated secondary electrons transfer their energy locally to the surrounding matter
by ionisation (Krieger 2007). Other interactions of photons are coherent scattering, photoelectric
absorption, pair production and photonuclear reaction. The photon fluence is attenuated due to
the interactions according to the Lambert-Beer law, but has no definite range, as for each energy
the probability exist that the photon is not absorbed. For therapeutic energy ranges and the
patient body as target the probability of other interactions compared to incoherent scattering is
small, as indicated by the mass attenuation coefficients displayed in Figure 2.1 (a).
Protons for RT are typically accelerated to a defined energy with a circular accelerator, e.g.
a cyclotron. The accelerated protons for therapeutic use are monoenergetic with energies in a
range of 70 MeV up to 250 MeV (Krieger 2007). The dominant interaction processes for protons at
these energies with the patient body as target are electro-magnetic interactions with the Coulomb
field of the electrons (ionisation and excitation) and of the nucleus (mainly scattering) (Gottschalk
2012). In these collisions, the protons constantly lose energy and are finally stopped in the matter
at a defined range determined by their initial energy. The average rate of energy loss is described
by the stopping power. The largest energy transfer takes place at the end of the proton range. As
shown in Figure 2.1 (b), the proton interactions with the electrons are the main cause for stopping
protons in matter. Other interactions of protons comprise nuclear interactions and the generation
of bremsstrahlung. However, in comparison to the electro-magnetic interactions they are very
rare and thus are negligible for dose consideration in RT treatment (Leo 1994).
Figure 2.1: (a) Mass attenuation coefficients per interaction type for photons in water for therapeutically
used initial energies in the photon spectra (grey shaded area). (b) Stopping power per interaction type for
protons in water for therapeutically used initial proton energies (grey area). Data taken from the PSTAR
(Berger et al. 1998a) and the XCOM (Berger et al. 1998b) databases of the National Institute of Standards
and Technology.
2.1.2 Biological effect of radiation
The main biological effect targeted in RT is the clonogenic death of tumour cells. This is achieved,
when the cells are hindered in their proliferation, such that they cannot contribute any longer to
tumour growth or metastases development. The deoxyribonucleic acid (DNA) is the main target
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molecule in the cell as it carries the genetic information. The most relevant cause of proliferative
cell death are double-strand breaks of the DNA molecule, which cannot be easily repaired by the
cell (Herrmann et al. 2006).
The energy deposited by irradiation can have a direct effect, i.e. by directly transferring the
energy to part of the molecule which destroys its molecular structure. Alternatively, the deposited
energy can have an indirect effect, e.g. by producing chemical radicals of molecules which are
present in the cell environment, e.g. water. These radicals then damage the molecular structure
in the cell. For living cells, the latter effect is dominant due to the large proportion of the cell
environment compared to the small size of the DNA molecule (Krieger 2007).
Double-strand breaks can be caused by two different mechanisms: first, a single particle track
can cause multiple energy transfers to the molecular structure which are in close proximity to each
other, causing multiple strand breaks which lead to a lethal cell damage. Second, multiple parti-
cles cause energy transfers to the molecular structure independent from each other, but again in
close proximity to each other. Each of the damages are sub-lethal, but lead in combination to a
lethal cell damage, if not repaired (Krieger 2007).
The biological effect of a dose deposition can be measured with cell survival curves in clono-
genic cell essays, in which the number of surviving clonogenic colonies after an irradiation with
the dose D is determined. The survival fraction SF of the initial cell population can be described
by the linear-quadratic model
SF = e−(αD+βD
2), (2.1)
depending on the two parameters α and β. The linear and the quadratic terms of Equation (2.1)
are often interpreted as representative for the two described cell damage mechanisms (Joiner
2002). Since the effect of the respective mechanism depends on the repair capacity and the
intrinsic radio-resistance of the cell, α and β are tissue specific parameters. A generally used
parameter describing the radio-sensitivity and the repair capacity of a specific cell type is the α to
β ratio: smaller α/β values indicate larger repair capacity (Herrmann et al. 2006). Figure 2.2 (a)
shows the linear-quadratic model and its contributions corresponding to α and β.
Furthermore, the cell survival also depends on the ionisation density of the used radiation type,
e.g. photons or protons. The biological effect of different radiation types can be quantified by
the relative biological effectiveness (RBE) (Herrmann et al. 2006). The RBE is defined as the
quotient of the doses administered by two types of radiation (Dref the reference radiation type,
Dnew the alternative radiation type), which are required to produce the same biological effect:
RBE =
Dref
Dnew
∣
∣
∣
∣
same biological effect
. (2.2)
This concept has an intrinsic limitation: the RBE value depends on the considered biological
effect, cf. Figure 2.2 (b). Furthermore, the RBE value is not necessarily a constant factor even
considering a specific effect. Paganetti (2014) pointed out that for protons relative to photons the
RBE increases along the proton path with values about 1.1 in the entrance region and higher
values of up to 1.7 at the distal dose fall-off. However, clinical practice today is the assumption
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Figure 2.2: (a) Schematic display of a cell survival curve illustrating the linear-quadratic model and its
parameters α and β, adapted from Bristow and Hill (2005). (b) The RBE depends on the considered
biological effect, e.g. different survival fractions, adapted from Paganetti (2012). (c) Fractionation allows
for the recovery of cells from sublethal damage, increasing the survival fraction depending on the α/β value
of the cells, adapted from Herrmann et al. (2006). (d) For the same survival fraction higher doses are
required for hypoxic cells, as indicated by the oxygen enhancement ratio (OER), adapted from Horsman
and Overgaard (2002).
of a constant RBE value between photons and protons, indicating their similar biological effect
(Debus and Kraft 2003). As a result, the dose of PT is usually given today as biologically weighted
dose in Gy(RBE) or formerly in GyE (Cobalt-Gray equivalent), scaling the physical dose with the
factor 1.1.
Additional factors can affect the cell survival after RT, e.g. the dose rate, the cell cycle, the
fractionation schedule and the micro environment in which the cell is located (Krieger 2007). The
fractionation concept uses the different repair capacity of tumour cells and healthy tissue cells
to improve the healthy tissue cell survival after irradiation. With fractionation, the dose is split
into several dose fractions instead of applying the dose at once. During the irradiation break, the
cells can start repair processes, fixing sublethal damages and thus increasing the surviving cell
fraction. The efficiency of fractionation depends on the repair capacity of the cells, indicated by
their α/β value. Cells with large α/β values (≥ 8) have a small repair capacity, typically seen in
tumours. Small α/β values indicate a large repair capacity, which is often the case for healthy
tissues (Herrmann et al. 2006). A standard fractionation comprises doses per fraction between
1.8–2.0 Gy. Treatments with higher doses per fraction are called hypofractionation, with lower
doses per fraction hyperfractionation. For the assessment of the biological effect of fractionation
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schedules different from the standard fractionation, an often used parameter is the equivalent
dose in 2 Gy fractions, the EQD2, calculated with the linear-quadratic model to
EQD2 = nd
1 + dα/β
1 + 2α/β
(2.3)
with n the number of fractions, d the dose per fraction and α/β the tissue specific parameter
of the tumour cells (Joiner and Bentzen 2002). The fractionation effect is exemplarily shown in
Figure 2.2 (c) for a treatment with 2 Gy fractions.
The micro environment can be influenced externally, e.g. by the administration of chemical or
biological sensitisers and protectors, or internally, e.g. by the oxygen status of the cells. Hypoxia,
the lack of oxygen in the tissue, is known to increase the radio-resistance of cells to photon
therapy by a factor of about 2.5–3, the so-called oxygen enhancement ratio (OER). This increase
in radio-resistance is caused by the reduced generation of oxygen radicals in the cells which
diminishes the indirect effect of the radiation (Horsman and Overgaard 2002). Thus, the killing of
hypoxic cells requires larger doses, cf. Figure 2.2 (d).
2.1.3 Depth dose distribution and lateral spread of photon and proton beams
Photon and proton beams in therapy are defined by their characteristics of the depth dose distri-
bution and their lateral spread, the penumbra. In Figure 2.3 (a) the depth dose distributions of a
mono-energetic photon and a mono-energetic proton beam are exemplarily shown.
The photon depth dose distribution has a characteristic build-up region in the first few centime-
tres, depending on the photon energy, followed by an exponential dose decrease (Krieger 2007).
As a consequence, clinically relevant dose distributions, aiming on the eradication of deep seated
tumour volumes while sparing healthy tissue, can only be achieved by combining multiple beams
from different directions. In the intersections of these beams high doses can be accumulated.
Figure 2.3: (a) Exemplary depth dose profiles of monoenergetic photons (red) and protons (blue) in water.
After a short build-up region, the dose generated by photons is exponentially reduced in the patient, while
protons deposit their energy up to a maximum range. (b) Generation of a SOBP by overlaying weighted
Bragg peaks with multiple energies between 100 and 120 MeV. (c) Lateral penumbra as distance between
80 % and 20 % relative dose for a 15 MV photon beam and a PS PT beam with 28 cm range and a SOBP
width (modulation) of 10 cm. Data of (a) and (b) are taken from depth dose simulations with the software
MCNP 6.1 (Los Alamos National Laboratory, USA), courtesy of C. Jakobi, the data of (c) is adapted from
Lu and Flanz (2012).
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The proton depth dose distribution has a finite range in depth with a small dose deposition in the
entrance path culminating in a localised high dose deposition at the end of the range, the so-
called Bragg-peak (Krieger 2007). The position of the Bragg-peak depends on the initial proton
energy. Using proton beams with different energies and intensities allows for the superposition
of Bragg-peaks, generating a so-called spread-out Bragg peak (SOBP), cf. Figure 2.3 (b). The
SOBP enables the homogeneous irradiation of a tumour volume with a single beam direction. As
a consequence, for a clinical application, protons allow for a complete sparing of healthy tissues
behind the range of the proton beam, while photons of clinically used energies always deposit
their energy in the whole patient along the beam path. The lateral spread of clinical photon and
proton beams is similar to each other, being favourable for protons in small depth and for photons
in larger depths (Lu and Flanz 2012). This is shown exemplarily for a clinical photon and proton
beam in Figure 2.3 (c).
Due to the different characteristics of the dose deposition along the beam, i.e. the exponential
reduction of the photon beam versus the maximum range of protons, photons and protons are
differently sensitive to changes of the matter composition they traverse (Goitein 2010). The
exponential reduction of the photon beam is only slightly impacted by the composition of the
traversed matter. The range of the protons, on the other hand, is more influenced by the matter
composition: dense matter like bones stop the protons earlier than light materials like the lung.
As a consequence, the substitution of dense material with less dense material will lead to a larger
range of the proton beam, resulting in an overshoot compared to the planned range, while the
impact on the dose deposited by photons is rather small. This is exemplarily shown in Figure 2.4
for the change of patient tissue to air. The range of the proton beam is supposed to end with
the tumour. Due to the tissue change, the proton beam overshoots, underdosing the tumour
but irradiating a distal organ at risk (OAR). In the clinical treatment of patients, density changes
occur when anatomical changes are present, e.g. tumour shrinkage or patient movement, and
thus need to be considered before implementing PT.
Figure 2.4: The change in the matter composition in the beam path, here the change from 2 cm of
patient tissue to 2 cm of air (indicated by the white bar), only slightly impact the photon dose deposition
(from dotted to solid red line), while largely shifting the dose deposition in depth for protons leading to an
unacceptable dose distribution (from dotted to solid blue line). The data source is identical to Figure 2.3 (a).
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2.1.4 Field formation with photon and proton beams
Depth dose and lateral dose distributions are usually acquired by measurements of reference
fields in homogeneous materials, preferably in a water phantom. The dose characteristics are
implemented in clinical treatment planning systems. Based on these empirically determined data,
treatment plans for individual patients can be generated. For both, XT and PT, there are several
clinically used technical options to deliver the treatment fields to the patient. These comprise
passive field formations, in which the treatment fields are applied as so-called "open fields" gen-
erating homogeneous two-dimensional fluences, and active field formations, in which inhomoge-
neous fluences can be created. In Figure 2.5 the main delivery techniques used in XT and PT
are illustrated. The field formation techniques used in the presented treatment planning studies
are active field formation techniques and thus described in more detail.
Photon beam application In modern XT based on X-ray computed tomography (CT) images,
photon field delivery techniques using the homogeneous fluence generated from the linear ac-
celerator comprise mainly two options (Kneschaurek and Nüsslin 2003): first, the use of three-
dimensional (3D)-conformal XT, where one treatment field per beam direction is used. This field
is laterally confined to the cross section of the target with a multi-leaf collimator. A high accumu-
lated dose in the target volume is achieved by using several beam directions with a homogeneous
fluence in the field cross section intersecting in the targeted area. Second, the fluence of these
photon fields can be modulated per beam direction such that each field comprises an inhomoge-
neous fluence, again resulting in the highest dose accumulation at the field intersections. Such
a fluence modulation can be achieved by using a series of field segments with different shapes
from one beam direction formed with a multi-leaf collimator, either dynamically or static. With this
technique, a better conformity to irregular target volumes can be obtained allowing for a better
sparing of close-by healthy tissues from high doses. With fixed beam directions, this technique
is called intensity modulated photon therapy (IMXT). Using a continuous change of the beam
direction during the treatment application by using the rotation of the gantry, this treatment form
is called volumetric modulated arc therapy (VMAT). The time scale of the sub-field formation is in
the range of seconds. The field directions or the rotation angles as well as the photon energy are
defined by the treatment planner beforehand. The treatment planning is performed "inversely",
such that the treatment planner defines dosimetric goals, e.g. for the target and the relevant OAR,
and an algorithm of the treatment planning system tries to match the actual dose distribution as
closely as possible to these goals by selecting the multi-leaf collimator segments (number, form,
dose per segment) per beam.
Proton beam application Therapeutic PT can be performed with two different field formation
techniques (ICRU 2007): First, in passive scatter proton therapy (PS PT) the narrow proton
pencil beam is widened perpendicular to the beam axis by the use of scatter material. The dose
coverage of the target in depth is achieved by using a modulator wheel with several steps, which
produces a spectrum of proton energies and generates a SOBP. Patient individual apertures
and compensators are used, shaping the beam to the lateral and distal edges of the target,
respectively. In the second technique, the so-called active-scanning or PBS PT, the narrow
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Figure 2.5: Passive (a, c) and active (b, d) field formation techniques for photon and proton therapy. The
patient is indicated by the grey oval, the target is represented by the thick black contour within. The high
dose area surrounding the target is shown in red, middle and low dose areas in yellow and cyan. The
field formation for photon beams is shown after the generation of homogeneous two-dimensional photon
fluences, the field formation for proton beams has the narrow proton pencil as input.
proton pencil beam is used to conform the dose to the target. Laterally, the proton beam is
deflected to several positions throughout the tumour volume by changing the magnetic fields of
the so-called sweeper magnets. In depth, the beam position is varied by changing the beam
energy using an energy degrader, generating subsequent monoenergetic pencil beams until the
whole target volume is covered. For very shallow targets, for which the proton energy cannot be
reduced sufficiently to reach these superficial areas, an additional range shifter can be placed in
the field in front of the patient. The planned positions for proton application can either be scanned
"spot by spot", the so-called spot scanning, where the beam is turned off between the spots,
or with the so-called raster scanning, where the beam remains turned on and the velocity and
dose rate determine the administered dose. The spot scanning technique is the more frequently
used approach. For spot scanning, the time scale of the spot positioning depends on the "dead
times" of the system, comprising the time the magnets need to position the beam spot at a
specific position laterally, which is in the range of milliseconds, and the time the degrader needs
to generate a new proton energy, which is in the range of seconds for most commercial systems.
Similar to IMXT, the treatment planning for PBS PT requires the beam angle definition by the
treatment planner. Furthermore, the treatment planning is also performed inversely using an
optimisation algorithm which determines the spot positions and the number of protons per spot.
Analogue to IMXT, PBS PT is often referred to as intensity modulated proton therapy (IMPT).
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2.2 Radiotherapy treatment planning
The goal in RT treatment planning is to focus the dose to the target volume while minimising the
dose to the surrounding healthy tissue. This goal requires the identification of the tumour and the
healthy tissue and their positions relative to each other, including motion effects if necessary. The
quality of a generated treatment plan is also assessed in terms of target coverage and healthy
tissue sparing.
2.2.1 Target definition
The identification of the tumour is a very important step in treatment planning: only if all tu-
mour cells are irradiated, RT has the chance to eliminate the tumour. The identification of the
tumour volume is usually done by a physician delineating a tumour contour on the CT images
of the patient which are then used for treatment planning. These clinically defined volumes
usually comprise the tumour bulk, the gross tumour volume (GTV), and a volume including a
potential subclinical spread of the tumour cells, the clinical target volume (CTV), (ICRU 2010).
The information of the CT data can be supplemented by magnetic resonance imaging (MRI) and
positron emission tomography (PET) datasets, as well as by clinical examinations like results from
a surgery (Stuschke et al. 2003). PET imaging visualises biological functions of cells. Depending
on the used tracer, different cell functions can be examined (Grosu et al. 2003). A frequently
used tracer is [18F]fluorodeoxyglucose (FDG). This tracer allows for a display of the glucose
metabolism, which is often increased in tumour cells. Another tracer is [18F]fluoromisonidazole
(FMISO), accumulating in volumes with increased hypoxia, i.e. in a micro-environment with in-
creased radio-resistance. The identification of (sub)volumes which differ in their radio-resistance
and thus might require a larger dose for cure allows for a patient individualised treatment intensi-
fication by inhomogeneous dose prescriptions.
Besides the clinically based tumour identification, the treatment target usually comprises addi-
tional geometric margins for uncertainties like setup uncertainties, resulting in a planning target
volume (PTV). These margin concepts are well established in XT and described in detail by the
ICRU (1999). The applicability of geometric margins to PT is arguable, due to the different effect
of changes in the setup when tissue heterogeneities are present, cf. the effect of the change from
water to air in the beam path shown in Figure 2.4. Thus, for PS PT, setup and range uncertain-
ties are included in the field formation hardware (aperture and compensator). For PBS PT, no
generally accepted concept to include uncertainties exist. For this reason, the margin concept
used in XT is often transferred to PT despite its questionable efficiency. A better way of including
uncertainties for PBS PT is a topic of ongoing research focusing on advanced approaches like
beam-specific margins or the implementation of robust optimisation (Albertini et al. 2011).
2.2.2 Dose prescription
Usually a homogeneous dose is prescribed to an identified target. However, for the eradication
of the tumour bulk higher dose levels are required compared to occult or elective volumes. This
higher dose is usually prescribed as an additional homogeneous dose to the smaller volume in a
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sequential boost treatment. With intensity-modulated techniques like IMXT, VMAT and PBS PT, a
desired inhomogeneous dose distribution consisting of different dose levels to different volumes
can be irradiated simultaneously with a so-called simultaneous integrated boost (SIB) (Wu et al.
2003). This technique can also be used when intrinsic differences in the radio-resistance of a
tumour should be targeted, e.g. via dose painting of hypoxic subvolumes in a tumour or even dose
painting to single voxels with different uptake of tracer (Thorwarth et al. 2007). With a SIB, the
same doses or even increased doses can be applied while reducing or at least not extending the
overall treatment time. This might be especially relevant for tumours with increased proliferation
after the initial treatment, e.g. HNSCC, and is becoming more and more state-of-the-art for such
tumours with the increased use of intensity-modulated techniques (Butler et al. 1999).
2.2.3 Image data for treatment planning
In modern RT, treatment planning is typically based on a 3D CT, representing the anatomy of
the patient in terms of tissue electron density, in which the clinical information of tumour and
healthy tissue locations can be delineated. The CT dataset is usally shown in grey values of
the Hounsfield scale using the so-called Hounsfield units (HU), which relate to the attenuation
coefficient of the tissue relative to water with HUwater = 0, lower values for less dense structures,
e.g. HUair = −1000, and higher values for more dense tissue, e.g. HUcortical bone ≥ 1000 (Grosu
et al. 2003; Wohlfahrt 2014). The 3D CT image dataset is used for generating a treatment plan
and for calculating its dose distribution based on the treatment machine specific data.
The basic assumption of this approach is the relevance of the recorded 3D CT dataset for the
whole treatment course. However, this dataset is always a snapshot of the patient anatomy at
the time of imaging and loses its validity when anatomical changes occur. Anatomical changes
comprise interfractional changes, which take place over a long time scale like hours, days and
weeks and are relevant because the treatment course lasts several weeks. Such changes might
be tumour shrinkage or growth, filling or emptying of cavities or similar. They could be identi-
fied within the scope of image-guidance with cone-beam CT or two-dimensional X-ray imaging,
or by taking sequential 3D CT datasets throughout the course of treatment. If necessary, the
treatment plan can be adapted to the new patient anatomy, i.e. a new 3D CT dataset is taken
and a new treatment plan is generated based on this dataset. Besides interfractional changes,
intrafractional changes can occur depending on the tumour location. These are changes on a
shorter time scale like seconds or minutes, which are mainly relevant for tumours in the thorax
or upper abdomen impacted by the breathing motion or the heartbeat (Langen and Jones 2001).
The fidelity of an acquired 3D CT image dataset in these cases is questionable because of the
arbitrary correlation between the start of the CT acquisition and the motion. The assessment of
intrafractional changes requires a time-resolved imaging technique. Such a technique is 4D CT
imaging, which allows for the reconstruction of the imaging data connected to an additional signal
representing the motion, e.g. a breathing signal based on spirometry or a heartbeat signal based
on an electrocardiogram. With that combined data, several 3D image datasets can be produced
showing the different anatomical states of the patient at different time intervals of the motion sig-
nal, each being representative for the respective time period (Korreman 2012). Figure 2.6 gives
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an example for two different data sorting possibilities based on a motion signal: in amplitude-
based sorting the data recorded at the same motion amplitude (window) are assembled and
resorted to the 3D images, while phase-based sorting simply sorts all images of a certain time
frame together. Combinations of the sampling options are possible. Using such a 4D CT dataset,
motion magnitudes can be identified, e.g. by assessing location changes of the tumour. These
can be included into the treatment planning process, e.g. by adding additional so-called internal
margins to the CTV, generating an internal target volume (ITV) (ICRU 1999). Furthermore, the
additional information of the 4D CT can be used to generate or select a representative 3D image
dataset for the treatment planning (Korreman 2012).
Figure 2.6: (a) Schematic display of the reconstruction of a 4D CT dataset: a motion signal is recorded,
e.g. a breathing pattern (black solid lines). Only the CT raw data recorded during a specific interval is
used to reconstruct a 3D image dataset. Using several intervals, a series of 3D image datasets can be
generated. The data sorting can be done by amplitude-based sorting or phase-based sorting. The number
of 3D image datasets depends on the chosen number of amplitudes or phase intervals. (b) Example of
reconstructed 3D image datasets for phase-based data sorting. White dotted lines are included to guide
the eye.
2.2.4 Interplay effect
The term interplay describes interference effects in the dose deposition, which occur because
of anatomical changes of the patient on the same time scale as the active field formation, i.e.
when using IMXT or PBS PT (Phillips et al. 1992). Consequently, these effects are relevant for
intrafractionally moving targets like tumours in the lung. The effect on the dose distribution is
schematically shown in Figure 2.7 for PBS PT: the planned proton spots are applied at wrong po-
sitions in the tumour due to its position change. The proton spot accumulation leads to overdose
regions where too many spots are applied and underdose regions where spots are missing. The
caused dose deterioration depends on the magnitude of the anatomical motion, e.g. the tumour
motion peak-to-peak amplitude (small changes have mainly small effects), the used radiation
type (cf. different effects of density changes for XT and PT) and the application method. Further-
more, the time coincidences are influenced by the patient anatomy at the treatment start. Thus,
the magnitude and pattern of the dose degradation also depend on the initial breathing phase at
the treatment start, as depicted in Case 1 and Case 2 in Figure 2.7 (c).
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Figure 2.7: Schematic display of the interplay effect in PBS PT caused by breathing induced tumour motion
(represented by the circles). (a) Recorded one-dimensional signal of the tumour motion, e.g. the breathing
pattern based on an external marker. (b) The PBS PT plan is calculated on a static representation of
the tumour. (c) The tumour moves during the treatment. The position of the anatomy relative to the spot
position is influenced by the initial breathing phase that coincides with the treatment start. For example, the
treatment start at the end inhalation (Case 1) results in a different spot pattern than the treatment start at
the end exhalation (Case 2). The resulting dose distribution is inhomogeneous with over- and underdose
regions depending on the spot accumulation in the tumour.
2.2.5 Treatment plan assessment
Physical dose parameters The quality of the dose distribution of a treatment plan is usually
assessed using the dose volume histogram (DVH) of delineated structures like the tumour or the
OAR. Extracted parameters comprise volume parameters VD , describing the volume of the con-
sidered structure (either in percentage of the structure volume or in absolute volume) in which the
dose D is absorbed. For target structures this dose is often expressed as percentage of the pre-
scribed dose, while for OAR usually absolute dose values are used. Similarly, dose parameters
DV are frequently used, describing the absorbed dose in a certain volume of a structure (ICRU
2010). An example of dose parameters taken from the DVH for an OAR and a tumour is shown
in Figure 2.8 (a).
For tumour structures a homogeneous dose distribution is usually targeted, such that low and
high doses differing from the prescribed dose level are assessed. Relevant parameters are D98
and D2 as near minimum and near maximum dose values, respectively. Furthermore, target
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Figure 2.8: Schematic display of possible treatment plan evaluation parameters. (a) DVH evaluation of
the physical dose distribution in the delineated structures. Example for a tumour in the head and neck
and the parotid gland as OAR. Physical dose parameters can be taken from the DVH, e.g. shown with the
median dose of the parotid gland (Dmedian) and the dose to 98 % of the tumour volume (D98). (b) NTCP
model for the incidence of xerostomia in the parotid gland based on a model developed by Houweling et al.
(2010). Median dose as the input parameter leads to a NTCP value of 9 % for the example of (a). (c) TCP
model for squamous cell carcinoma in the head and neck (Okunieff et al. 1995). Using D98 of (a) as input
parameter, the TCP would be 37 %.
coverage can be assessed with the tumour volume receiving between 95 % and 107 % of the
prescribed dose (V95, V107). The mean dose should be close to the prescribed dose. This
dosimetric treatment plan evaluation approach is described by the International Commission on
Radiation Units and Measurements (ICRU) in several reports (ICRU 1999, 2007, 2010) and is
frequently applied in clinical practice.
For OAR, physical dose thresholds are defined with different priorities relative to other OAR
and the tumour volume, depending on the severity of a corresponding side effect. For example
in treatment of HNSCC, the spinal cord usually has highest priority and the dose constraint is
not allowed to be exceeded in any case, while dose constraints to other organs like the parotid
glands can be exceeded if this is required to maintain the targeted tumour coverage. Although
such constraints are usually developed from clinical experience and detailed studies of dose-
response relationships, for many organs no internationally accepted dose constraints exist. A
good example is the dose limit for the spinal cord, which varies between maximum accepted
doses of 45 Gy, e.g. used by Cozzi et al. (2001), and 54 Gy, e.g. used by van der Laan et al.
(2013), depending on the treating institution. Nevertheless, the clinical treatment plan quality
assessment is standardly based on institutionally defined physical dose parameters.
Clinical outcome parameters For a more universal assessment of the treatment plan quality,
the prediction of the clinical outcome of the patient would be preferable. This requires to know the
biological effect of a physical dose distribution for defined clinical endpoints. To determine the bi-
ological effect, dose-response relationships are examined, which relate the patient outcome, e.g.
the occurrence of a specific toxicity assessed in follow-up examinations, to the dose distribution in
the relevant organs (van Luijk and Schippers 2012). If clear dose-response relationships can be
identified, models can be developed which predict the probability that a clinical endpoint occurs
depending on the physical dose distribution. As a consequence, a more conclusive interpretation
of the data might be possible. However, in contrast to mere physical dose values, biological mod-
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elling underlies higher uncertainties, which might also limit its informative value. Nevertheless,
relative comparisons using one model are less dependent on uncertainties, such that biological
effect parameters may be reasonably used in these cases (Guckenberger et al. 2011).
For a toxicity risk prediction, so-called normal tissue complication probability (NTCP) models
are developed based on different modelling approaches. A widely used concept is the Lyman-
Kutcher-Burman (LKB)-model for NTCP calculations based on the DVH information of an OAR
(Lyman 1985; Kutcher and Burman 1989). In this model, the 3D dose distribution of an organ
is reduced to a single parameter. This input parameter is the uniform dose that would lead
to the same effect as the real non-uniform dose distribution, often referred to as generalised
equivalent uniform dose (gEUD) introduced by Niemierko (Niemierko 1997). The modelling of
specific toxicities with the LKB-model is based on three parameters that are organ and endpoint
dependent: the organ tolerance dose D50, that leads to the considered effect in 50 % of the
patients, the parameter m which inversely relates to the steepness of the NTCP curve at D50 and
the parameter n, which describes the dependence on the irradiated partial volume of the organ.
With these parameters, the LKB-model predicts the NTCP as
NTCP = Φ
(
gEUD − D50
m · D50
)
with (2.4)
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where in Equation (2.5) the sum is over the fractional volumes vi receiving the dose Di .
Similar to the LKB-model, several other approaches exist, modelling the dose response with a
single dose parameter (van Luijk and Schippers 2012): the functional subunit models for serial
organs (critical element), for parallel organs (critical volume) and for organs with mixed behaviour
(relative seriality model). Figure 2.8 (b) exemplarily shows a NTCP model for the incidence of
developing xerostomia, a toxicity in the parotid gland, based on the median dose. The dose
value can be taken from the DVH and an individual risk assessment for the specific patient can
be performed with the model.
However, a single dose parameter might be insufficient to model certain toxicities which under-
lie several reasons for development. This might be especially relevant for side effects which are
caused by the dysfunction of multiple organs or when a clear dependence on additional clinical
factors like age or co-morbidities exist. Therefore, the use of multivariate models which allow for
the incorporation of several input factors were increasingly considered recently. These models
are often based on a logistic regression
NTCP =
1
1 + e−z
with z = c0 + c1 · P1 + c2 · P2 + ..., (2.6)
where the variables Px , which influence the NTCP, enter in the linear predictor z with different
weights cx (van Luijk and Schippers 2012).
16
2.2 Radiotherapy treatment planning
Similar to NTCP calculations for the toxicity risk assessment, tumour control probability (TCP)
models can be developed which estimate the probability to control the tumour with the applied
dose. Figure 2.8 (c) exemplarily shows the expected tumour control for the example of Fig-
ure 2.8 (a) based on a TCP model for head and neck cancer (Okunieff et al. 1995). Most TCP
models are based on the linear-quadratic cell survival model, Equation (2.1), assuming tumour
control if no cell of the initial cell population N0 survives the treatment. Due to the random proba-
bility of radiation to kill a cell, the TCP can be modelled by a Poisson distribution
TCP = e−N0·SF, (2.7)
which is often referred to as the standard model of tumour control (Bentzen 2002). Based on
the Poisson model, the TCP is often described by a function depending on two parameters: D50,
the dose where 50 % of the tumours are controlled, and γ50 representing the normalised slope at
D50:
TCP = 2
− exp
[
2
ln(2)
γ50
(
1− D
D50
)]
. (2.8)
Extensions to this simple model exist, e.g. by incorporating the effect of inhomogeneous dose
distributions in a tumour, different radio-sensitivities of cells within the tumour and tumour cell
repopulation, amongst others (O’Rourke et al. 2009).
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Patients with advanced HNSCC have only moderate 5-year survival rates of approximately 30–
50 % (Pignon et al. 2009; Skladowski et al. 2012; Gatta et al. 2015). A treatment intensification
using radiation dose escalation may improve the patient outcome (Marks et al. 1982). Such
an approach however bears the risk of increasing toxicities. PT of HNSCC has the potential of
decreasing the dose to healthy tissue while offering similar or even better tumour coverage than
modern XT techniques like IMXT or helical tomotherapy (Cozzi et al. 2001; Lomax et al. 2003;
Johansson et al. 2004; Steneker et al. 2006; Widesott et al. 2008; van de Water et al. 2011;
Kandula et al. 2013; van der Laan et al. 2013). Considering the limited PT resources at the
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present time and the limited manpower in the clinical setting, a pre-selection of patients who may
benefit more than others from PT is desired, preferably based on simple and robust parameters.
The presented treatment planning study was designed to examine these aspects based on
NTCP modelling and physical dose parameter evaluation focusing on the following three ques-
tions:
1. Is the created treatment schedule, based on biological imaging and including a dose es-
calation for a treatment intensification, feasible and which impact has the dose escalation
level?
2. What is the expected benefit of PT over modern XT and is there an advantage of the use
of PT for sequential boost only?
3. Is it possible to subgroup HNSCC patients according to the primary tumour location for the
identification of patients with a high disadvantage of dose escalation or for the identification
of patients with the most benefit of PT?
Parts of the work presented in this chapter have been published in international journals and
and at international conferences (Jakobi et al. 2015a,b,c). The treatment planning study was
approved by the institutional ethics committee (EK 10012015).
3.1 Head and neck squamous cell carcinoma
3.1.1 Clinical background
Head and neck squamous cell carcinoma (HNSCC) comprise tumours occurring in the head
and neck area, e.g. malignant neoplasm developing from tissue in nose, paranasal sinuses,
oral cavity, pharynx, larynx and salivary glands; the anatomical sites are illustrated in Figure 3.1
(Vorwerk and Hess 2011). Worldwide incidence of HNSCC is about 7 %, with 5 % of all cancer
deaths being related to this disease (Jemal et al. 2011).
Figure 3.1: Sagittal CT slice illustrating the anatomical areas where head and neck squamous cell carci-
noma can occur (adapted from Vorwerk and Hess (2011)).
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Main risk factors for the development of HNSCC are tobacco and (high-proof) alcohol abuse
(Vineis et al. 2004; Blot et al. 1988). Factors with a smaller impact include unhealthy diet as
well as poor oral hygiene (Pavia et al. 2006; Maier et al. 1993). Beside that, new research
revealed the increased risk of developing HNSCC due to an infection with the human papilloma
virus particularly in the oropharynx region. However, patients with tumours which can be related
to such an infection have higher survival probabilities (McKaig et al. 1998; Kreimer et al. 2005;
Marur et al. 2010).
Although tumour characteristics of HNSCC may differ depending on the originating tissue and
cause of disease, similar treatment strategies are chosen for these tumours due to their common
anatomical location and common histology except for nasopharyngeal carcinoma (Argiris et al.
2008). Tumours in the head and neck are surrounded by a multitude of organs that are funda-
mental for vision, sensation, communication and alimentation. Consequently, HNSCC treatment
present the risk of degrading the patients’ quality of life by impacting organ functionalities. Hence,
besides the goal of improving tumour control rates, improvements in in sensitive tissue sparing
and thus the reduction of side effects are a main focus of the RT treatment of HNSCC patients.
Treatment options include surgery, RT and chemotherapy. Which therapy option is selected,
is an interdisciplinary decision involving specialists from several fields. Multiple individual tumour
and patient factors need to be considered to generate an individual treatment approach with the
best possible outcome regarding cure and side effect probabilities for a specific patient (Argiris
et al. 2008). The treatment of choice is thus an individual decision depending on the exact
tumour location, the tumour stage, the condition and comorbidities of the patient, amongst others,
although standard therapy options for specific disease patterns exist: for limited diseases (stage I
or II), surgery is usually the treatment of choice. If a deficient organ preservation is expected
using surgery, primary RT is preferred. For advanced diseases (stage III and IV), the treatment is
preferentially performed using multiple modalities, e.g. surgery with adjuvant radiochemotherapy.
Primary radiochemotherapy is mostly chosen for settings where a surgery is not possible due to
the tumour location and infiltration or the patient condition, for patients where a surgery would
create significant morbidity as well as when patients refuse a surgery (Argiris et al. 2008; Grégoire
et al. 2010). For limited diseases, the overall survival rates at 5 years post treatment range
between 70–90 %, while patients with advanced diseases show poorer survival rates of only 30–
50 % (Pignon et al. 2009; Skladowski et al. 2012; Gatta et al. 2015).
Various side effects may occur in HNSCC treatments due to the multitude of healthy tissues sur-
rounding the tumour. Side effects which rarely occur but would unacceptably impair the patients’
quality of life are myelopathy and brain stem necrosis. For this reason, rigorous constraints in RT
treatment aim to prevent them. Toxicities which frequently occur and have a big impact on the
patients’ quality of life but are rated more acceptable are oral mucositis, xerostomia and dyspha-
gia. Oral mucositis, an inflammation of the mucous membranes in the oral cavity, is a side effect
that usually develops during treatment and occurs with different severity in almost all HNSCC pa-
tients (Raber-Durlacher et al. 2010). High grade mucositis prevents the patient from oral nutrition
and might lead to a disadvantageous interruption of treatment (Sciubba and Goldenberg 2006).
Xerostomia, a frequently occurring side effect in RT treatment of HNSCC patients, is caused by
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a reduced function of the salivary glands. Due to the impact on mastication, swallowing, speech,
taste as well as the increase of the risk of caries and bone necrosis development, xerostomia
is rated as one of the most important side effects of HNSCC RT impacting the patients’ quality
of life (Langendijk et al. 2008). Dysphagia describes side effects related to swallowing dysfunc-
tions. Since swallowing is a complicated process including a multitude of muscles and several
nerves, the cause of dysphagia is diverse and may be affected by several organs. For example,
acute oesophagitis and oesophageal stricture are side effects that can lead to dysphagia. Larynx
oedema, the swelling of the larynx, leads to a reduced larynx motility which may also result in
swallowing dysfunction. Aspiration of liquid or solid food may be a consequence of a damaged
swallowing apparatus. Other side effects which are less frequently considered in RT either due to
their rare occurrence or the minor rated impact on the patients’ quality of life include nerve or ves-
sel damage, trismus, osteoradionecrosis, skin necrosis and ulceration. An overview of toxicities
and the impacted organs is given in Table 3.1.
Table 3.1: Toxicities in HNSCC RT and impacted organs.
Toxicity Impacted organ(s)
Myelitis / Myelopathy Spinal cord
Brainstem necrosis Brain stem
Oral mucositis Oral mucosa
Xerostomia / Salivary flow reduction Salivary glands
Dysphagia (Aspiration) Larynx / Swallowing muscles
Specific swallowing related problems Larynx / Swallowing muscles
Larynx oedema Larynx
Oesophageal stricture Oesophagus
Nerve damage / Plexopathy Brachial plexus
Vessel damage Carotid arteries
Trismus Masseter / Temporo-mandibular joints
Osteoradionecrosis Mandible
Skin necrosis Skin
High dose effects, e.g. ulceration, necrosis Unspecified tissue
3.1.2 Approaches for treatment improvements
Dose escalation Higher tumour control rates my be achieved with a more aggressive treat-
ment, e.g. by escalating the RT dose (Marks et al. 1982). However, to maintain or even still
improve the patients’ quality of life with these treatments, it is necessary to confine the RT dose
as much as possible to the tumour volume. Introducing advanced treatment techniques like IMXT,
which allows for more precise dose deposition, as a standard of care for HNSCC led to therapy
improvements over the last decade especially in terms of quality of life (Lee et al. 2007; Lee and
Le 2008). PT with its advantageous distal dose fall-off and steep dose gradients may lead to
further improvements. A treatment intensification based on dose escalation can be done with
the SIB technique, applying larger doses per fraction to a specified subvolume inside the general
target volume, while the remaining part of the target volume still receives standard fractionation
(Butler et al. 1999; Wu et al. 2003). This technique has the advantage of not extending the overall
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treatment time, which is a critical factor in HNSCC RT treatment due to tumour cell repopulation
(Van den Bogaert et al. 1995; Hansen et al. 1997), and showed promising results in the clinical
setting (Lauve et al. 2004).
Identification of high risk volumes In addition to improvements due to technological advance,
a better understanding of the tumour biology and a thereby increased capability of well defining
tumour (sub)volumes of high risk may increase the patient outcome (Vorwerk and Hess 2011).
Important for the use of dose escalation is the identification of tumour (sub)volumes in which
higher RT doses are needed for cure. Functional imaging such as PET is capable of indicating
resistant tumour areas which have a potentially increased risk of relapse. Based on that idea,
several groups proposed dose painting, e.g. by using hypoxia imaging with FMISO PET for target
definition (Thorwarth et al. 2007; Flynn et al. 2008; Lee et al. 2008; Hendrickson et al. 2011). FDG
PET has been identified to give information about recurrence probability identifying aggressive
tumour subvolumes (Due et al. 2014). However, it is currently unclear whether dose painting ap-
proaches applying inhomogeneous doses to the tumour volume according to tracer accumulation
are able to increase local tumour control. Especially considering that the pattern of tracer uptake
was identified as being variable at different imaging time-points before or during the course of
RT, a dose escalation on (sub)volumes identified in a single functional imaging dataset needs to
be evaluated carefully (Lin et al. 2008). Analyses of specific tumour areas showed discordances
between initial hypoxia location and later recurrence (Zschaeck et al. 2015). Furthermore, the
number and size of hypoxic tumour areas identified with FMISO imaging decrease substantially
between imaging before and druing treatment, reducing the applicability of functional datasets
which were recorded before treatment (Bittner et al. 2013).
Regarding these uncertainties, another approach, the use of functional imaging solely as
biomarker, has been proposed aiming on the general identification of patients with tumours hav-
ing a potentially increased risk of recurrence (Zips et al. 2012). Such an approach allows for the
stratification of patients according to their risk, such that a treatment intensification can be done
only for patients who will probably need it, e.g. by dose escalation to the whole tumour. Patterns
of failure analyses demonstrated that relapses mainly occurs inside the primary tumour volume
motivating the approach of dose escalation to the whole tumour independent of subvolume iden-
tification (Dawson et al. 2000; Daly et al. 2007; Stromberger et al. 2014).
Adaptation of treatment During the course of RT, lasting 6–7 weeks, patients may undergo
anatomical changes. Especially in the treatment of advanced HNSCC, shrinkage of large tumour
bulks, weight loss and shifts of organs are common, leading to changed tissue in the beam path
(Barker et al. 2004). Not counteracting for this problem may compromise treatment efficiency due
to reduced dose to the tumour volume or may increase side effects caused by increased normal
tissue doses (Schwartz and Dong 2011). A proposed treatment strategy to reduce the impact
of anatomy changes is the adaptation of the treatment plan. Optimal timing and frequency of
treatment adaptation are difficult to predict and may even depend on the individual patient. Thus,
adaptation strategies are currently highly discussed in research (van Kranen et al. 2010; Simone
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et al. 2011; Schwartz et al. 2013; Nishi et al. 2013; Berwouts et al. 2013; Olteanu et al. 2014). For
PT, these uncertainties may lead to a larger dose degradation in comparison to XT because of
the finite proton range which is highly sensitive to density changes in the beam path (Müller et al.
2015; Góra et al. 2015). Consequently, the definition of an adaptation schedule or at least of an
approach allowing for the identification of the necessity of replanning is crucial in PT treatment of
HNSCC patients.
Efficient use of proton therapy Although the reduced dose to normal tissue using PT is uni-
versally acknowledged, this therapy form is only available to a small patient cohort. This is caused
by the limited number of PT treatment facilities influenced by the high financial burden the invest-
ment and operation represents. To improve RT treatment for the patient collective, it is essential
to identify those patients for whom the use of PT will bring a substantial benefit. The identification
of such patients based on treatment plan comparisons is a generally accepted approach (Lan-
gendijk et al. 2013). However, such comparisons are time consuming and may be dispensable
for a large number of patients when only a small benefit of PT is determined. For not increasing
the workload unacceptably, early patient identification would be required using easily assessable
patient features, which are preferentially determined by default for all patients referred to any type
of RT. For cancer entities encompassing a large variation of actual tumour sites, as it is the case
in HNSCC, tumour location may be a criterion for stratification.
In addition to a well defined patient stratification, an improved use of the limited PT resources
for the whole patient collective may be achieved by reducing the number of fractions per patient.
One possibility is the use of hypofractionation, i.e. the use of less fractions for the whole treat-
ment course while increasing the dose per fraction above 2 Gy(RBE). At the present time, this
treatment approach is mainly used for palliative cases. Hypofractionated RT with curative intent
is mainly limited to breast (Whelan et al. 2008) and prostate cancer (Ritter 2008) as well as to
ablative stereotactic treatments, e.g. in the lung and brain (Nedzi 2008), and is still subject of
clinical trials (Arcangeli et al. 2010; Haviland et al. 2013). The use of hypofractionation is strongly
restricted by the altered biological impact, especially regarding increased late side effects and
is a highly controversial topic (Timmerman 2008). A reduction of the number of PT treatment
fractions per patient could also be achieved by splitting the treatment into XT and PT, e.g. by
using PT only for the sequential boost application. The treatment with both modalities could ad-
ditionally address the question of treatment adaptation, automatically including such a step in the
treatment protocol when moving from XT to PT or vice versa. However, up to now the benefit of
using PT for partial treatment only has not been shown. The use of carbon ions for partial treat-
ment with the aim of treatment intensification was investigated by several groups showing similar
toxicities compared to pure photon therapy (Schulz-Ertner et al. 2005; Jensen et al. 2012). For
primary glioblastoma and meningeoma, the clinical studies CLEOPATRA and MARCIE analysing
the effect of boost treatment with carbon ions are currently performed at the Heidelberg Ion-Beam
Therapy Center (Combs et al. 2010). The benefit of partial treatment of HNSCC with PT has not
yet been evaluated.
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3.2 Design of the treatment planning study
The presented treatment planning study was designed to allow for the evaluation of the formerly
described three aspects. For this purpose the treatment planning study required a comprehensive
structure which is described in detail in the following sections.
3.2.1 Treatment schedule
Accelerated RT, which reduces the total treatment time, and hyperfractionated RT, which in-
creases the number of fractions per day, as well as combinations of both have been shown to
be advantageous for local control in HNSCC patient treatment compared to standard fractiona-
tion schedules with five fractions per week administered once daily (Baujat et al. 2010). For PT
with its increased demands in patient positioning accuracy, hyperfractionated treatments requir-
ing multiple patient positioning per day are unfavourable. Consequently, accelerated treatment
schedules are preferred. For this reason, the fractionation schedule in the presented treatment
planning study is based on the accelerated treatment schedule used standardly in Denmark, first
examined by the Danish Head and Neck Cancer Study Group (DAHANCA) (Overgaard et al.
2003). In this schedule the dose is administered in six fractions per week once daily. The DA-
HANCA fractionation schedule was altered to allow for a patient stratification after the application
of 20 Gy(RBE) of the RT treatment dose. This time point was identified as ideal for a patient
stratification according to their risk of relapse based on functional imaging of hypoxia used as
biomarker (Zips et al. 2012). The modified schedule offers two treatment paths: for patients
identified as having a low risk of relapse, the standard DAHANCA treatment is performed. For
patients with a high risk of relapse, a treatment intensification to increase the chance of cure
is possible by changing the treatment plan after the initial 20 Gy(RBE) (Series II). The treatment
intensification is a dose escalation performed via SIB for the defined GTV, which prevents an
extension of the overall treatment time. Since Jeong et al. (2014) determined a dose escalation
of 10 %–30 % as necessary for cure improvement, two dose escalation levels were tested in the
presented treatment planning study: a low dose escalation level of 2.3 Gy(RBE) per fraction re-
sulting in an accumulated dose of 79.8 Gy(RBE) and a high dose escalation level of 2.6 Gy(RBE)
per fraction resulting in 87.6 Gy(RBE). A plan adaptation step using an updated CT for the se-
quential boost treatment (Series III) was included in the treatment schedule after 25 fractions to
incorporate patient anatomy changes. For the boost plan, the SIB volume was adapted to focus
the treatment intensification on the volume with the highest risk of relapse (cf. Section 3.2.3 for
details of the volume definition). With those two separated pathways, one with dose escalation
and one without, the cure probability of high risk patients may be increased, while low risk pa-
tients are still completely treated with a standard fractionation schedule without further increase
of toxicity risk. In the presented treatment planning study, focusing on the raised three questions,
only the dose escalation pathway for patients with high hypoxia was simulated for all patients re-
gardless of the actual classification of the patient. The treatment schedule including an example
of the target volumes is illustrated in Figure 3.2.
25
3 Dose escalated intensity-modulated photon and proton therapy for advanced HNSCC
Figure 3.2: Treatment schedule illustrating the option of using functional imaging as biomarker for patient
stratification according to their recurrence risk, allowing for a treatment intensification for high risk patients
only (patients with high level of hypoxia). Treatment plans for Series I, Series II with SIB and Series III with
SIB were generated in the presented treatment planning study (black path). The respective volumes are
illustrated in axial CT slices of an exemplary patient, including a FDG-PET overlay used for the SIB volume
definition in Series III. The optional schedule for low risk patients which was not simulated is illustrated in
grey.
3.2.2 Patient data
The defined treatment schedule required the use of two image datasets for treatment planning:
first, a CT dataset recorded prior to treatment for the treatment planning of Series I and Series II
(CTbaseline) and second, a FDG PET/CT for the adaptive treatment plan of Series III, the sequen-
tial boost treatment, which starts after 25 treatment fractions (CTadapt). Such image datasets
could be taken from a prospective clinical imaging trial which started 2006 and explored the prog-
nostic value of functional imaging with FMISO PET/CT in primary radiochemotherapy treatment
of patients with histologically proven HNSCC in advanced stages (Zips et al. 2012). For the pre-
sented treatment planning study, datasets comprising an initial CT and a sequential FDG PET/CT
recorded approximately after four weeks of RT were collected for 45 patients.
Patients were assigned to three subgroups depending on the location of the primary tumour:
Subgroup A consisting of 18 patients with tumours in the upper head and neck area, e.g. tumours
in the oropharynx or oral cavity, Subgroup B including 13 patients with tumours in the lower area,
e.g. larynx or hypopharynx tumours, and Subgroup C, 14 patients with tumours extending in both
areas. Patient characteristics are presented in Table 3.2 and subgroup assignment is illustrated
in Figure 3.3.
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Table 3.2: Patient and tumour characteristics.
Patient characteristics Number
Gender Female 7
Male 38
Tumour classification T3 18
T4 27
Node classification N0 5
N1 6
N2 32
N3 2
Primary site Hypopharynx 17
(12 in Subgroup B,
5 in Subgroup C)
Oropharynx 14
(8 in Subgroup A,
6 in Subgroup C)
Oral cavity 12
(10 in Subgroup A,
2 in Subgroup C)
Larynx 2
(1 in Subgroup B,
1 in Subgroup C)
Tumour characteristics Median volume (range)
CTbaseline CTadapt
Gross Tumour Volume / ml 31 ( 4 − 292) 11 ( 2 − 150)
Clinical Target Volume1 / ml 326 (209 − 834) 98 (24 − 395)
Planning Target Volume1 / ml 678 (451 − 1249) 204 (56 − 586)
1 For CTbaseline: elective volumes
For CTadapt: volumes based on geometrical margins of macroscopic tumour and lymph nodes
3.2.3 Volume definition
The resolution of the CT datasets used for treatment planning was either 1.0×1.0×3.0 mm3 or
1.4×1.4×5.0 mm3. All clinical anatomy-based contours were delineated by one experienced
physician to avoid interobserver variability. In addition to the FDG PET/CT datasets, contrast-
enhanced CT and MRI datasets, as well as data from the physical examination of the patients
noted in the health record, were collected, if available, to improve the contouring of the tumour
volumes and OAR. In addition, non-anatomy based volumes which were required for the optimi-
sation process in treatment planning were defined. In Table 3.3 all clinical contours are listed. In
Figure 3.3 the delineated anatomical OAR are visualised.
Organs at risk Multiple OAR were contoured on the CTbaseline. Published contouring guidelines
were applied for the delineation of swallowing muscles, xerostomia related OAR and brachial
plexus (Christianen et al. 2011; van de Water et al. 2009; Hall et al. 2008; Truong et al. 2010).
For other OAR, internal guidelines were used. Infiltrated parts of OAR were not delineated, i.e.
all OAR were only delineated outside the GTV and if a substantial portion of the OAR existed. All
delineated OAR were transferred to the CTadapt using a deformable image registration. The OAR
with defined treatment planning goals were visually examined and corrected, if necessary. Thus,
the CTadapt dataset comprised only a reduced set of approved OAR.
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Figure 3.3: Sagittal CT slices illustrating (a) the primary tumour locations for subgroup assignment and
(b) the delineated OAR. (i-viii) Illustration of the delineated OAR on several axial CT slices. White lines in
(b) represent the axial slice intersections.
Target structures The target structures include medical volumes like the GTV and the CTV
defined by the physician, as well as the PTV defined for treatment planning by the treatment
planner. The target structures used for the treatment planning of the different series are illustrated
in Figure 3.2 in a CT image dataset of an exemplary patient.
The GTV consisted of two separate volumes: one for the primary tumour (GTVtumour) and one
for pathologic lymph nodes (GTVlymph node). The GTVtumour was defined as volume for the dose
escalation using the SIB technique in Series II, the GTVSIB, except for patients with at least one
patholgic lymph node with a diameter > 6 cm (nodal status ≥ 3). For these patients, the GTVSIB
was the union of the GTVtumour and the GTVlymph node. A re-definition of the GTVSIB was performed
for Series III (GTVSIB, adapt) based on the biological information of the FDG PET/CT for focusing
the dose escalation on the volume which has the highest probability of recurrence. Several
groups identified the volume with FDG uptake in PET imaging at the start of or in-treatment as
a prognostic factor (Halfpenny et al. 2002; Brun et al. 2002; Schwartz et al. 2004; Hentschel
et al. 2011). For this reason, the GTVSIB, adapt was defined as the FDG-avid region in the CTadapt.
The delineation of this FDG-avid region was based on an auto-segmentation with an adaptive-
thresholding algorithm of the software Rover (Hofheinz et al. 2012). A manual exclusion of regions
with inflammation having a similar FDG uptake was performed.
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On the CTbaseline a potential subclinical spread was included in the CTV by adding geometric
margins of 10 mm to the GTVtumour and the GTVlymph node with present extra capsular invasion,
or 5 mm for the GTVlymph node without extra capsular invasion. This CTVbaseline was corrected for
air cavities, bones and vessels, if these were not infiltrated, and transferred with a deformable
image registration to the CTadapt for the CTV delineation for Series III (cf. Section 3.2.5 for details
of the deformable image registration). Thus, independent of occurring tumour shrinkage, the
CTVadapt was based on the original size of the CTVbaseline, only corrected for obvious errors in
the deformable image registration and for not infiltrated physical boundaries. This approach was
chosen due to the unknown pattern of tumour shrinkage, which may be a consequence of a
concentric volume reduction of the tumour where no viable cells outside the tumour bulk are left,
but could also be a result of tumour cell killing in a patchy pattern, where the tumour seems to
shrink in imaging, but still viable cells are present outside the visible tumour bulk (Tozaki et al.
2006; Sonke and Belderbos 2010). In addition to the CTV based on the geometric increase of
the GTV, an elective CTV was delineated for Series I and II (CTVelective) to include a prophylactic
irradiation of the lymphatic pathways which are prone to metastatic spread. The CTVelective was
delineated bilaterally according to published guidelines (Grégoire et al. 2004).
Taking into account setup uncertainties, the PTV were created by adding geometric margins of
4 mm in plane and 5 mm in cranio-caudal direction to the respective CTV, generating a PTVelective
and a PTVadapt. 3 mm distance to the body contour of the patient were retained if the skin was
not infiltrated.
Additional structures for treatment planning and evaluation Non-anatomy based struc-
tures, similarly created on the CTbaseline and the CTadapt, include structures for the dose reduction
in non-specified normal tissues in the mouth, neck and larynx area, structures to maintain hard
dose constraints considering setup uncertainties for spinal cord, brain stem and brachial plexus
and structures to increase the dose conformity based on the target volumes. Such structures may
be different for IMXT and IMPT treatment planning due to different requirements of the optimisa-
tion algorithms. Additionally, the structure PTVring for dose evaluation in the PTV was created by
subtracting the GTVSIB with an additional margin of 5 mm from the PTV. This allows for a better
dose coverage of the GTVSIB in treatment planning and additionally excludes the inevitable and
thus accepted high-dose rim surrounding the GTVSIB for the evaluation of hot-spots in the PTV.
3.2.4 Treatment planning
The treatment planning was performed for the available treatment techniques at the UKD: step
and shoot IMXT and multifield IMPT. The planning goals and dose constraints for the OAR were
the same in the planning optimisation processes for IMXT and IMPT. The planning goals for the
targets were based on the recommendations by the ICRU for IMXT and PT (ICRU 2007, 2010).
The described planning concepts were complemented by internal guidelines for IMXT treatment
planning and literature for IMPT treatment planning studies (Cozzi et al. 2001; Steneker et al.
2006; van de Water et al. 2011; Kraan et al. 2013; van der Laan et al. 2013).
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Photon treatment planning The treatment planning of step and shoot IMXT was performed
with the Pinnacle3 treatment planning system (Philips Healthcare, Amsterdam, the Netherlands).
The optimal number of beams in IMXT is a trade-off between the degrees of freedom for dose ap-
plication and the required treatment time influencing patient comfort and compliance. The use of
five beams is the standard treatment planning approach for HNSCC patient treatment with IMXT
at the UKD. For the treatment schedule including a SIB, five beams turned out to have too little de-
grees of freedom for the generation of acceptable treatment plans. The difference between seven
and nine beams was small. Therefore, a standard set of seven coplanar, equally-distributed beam
angles was chosen (27◦, 78◦, 129◦, 180◦, 234◦, 282◦, 333◦). Slight adaptations of the beam an-
gling were made to avoid unfavourable beam paths, e.g. an entrance beam through the shoulder
joint. For Series III with the reduced target volume, a beam reduction to five beams was con-
sidered in case of a one-sided PTVadapt, depending on the individual anatomical configuration.
The photon energy was set to 6 MV due to the superficial elective target volume. The treatment
planning was based on the beam data of a Siemens Artiste linear accelerator with 80 leaf pairs
of 5 mm width and a maximum field size of 40×40 cm2. Direct aperture optimisation (in contrast
to fluence optimisation) was used with restricting the number of segments to 70, the minimum
field size to 3×3 cm2 and the minimum number of monitor units per segment to 3. The dose
calculation grid was set to 3×3×3 mm3. The dose calculation algorithm was a collapsed-cone
algorithm available in the Pinnacle3 platform. The evaluations were performed for the calculated
nominal dose distributions.
Besides the use of static beam IMXT, rotational IMXT, the so-called VMAT, is increasingly used
in clinical practice. Which form of IMXT allows for the generation of better treatment plans, is not
yet determined and a subject of discussion in the community (Guckenberger et al. 2009; Wiezorek
et al. 2011; Broggi et al. 2014). To validate the quality of the created static beam IMXT treatment
plans, additional VMAT treatment plans were created by an independent treatment planner at the
University Hospital Tübingen for five randomly selected patients. The treatment planning was
performed with the non-commercial treatment planning system Hyperion. Sliding window VMAT
plans were created using two full gantry rotations. The photon energy was set to 6 MV. The
treatment planning was based on the beam data of an Elekta AgilityTM linear accelerator with 80
leaf pairs of 5 mm width and a maximum field size of 40×40 cm2. The minimum segment size was
set to 1×1 cm2, 3◦ rotation were set between the control points of the sliding window segments,
the rotation speed was 360◦ per minute. The dose calculation grid was set to 3×3×3 mm3. The
dose calculation algorithm was a pencil-beam algorithm available in the Hyperion platform. The
IMXT and VMAT treatment plans were qualitatively compared visualising the dose on the CT
images and quantitatively compared in terms of the dose constraints of targets and OAR used for
the treatment planning.
Proton treatment planning IMPT treatment plans using multifield optimisation were generated
in the XIO® treatment planning system (Elekta AB, Stockholm, Sweden). Similar to other studies,
a 3-field beam configuration was chosen with a posterior and two anterior-oblique beam angles
(180◦, 320◦, 40◦) (Cozzi et al. 2001; van de Water et al. 2011). Such a small number of beams
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may be applied quicker and thus improve patient comfort and compliance. A higher number of
beams did not show a general improvement in tumour coverage, OAR sparing or robustness
(Steneker et al. 2006; Kraan et al. 2013), although some patients may benefit from a larger num-
ber of beams when no individual beam angle adaptations are performed (van der Laan et al.
2013). The 3-field beam configuration was individually adapted to the specific anatomical confi-
guration. For example, for a one-sided PTVadapt the beam of the contralateral side was replaced
by another beam from the ipsilateral side, subsequently changing all three beam angles. The
treatment planning was based on the beam data of an IBA universal nozzle with a gaussian spot
size with a nominal sigma of 4 mm in air at isocentre for the highest proton energy of 230 MeV.
The spot spacing was set to one sigma on a regular spot grid. The energy layer distance was
chosen automatically by the treatment planning system. The minimum number of monitor units
required per spot was set to 0.01. A range shifter was inserted to enable the application of spots
close to the patient surface. The air gap between range shifter and patient surface was set to
5 cm. The dose calculation grid was set to 3×3×3 mm3. The dose calculation algorithm was
a proton pencil-beam algorithm including heterogeneity corrections available in the XIO system.
The evaluations were performed for the calculated nominal dose distributions with a constant
RBE correction factor of 1.1.
Treatment planning for mixed modality treatment The treatment plans for a mixed modality
treatment consisted of the IMXT treatment plans of Series I and II and the IMPT treatment plan for
Series III. No additional treatment planning was performed as all treatment plans were evaluated
separately to be of good quality and no different planning process would be performed for mixed
modality treatment in a clinical setting.
Treatment plan optimisation The main planning goal for the targets was to irradiate at least
95 % of the target volumes (GTVSIB, GTVSIB, adapt, PTV, PTVadapt) to 95 % of the respective pre-
scribed doses (V95 ≥ 95 % of Dprescribed). Furthermore, volumes exceeding 107 % (V107) of the
prescribed dose were to be minimised and the mean target doses were planned to be close
to the prescribed doses. The coverage of the GTVSIB (V95) was prioritised over the V107 of
the PTV. However, doses above 107 % of the prescribed dose in the PTV were strictly con-
fined to the volume surrounding the GTVSIB. The prescribed doses for the respective PTV were
20 Gy(RBE), 30 Gy(RBE) and 22 Gy(RBE) for Series I, II and III. The GTVSIB doses in Series II
and III were 34.5 Gy(RBE) and 25.3 Gy(RBE) with the low dose escalation level and 39 Gy(RBE)
and 28.6 Gy(RBE) with the high dose escalation level, resulting in accumulated target doses of
79.8 Gy(RBE) and 87.6 Gy(RBE).
OAR constraints with higher priority than the target coverage were defined for the spinal cord,
the brain stem and the brachial plexus. Consequently, the dose to these structures could influ-
ence the ability to achieve the planning goals for the targets. Since these structures are highly
sensitive to an excess of the maximal tolerable dose, the prescribed constraints were fulfilled in a
3 mm margin surrounding the OAR. Dose constraints for OAR with priorities less than the target
planning goals were defined for the parotid glands, the laryngeal structures and the mandible.
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For those OAR, higher doses than the constraints were accepted if these were required to fulfil
the target prescription. For other anatomical structures, no specific planning goals were defined.
The dose in these structures was to be minimised without a certain dose goal. To enable the op-
timisation algorithm of the treatment planning system to reduce the dose in these non-specified
anatomical regions, further constraints were set to the additional structures delineated in the
mouth, neck and larynx area. Table 3.3 lists the treatment planning goals and priorities for the
delineated anatomical volumes.
Table 3.3: Delineated anatomical volumes, the respective treatment planning goals for the accumulated
dose distribution and the priority in treatment planning relative to each other.
Delineated volume Treatment planning goal Priority
Spinal cord Dmax ≤ 45 Gy(RBE) 1
Brain stem Dmax ≤ 54 Gy(RBE) 2
Brachial plexus1 Dmax ≤ 72 Gy(RBE) 3
GTVSIB V1072 < 2 % 4
V95
2
≥ 95 % 4
Dmean, rel. = 100 %2 4
PTV V1072 < 2 % 5
V95
2
≥ 95 % 5
Dmean, rel. = 100 %2 5
Parotid gland1 Dmean ≤ 26 Gy(RBE) 6
Glottic larynx D2 ≤ 70 Gy(RBE) 6
Supraglottic larynx D2 ≤ 80 Gy(RBE) 6
Complete larynx3 Dmean ≤ 45 Gy(RBE) 6
Mandible D1ml ≤ 75 Gy(RBE) 6
Mucosa4 no specific goal
Carotid sinus1 no specific goal
Sublingual gland1 no specific goal
Submandibular gland1 no specific goal
Temporo-mandibular joint1 no specific goal
Base of tongue no specific goal
Oesophagus no specific goal
Oesophagus inlet muscle no specific goal
Pharyngeal constrictor muscles5 no specific goal
Skin6 no specific goal
Body contour no specific goal
1 Pairwise organs (left, right) 4 Including inner surfaces of lips and cheeks, soft palate
2 Percentage of prescribed dose 5 Consisting of superior, middle and inferior muscles
3 Union of glottic and supraglottic larynx 6 Volume 3 mm from the outer body contour
In addition to these quantitative treatment planning goals, a qualitative evaluation via visualising
the dose distribution on transversal CT image slices was performed. Based on this evaluation,
treatment plans which fulfilled the nominal quantitative treatment planning goals could be still
rated as unacceptable for therapy. Such a situation can occur in the case of the target cover-
age prescription, where doses less than 95 % of the prescribed dose would only be accepted at
the border of the PTV, which cannot be accurately described by the V95 parameter alone. Fur-
thermore, in case of the maximum doses in the spinal cord and brain stem, the dose gradient
was evaluated additionally to ensure that uncertainties in positioning would not lead to a dose
exceeding the nominal constraint.
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3.2.5 Image registration
For the dose accumulation of the treatment plans created on the two different CT datasets, an
image registration between the two datasets was required. Since in the highly flexible head and
neck area deformations and anatomical changes, e.g. weight loss and tumour shrinkage, occur
throughout a RT treatment (Zhang et al. 2006; van Kranen et al. 2009), a deformable image regis-
tration is mandatory. However, every deformable image registration is afflicted with uncertainties
(van Rijssel et al. 2014). To reduce the impact of such inevitable uncertainties, the CTbaseline
was defined as the dataset for evaluation. Since Series I and II are both planned on this CT and
represent about 2/3 of the targeted treatment dose, uncertainties in the evaluation introduced by
improper deformable image registration are limited to the deformed dose of Series III.
The image registration was performed using the open source software package 3D-Slicer (Fe-
dorov et al. 2012). Two registration steps were executed. First, a rigid registration with three
degrees of freedom was carried out manually. With that, the two CT datasets were roughly
aligned to the same space coordinates and cut to the same image section. Both, alignment and
cut, improved the quality of the second step, the deformable image registration, which performed
substantially better with this preparation. The available algorithms in 3D-Slicer for the deformable
image registration include B-Spline and Demon algorithms (Johnson and Zhao 2009). Castadot
et al. (2008) identified the Demon algorithm to provide better results in registrations of HNSCC
datasets with large changes in anatomy caused by tissue reduction like tumour shrinkage or
weight loss. An exemplary examination of 20 landmarks in both CT datasets of one patient com-
paring both available algorithms confirmed this result. For the B-Spline and the Demon algorithm
a mean error vector with standard deviation of (2.4±1.3) mm and of (1.8±0.9) mm were deter-
mined, respectively. Consequently, the deformable image registration of the image datasets was
performed using the Diffeomorphic Demon algorithm implemented in 3D-Slicer.
Stützer et al. (2014) performed a validation of the image registrations of all patients qualita-
tively by visualising the vector fields and quantitatively based on contour and dose parameter
comparisons. In this analysis, the visual inspection of the vector fields showed an overall ac-
ceptable incorporation of differences in the patient positioning (e.g. tilted head, lifted chin, raised
shoulders) and changes in the tumour size. Non-physiological deformations were identified for
structures with low contrast in the CT images such as the brain and for areas with artefacts in
the CT images, e.g. caused by dental fillings. The quantitative assessment with contour compar-
isons revealed sufficient quality of the deformable image registration. Most deviations could be
explained by intraobserver variability in the contouring of structures. Considering the influence
of the deformable image registration on the dose distribution, the mean differences between the
relevant dose parameters were below 0.2 Gy(RBE), with no differences exceeding 0.5 Gy(RBE),
which was defined as threshold for further inspection, in about 75 % of the cases. Larger differ-
ences occurred in areas of very steep dose gradients, but were similar for IMXT and IMPT. These
results are comparable with an evaluation of dose parameter changes introduced by inaccurate
deformable image registration performed by Cunliffe et al. (2015) for CT image series of lung
cancer patients and could not be further reduced with the used deformable image registration
algorithm. For the evaluation, both IMXT and IMPT dose distributions are deformed with the
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same algorithm inducing similar uncertainties for the majority of the evaluated parameters. Thus,
uncertainties in the deformable image registration were acceptable considering the purpose of
comparing similarly deformed dose distributions in the presented treatment planning study.
3.2.6 Evaluation parameters
For treatment plan comparisons, measures need to be defined which allow for an assessment
of the advantages and disadvantages of the particular treatment plan. Physical dose parameters
based on the DVH, i.e. DVH parameters like the dose received by a certain organ volume or
the organ volume receiving a certain dose, are generally used as they are easy to determine in
conventional treatment planning systems. The target structure evaluation was performed for the
treatment planning goal parameters V95, V107 and Dmean. The allowed high-dose rim surrounding
the SIB volume deteriorated the PTV evaluation. Hence, the evaluation was based on the PTVring
structure. For a visual inspection of the dose distribution in the target volumes, a relative dose
distribution was created, depicting a dose distribution where all voxels inside the target volumes
are normalised to their specific fraction doses and dose to unspecified voxels is not shown, cf.
Figure 3.4.
Figure 3.4: Method for relative dose distribution calculations in a target volume with a prescription of two
different dose levels realised with a SIB (figure courtesy of Dr. K. Stützer).
The evaluation of OAR with DVH parameters is based on the assumption that higher doses
lead to higher toxicities, although the effect may vary for each individual patient. An estimation
of the biological impact of different dose distributions is possible with NTCP models for OAR and
TCP models for target structures. Such modelling has the advantage that a specific benefit due
to a reduced dose in an OAR can be directly quantified. NTCP models refer to specific toxicities.
Thus, important patients’ quality of life impacting toxicities and their dose-response relationships
needed to be identified for the risk evaluation. The presented treatment planning study focused
on the side effects described in Table 3.1. An extensive literature research was performed to
identify current NTCP models for the described toxicities that could be used for the patient popu-
lation of the treatment planning study. In the interest of greater clarity, the results of the literature
research are described in detail in the following section, Section 3.2.7. The choice of models
and DVH parameters was discussed with and approved by the clinicians at the UKD. Models
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developed at other institutions need to be validated if used on a patient population which differs
from the original one. The best way to ensure the validity of a NTCP model for a different patient
population is to compare the clinical outcome of this patient population with the prediction of the
model (van Luijk and Schippers 2012). Due to the lack of these data or inconsistencies in data
acquisition, this method can often not be performed. In the presented treatment planning study,
the generated treatment plans were not used for the patient treatment, such that treatment com-
plications were based on another treatment. Therefore, a validation was impossible. To maintain
a valid estimation of the side effects, the used NTCP models needed to fulfil several require-
ments: a model was rated applicable if the patient population and treatment technique used for
establishing the model were similar in tumour site, in used dose per fraction and total dose, or if a
method was used in modelling to compensate for such differences, e.g. a fractionation correction.
With this requirement, reasonable models could not be found for all interesting toxicities, while for
other toxicities several models were identified based on different toxicity assessment methods.
For side effects without adequate models, DVH parameters of the impacted organs identified in
dose-response relationship analyses were used instead. For toxicities with several applicable
models, more than one model was chosen if the toxicity assessment differed, resulting in mul-
tiple models for dysphagia (videofluoroscopic assessed aspiration, physician-rated dysfunction,
patient-rated dysfunctions of different grades and larynx oedema) and xerostomia (assessment
at different time points after RT). Altogether, seven different domains of toxicities impacting the
patients’ quality of life were evaluated with NTCP models: myelopathy, brain stem necrosis, oral
mucositis, xerostomia, dysphagia, brachial plexopathy and trismus. All parameters for NTCP
models were taken from literature (Dijkema et al. 2008; Schultheiss 2008; Rancati et al. 2009;
Houweling et al. 2010; Eisbruch et al. 2011; Bender 2012; Bhide et al. 2012; Chen et al. 2012;
Christianen et al. 2012; Lindblom et al. 2014) and supplemented by personal communication in
the case of Eisbruch et al. (2011). The models were based on different modelling approaches:
the LKB model, different logistic models and a multimodal model. An overview of the used NTCP
models and parameters is given in Table 3.4, the evaluated DVH parameters for toxicities of OAR
without a valid NTCP model are stated in Table 3.5.
Absolute NTCP values and DVH parameters (DV or VD , cf. Section 2.2.5) were assessed for
the estimation of the probability of toxicity development for a patient. Differences in NTCP and
DVH parameters were evaluated for each patient individually to estimate the effect of treatment
changes, such as the different modalities IMXT and IMPT,
∆NTCPMod = NTCPIMXT − NTCPIMPT, (3.1)
∆DMod = DIMXT − DIMPT, (3.2)
∆VMod = VIMXT − VIMPT, (3.3)
IMXT and the mixed modality treatment,
∆NTCPMixMod = NTCPIMXT − NTCPMixed Modality, (3.4)
∆DMixMod = DIMXT − DMixed Modality, (3.5)
∆VMixMod = VIMXT − VMixed Modality, (3.6)
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and the dose escalation levels of 2.3 Gy(RBE) and 2.6 Gy(RBE),
∆NTCPDE = NTCPDE 2.6 Gy(RBE) − NTCPDE 2.3 Gy(RBE), (3.7)
∆DDE = DDE 2.6 Gy(RBE) − DDE 2.3 Gy(RBE), (3.8)
∆VDE = VDE 2.6 Gy(RBE) − VDE 2.3 Gy(RBE). (3.9)
A substantial benefit of IMPT or the mixed modality treatment compared to IMXT was defined
as ∆NTCPMod and ∆NTCPMixMod values of ≥ 10 %, a moderate benefit as differences between
5 % and 10 %. Substantial and moderate disadvantages of the higher dose escalation were de-
fined with the same values of ∆NTCPDE. The cohort and subgroup evaluations were performed
focusing on median values and ranges determined with the 5th and 95th percentiles (P5 and P95)
for exclusion of outliers, if not stated differently. Statistical significance of differences in NTCP and
in DVH parameters was tested for all patients using paired t-tests. The mean of these differences
was compared for Subgroup A, B and C by a one-way analysis of variance. If significant, two-
sample t-tests between all combinations of subgroups were performed. A Bonferroni correction
was applied to account for multiple testing. The significance level was set to 0.05.
Table 3.4: Considered toxicities and used NTCP models (literature reference and used parameters).
Toxicity NTCP model NTCP model parameters
Myelopathy
NTCP =
(
1 +
(
D50
D
)k
)
−1
D = Dmax of spinal cord,
Schultheiss et al. 2008 D50 = 69.4 Gy, k = 18.8
Brain stem necrosis
NTCP =
(
1 +
(
D50
EQD2
)4γ
)
−1 EQD2 of brain stem,
Bender et al. 2012 D50 = 109.0 Gy, γ = 2.8
Oral mucositis
NTCP =
(
1 +
(
D50
D
)k
)
−1
D = Dmean of oral mucosa,
Bhide et al. 2012 D50 = 51.0 Gy, k = 1
Xerostomia
NTCP = Φ
(
gEUD(n)−D50
m·D50
)
gEUD of contralateral parotid gland, after
Dijkema et al. 2008 6 months: D50 = 31.0 Gy, m = 0.63, n = 1
Houweling et al. 2010 12 months: D50 = 39.9 Gy, m = 0.40, n = 1
Aspiration
NTCP = Φ
(
gEUD(n)−D50
m·D50
)
gEUD of PCM1,
Eisbruch et al. 2011 D50 = 64.5 Gy, m = 0.09, n = 0.2
Physician-rated dysphagia
NTCP =
(
1 + ea−b·X1−c·X2
)
−1 X1 = Dmean of superior PCM1,
Christianen et al. 2012 X2 = Dmean of supraglottic larynx,
a = 6.09, b = 0.057 Gy−1, c = 0.037 Gy−1
Problems swallowing solids2
NTCP =
(
1 + ea−b·X1−c·X2
)
−1 X1 = Dmean of supraglottic larynx, X2 = 1,
Christianen et al. 2012 a = 5.98, b = 0.074 Gy−1, c = −1.209
Problems swallowing liquids2
NTCP =
(
1 + ea−b·X1−c·X2
)
−1 X1 = Dmean of superior PCM1,
Christianen et al. 2012 X2 = Dmean of supraglottic larynx,
a = 6.89, b = 0.049 Gy−1, c = 0.048 Gy−1
Larynx oedema
NTCP = Φ
(
gEUD(n)−D50
m·D50
)
gEUD of larynx,
Rancati et al. 2009 D50 = 47.3 Gy, m = 0.23, n = 1.17
Brachial plexopathy
NTCP =
(
1 +
(
D50
D
)k
)
−1
D = Dmax of brachial plexus,
Chen et al. 2012 D50 = 75.0 Gy, k = 23.2
Trismus
NTCP =
(
1 + e
4γ·
(
1− D
D50
)
)
−1
D = Dmean of temporo-mandibular joint,
Lindblom et al. 2014 D50 = 44.1 Gy, γ = 0.3
1 Pharyngeal constrictor muscles 2 Patient-rated
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Table 3.5: Considered toxicities and DVH parameters.
Toxicity Impacted organ(s) Physical dose parameters
Xerostomia1 Sublingual and submandibular salivary glands Dmean
Oesophageal stricture Oesophagus Dcirc2, V60 Gy(RBE)
Vessel injury Carotid sinuses Dcirc2, D2
Osteoradionecrosis Mandible D1ml, V50 Gy(RBE)
Skin necrosis Skin3 D25cm2
4, V70 Gy(RBE)
1 Several salivary glands which were not included in the NTCP model may impact xerostomia
2 Circumference dose indicating the highest dose that completely encloses the organ
3 Defined as volume 3 mm from the patient body contour
4 Highest mean dose in a skin surface area of 25 cm2
The treatment plan evaluation for OAR was performed for the accumulated dose distributions
of Series I, II and III for the structures delineated on the CTbaseline. Since the target structures
in Series III are adapted and thus do not exist in the CTbaseline, the evaluation of target parame-
ters was performed separately for the three series on the respective CT images. Based on the
CTbaseline, the distances between the GTVSIB surface and the center of mass of a specific OAR
were examined in the context of their correlation to the NTCP and ∆NTCP values.
3.2.7 Choice of normal tissue complication probability models
The NTCP models used in the presented treatment planning study were based on literature,
which is described in detail in this section. Reasons for the choice of the models are stated. A
description of the model parameters is given in Table 3.4.
Myelopathy and brain stem necrosis Myelopathy and brain stem necrosis are very severe
late side effects which are usually prevented in RT treatment by appropriate treatment planning.
Dose constraints for spinal cord and brain stem are conservatively chosen and have a high prior-
ity during treatment planning, limiting the irradiation dose to the tumour if necessary (Schultheiss
1990). The maximum allowed dose is based on several animal studies done in the last century.
The assessed values were confirmed by the first large RT tolerance dose study of Emami et al.
(1991). Due to the conservative planning approach, myelopathy and brain stem necrosis are
rarely encountered in treatments today which makes it difficult to create a valid dose-response-
model based on current treatment techniques. Newer research suggest that a higher tolerance
dose than the standard constraints seems applicable (Schultheiss et al. 1995; Gocheva 2000;
Mayo et al. 2010). An approach to create dose-response-models valid for current treatment tech-
niques despite the problem of the small case numbers is given by assembling case reports of
several institutions and fitting model parameters to the reported dose distribution data. Based on
this approach, Schultheiss (2008) determined a logistic model for myelopathy of the cervical spine
and Bender (2012) created a model for brain necrosis. The patient population and treatment tech-
nique was mixed throughout the patient cohort due to the case report approach. However, since
these toxicities are very important and both models generally were based on patients receiving
modern XT treatment, both models were used for the presented treatment planning study.
37
3 Dose escalated intensity-modulated photon and proton therapy for advanced HNSCC
Oral mucositis Oral mucositis describes the inflammation of the mucous membranes in the
oral cavity. It is a side effect that usually develops during treatment and occurs with differ-
ent severity in almost all HNSCC patients (Raber-Durlacher et al. 2010). High grade mucositis
(grade≥ 3) interferes with the oral nutrition of the patient, requires medical intervention such as
tube feeding and may lead to a disadvantageous interruption of treatment (Sciubba and Golden-
berg 2006; DHHS et al. 2009). Dose-response-relationship descriptions are rare with only four
different groups evaluating the dose effect and only one of those groups performing a specific
NTCP modelling. Narayan et al. (2008) based their evaluation on a patient cohort with twelve
patients treated with different treatment approaches, IMXT or 3D-conformal XT with or without
concurrent chemotherapy. They described a dependence of the duration and severity of mucosi-
tis on high local doses in the mucosa after correction for fractionation. Sanguineti et al. (2012)
found a correlation between incidence of mucositis grade≥ 3 and several dose volume parame-
ters (mucosa volume receiving more than 10.1 Gy per week, the dose received by 21 ml) based
on an analysis of 164 patients treated with IMXT and mixed chemotherapy regimens. A depen-
dence of grade 3 oral mucositis on the mean dose to the oral mucosa was described by Otter et al.
(2015) considering outcome data of 253 patients treated with IMXT with or without chemotherapy.
This dose parameter was also found relevant by Bhide et al. (2012) for the incidence probability
of oral mucositis with grade≥ 3. Bhide et al. (2012) generated a NTCP model with a logistic func-
tion based on 144 HNSCC patients treated with concomitant chemo-IMXT using a SIB technique
similar to the presented treatment planning study. A biological dose correction for fractionation
was done for the mean dose of the oral mucosa. The model by Bhide et al. (2012) was well
described. The patient population and treatment regimens showed essential similarities to the
presented treatment planning study allowing for the use of this model.
Xerostomia Xerostomia is another frequently occurring side effect in RT treatment of HNSCC
patients which is caused by a reduced function of the salivary glands. The introduction of ad-
vanced treatment techniques like IMXT allowed for a reduction of dose to the salivary glands in
most treated patients resulting in reduced toxicity incidences. Considering the impact of xerosto-
mia on the patients’ quality of life, a further reduction is still a worthwhile goal in RT (Eisbruch et al.
1999a). Main focus thereby lies on the parotid glands, the main salivary glands producing the
majority of the oral salivary output (Eisbruch et al. 1999b). However, minor salivary glands such
as the submandibular or sublingual glands may impact the degree of xerostomia as well (Jellema
et al. 2005; Murdoch-Kinch et al. 2008). Due to the large long-time effect on the patients’ quality
of life by impacting mastication, swallowing, speech, taste as well as increasing the risk of caries
and mandible necrosis, the dose-response-relationship for xerostomia is well examined and mul-
tiple NTCP models exist (Eisbruch et al. 1999b; Roesink et al. 2001; Semenenko and Li 2008;
Marzi et al. 2009; Porter et al. 2010; Dijkema et al. 2010; Houweling et al. 2010; Beetz et al.
2012; Lee et al. 2012). They mainly differ in the considered number of patients (from a small
patient group of 31 patients to a large patient group of 221 patients), the treatment technique
(3D-conformal XT versus IMXT), the toxicity evaluation technique (salivary flow measurement
versus patient-rated xerostomia via questionnaire) and the time point for toxicity evaluation (from
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a few weeks to a year). Due to tissue recovery after RT, xerostomia symptoms decrease partly
over time. The most proper time point for xerostomia evaluation is not clear and different time
points are used in other treatment planning studies in literature. To ensure comparability to those
studies, two model time points were chosen: xerostomia 6 months after RT and xerostomia 12
months after RT, using the models presented by Dijkema et al. (2008) and Houweling et al. (2010)
which were both based on large HNSCC patient populations treated with IMXT assessing xeros-
tomia with salivary flow measurements including a pre-treatment evaluation. Since both models
only include the parotid gland dose, the mean doses (Dmean) of the submandibular and sublingual
glands were evaluated additionally as DVH parameters.
Dysphagia Dysphagia describes side effects which are related to swallowing dysfunctions. To-
gether with xerostomia, dysphagia is rated as the main side effect impacting the patients’ quality
of life. Thus the identification of the dose-response-relationship of dysphagia came into focus in
the last years (Langendijk et al. 2008). Swallowing is a very complex process involving a multi-
tude of structures, e.g. the oral cavity, the pharynx, the tongue, the larynx, the oesophagus and
numerous muscles. As a consequence, dysphagia can have a multitude of causes including the
damage of swallowing muscles, nerves and the larynx, larynx oedema and oesophageal stric-
ture. Larynx oedema and oesophageal stricture are usually assessed separately and thus are
also discussed separately in the next two paragraphs.
The assessment of dysphagia is similarly numerous: Dysphagia can be rated subjectively using
questionnaires enquiring about the patients’ difficulties in swallowing (Bjordal et al. 2000; Chen
et al. 2001; Rosenthal et al. 2007). With this commonly used method the effect on the patients’
quality of life is evaluated while the cause is not identified. As a consequence, dysphagia can be
underrated or even missed, e.g. when the symptoms are not very severe, as the patient may con-
found them with other problems or even does not perceive the side effect (Logemann et al. 2003).
In contrast, the swallowing mechanism can be visualised with videofluoroscopy measurements
of modified barium swallowing. Thereby, swallowing dysfunctions can be identified objectively by
assessing aspiration, larynx oedema or oesophageal strictures (Logemann 1997; Martin-Harris
et al. 2000). However, the impact on the patients’ quality of life cannot be determined with this
method.
The identification of anatomical structures whose damage promotes the development of dys-
phagia is essential for dose-response modelling, especially since swallowing is a complicated
process including a multitude of muscles and nerves (Rosenthal et al. 2006). Several groups
identified two main organ complexes influencing the development of dysphagia in HNSCC RT:
complete or parts of the pharyngeal constrictor muscles and complete or parts of the larynx (Eis-
bruch et al. 2004; Jensen et al. 2007; Levendag et al. 2007; Caglar et al. 2008). Identified dose
parameters for these organs correlating with dysphagia development were V50-65 and Dmean (Lev-
endag et al. 2007; Feng et al. 2007; Caglar et al. 2008; Dirix et al. 2009; Schwartz et al. 2010;
Caudell et al. 2010). Two groups developed NTCP models for dysphagia endpoints based on
patient populations and treatment techniques similar to the presented treatment planning study
with different approaches: Christianen et al. (2012) created models for physician-rated swallow-
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ing dysfunction of grade 2-4 according to the Late Radiation Morbidity Scoring Criteria of the
Radiation Therapy Oncology Group (RTOG) and the European Organisation for Research and
Treatment of Cancer (Cox et al. 1995) and several patient-rated swallowing dysfunctions based
on questionnaires, all assessed at six months after RT. The second group based the modelling of
dysphagia on videofluoroscopy imaging of aspiration more than twelve months after RT (Eisbruch
et al. 2011). Both groups identified more than a single organ as relevant for the development of
dysphagia. Doses to the larynx and the pharyngeal constrictor muscles were found to be predic-
tive for dysphagia development. Christianen et al. (2012) created multimodal models where the
input of several parameters is possible. Eisbruch et al. (2011) used the LKB-model allowing only
a single input parameter. Consequently, they defined two model parameter sets, one based on
the dose to the larnyx and one on the dose to the pharyngeal constrictor muscles, and identified
the model based on the pharyngeal constrictor muscles dose as better representation of their
toxicity data (Eisbruch 2014).
Dysphagia is a very important complication in RT which has a substantial effect on the patients’
quality of life and which also carries a risk to the patients’ health, e.g. by causing aspiration pneu-
monia. The two endpoints, subjectively and objectively rated dysphagia, are equally important
in dysphaia assessment. Thus, three models by Christianen et al. (2012) based on question-
naires which evaluated the restrictions in swallowing by physician and patient assessment after
RT were used as subjective measure in the presented treatment planning study. In addition, one
model by Eisbruch et al. (2011) based on videofluoroscopy was used for objective dysphagia risk
estimation.
Larynx oedema Larynx oedema is the swelling of the larynx leading to a reduced larynx motility
which may result in dysphagia. Dose-response relationship analyses for this endpoint are scarce
(Sanguineti et al. 2007; Rancati et al. 2009). NTCP modelling was done by Rancati et al. (2009)
for the development of a symptomatic larynx oedema (grade≥ 2, DHHS et al. (2009)) for a pa-
tient cohort mainly treated with IMXT. The patient population used for assessment of the model
parameters was similar to the present treatment planning study. Thus this model was included
in the presented treatment planning study complementing the toxicity modelling of the dysphagia
domain.
Oesophagitis and oesophageal stricture Oesophagitis and oesophageal stricture are side
effects which can lead to a swallowing dysfunction during of after RT. Both side effects may oc-
cur in lung cancer RT and their dose-response relationship is well examined for this therapy site
(overview of studies given in Werner-Wasik et al. (2010)). Since the proximal part of the oesopha-
gus is irradiated in HNSCC RT, especially in treatment of hypopharyngeal primary tumours, both
side effects can occur in this patient cohort as well, although with lower incidence rates (Lawson
et al. 2008). The irradiated part of the oesophagus differs between lung cancer RT (thoracic
part of the oesophagus) and HNSCC RT (proximal part of the oesophagus) which may influence
the dose-response relationship such that data determined in lung cancer RT cannot simply be
transferred to HNSCC RT (Mavroidis et al. 2003). This assumption is supported by studies identi-
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fying an increased risk of oesophageal stricture following oesophagitis induced in lung cancer RT
while such a dependence was not found for HNSCC RT (Ahn et al. 2005; Jiang et al. 2012; Lau-
rell et al. 2003). For HNSCC only two studies attempted to develop a dose-response model both
lacking comparability to the present treatment planning study: Mavroidis et al. (2003) based their
retrospective analysis on patients treated with 3D-conformal XT with larynx blocks and a largely
differing dose prescription compared to the presented treatment planning study. Alevronta et al.
(2010) used patients with a mixed treatment in terms of technique, target dose and overall treat-
ment time for their analysis. They could not find modelling parameters when including all data
emphasizing the impact of the treatment approach on NTCP modelling. The model they could
establish for IMXT treatment was based on only 28 patients with eight patients who developed
a stricture. Altogether, no model for HNSCC RT was applicable for the presented treatment
planning study. Consequently, DVH parameters were evaluated for the oesophagus. Chosen
parameters were the circumference dose, Dcirc, as indicator for elasticity reduction of the whole
transverse section of the oesophagus narrowing the oesophagus (Werner-Wasik et al. 2010), and
the relative volume of the oesophagus receiving more than 60 Gy(RBE), V60 Gy(RBE), since it was
shown that above 60 Gy the incidence risk of oesophageal stricture increases (Mavroidis et al.
2003; Lawson et al. 2008).
Brachial plexopathy Nerve damage of the brachial plexus, the so-called brachial plexopathy,
can lead to an impaired function of the upper extremity like the loss of strength, motility limitations
and hypo-sensitivity impacting the patients’ quality of life. Nerve damage usually develops only
at high doses to the brachial plexus (Herrmann et al. 2006). Thus, brachial plexopathy mainly
occurs in patients with tumours growing in a close-by anatomical area and may develop especially
in patients with tumours and lymph node metastases in the lower head and neck area. Several
studies of HNSCC patients treated with RT showed that the incidence of brachial plexopathy rises
with maximum doses greater than 60 to 70 Gy (Platteaux et al. 2010; Truong et al. 2012; Chen
et al. 2014). The only available NTCP model was developed by Chen et al. (2012) determining
brachial plexopathy based on questionnaires for neuropathic symptoms impacting the activities
of daily living including moderate and severe symptoms (DHHS et al. 2009). The study included
330 patients treated with IMXT or 3D-conformal XT with different chemotherapy regimens. The
patient population and treatment techniques were rated as sufficiently similar to the presented
treatment planning study to include the model.
Vessel damage Vessel damage caused by RT can manifest clinically as bleeding being a con-
sequence of vascular wall degradation or later on as vascular stenosis increasing the risk of
stroke. In RT of HNSCC affected large vessels are mainly the carotid arteries including the
carotid sinuses, which are a branching structure of the carotids (Abayomi 2004). Bleeding as a
complication after RT is very rare and dose-response relationships as well as NTCP models are
missing. However, the risk of bleeding caused by vascular wall degradation may be the largest
within high focal doses. This was assessed in the presented treatment planning study with the
dose to 2 % of the delineated vessel (D2). Dorresteijn et al. (2002) identified an increased relative
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risk of stroke for HNSCC patients who underwent RT. However, due to additional factors, which
also contribute to the development of a stroke independent of RT, e.g. diet, smoking, diabetes
and hypercholesterolemia, it is difficult to determine whether a stenosis is caused by the RT
treatment. No dose-response relationship or NTCP models are described. The risk of stenosis
development may be influenced by the elasticity capacity of the vessel. This elasticity can be
reduced by high doses which completely enclose the vessel. Thus, in addition to the D2, the
circumference dose Dcirc was assessed.
Trismus Trismus describes a restricted mouth opening and can be a consequence of the irradi-
ation of the mastication muscles and the temporo-mandibular joint. There are several methods for
assessing trismus (Dijkstra et al. 2004): first, the objective determination of the size of the mouth
opening with maximum interincisal distance measurements and second, the subjective evaluation
with questionnaires asking the patients about their mouth opening capabilities. Several studies
examined the dose-response relationship for trismus with these two endpoint definitions (Teguh
et al. 2008; van der Molen et al. 2013). Organs determined to be relevant for trismus risk predic-
tion are the masseter (Teguh et al. 2008; van der Molen et al. 2013), the pterygoid muscles (Teguh
et al. 2008; van der Molen et al. 2013) and the temporo-mandibular joint (Dijkstra et al. 2004). For
these structures, Lindblom et al. (2014) determined NTCP model parameters for objective and
subjective trismus evaluation. The quality of the models generated with the two different assess-
ment methods was similar. Although the patient population was mainly treated with 3D-conformal
XT, differences in the dose distribution compared to IMXT in that anatomical area based on the
treatment plans are rather small. Thus, the model of Lindblom et al. (2014) was used in the
presented treatment planning study taking the parameter set for the temporo-mandibular joint,
objectively rating trismus with measurements of the maximum interincisal distance.
Osteoradionecrosis Osteoradionecrosis describes the cell death within an irradiated bone and
may occur after RT treatment of HNSCC patients mainly in the mandible. Incidence analyses
show a large variability in literature depending on the time point of evaluation (follow-up time)
and the used definition of a symptomatic osteoradionecrosis (Studer et al. 2006; Ben-David et al.
2007; Nabil and Samman 2012; Tsai et al. 2013). Surgery and dental status were identified as the
two most important factors influencing the risk of osteoradionecrosis independent of the RT dose
(Lee et al. 2009; Monnier et al. 2011; Sasahara et al. 2014). As a consequence, a clear dose-
response relationship could not be identified and NTCP models for osteoradionecrosis do not
exist. However, Lee et al. (2009) identified high local radiation doses as risk factor, while Sasa-
hara et al. (2014) found the volume receiving more than 50 Gy as relevant parameter. Therefore,
the dose to 1 ml of the mandible (D1ml), as well as the volume receiving doses above 50 Gy(RBE)
(V50 Gy(RBE)) were chosen as DVH dose parameters analysed in the presented treatment planning
study.
Skin toxicity Skin toxicity may present early during treatment as dermatitis including erythema
and dry or moist desquamation and later on as atrophy, telangiectasia, ulceration or necrosis
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(ICRP 2012). Using high-voltage XT reduces the risk of severe skin reactions like necrosis due to
the larger build-up effect diminishing the surface doses such that skin toxicity is of less relevance
in modern XT (Dische et al. 1997). However, in IMXT for HNSCC RT, multiple factors like the
bolus effect of fixation masks and the reduced build-up effect in tangential fields may increase
the skin dose, leading to severe skin reactions in rare cases (Lee et al. 2002). Additional factors
independent of the radiation dose like the treatment with cetuximab may increase the risk of skin
toxicity even more (Cabezón Gutiérrez et al. 2012). In PT, no build-up effect similar to photons
is present. Consequently, larger skin doses can be expected which may translate into a higher
incidence of severe skin reactions (Bentzen et al. 2001; Ginot et al. 2010). Despite that, up to
now, no NTCP modelling for skin reactions based on modern XT techniques or even PT exists.
Known dose-response relationships are based on orthovolt therapy and the transfer to other
methods is arguable (Turesson and Thames 1989; Hopewell 1990; Turesson 1991). Dörr (2006)
described three influencing factors for the development of skin reactions: first, the location of
the radiation dose influences the tolerance of the skin to the administered dose, such that areas
with additional mechanic stress like skin folds are more sensitive to irradiation. Second, high
local doses can lead to permanent non-healing skin reactions, e.g. an increased risk of ulcers
was seen with doses above 70 Gy (Herrmann et al. 2006). Third, the area of the skin which is
exposed to a certain dose is a relevant factor, e.g. an increased risk of the development of a skin
reaction was seen for contiguous skin areas receiving 50–60 Gy. Therefore, DVH parameters
taken for evaluation comprised the highest mean dose to a skin area of 25 cm2 (D25cm2) and the
volume receiving dose above 70 Gy(RBE) (V70 Gy(RBE)).
Other side effects In addition to the described side effects, the induction of secondary cancer
in different tissues may be a consequence of RT treatment. Secondary cancer is induced by cell
mutations, which may be generated by RT when cells are damaged but not killed. The proba-
bility of the secondary cancer induction depends on the tissue architecture and is tissue specific
(Schneider et al. 2011). Most models are developed for radiation protection reasons considering
much smaller doses than in-field or out-of-field doses in RT and are based on survivors of nu-
clear bombs. These models cannot be simply transferred to the clinical setting considering the
fractionated treatment in contrast to an one-time exposure (Schneider 2011). Induced secondary
solid cancer usually develops several years after RT. For the HNSCC patients in the presented
study, the survival rates are usually too low to find secondary cancers, such as that no valid mod-
els for this patient cohort exist. The integral dose within the patient body excluding the PTV was
considered as DVH parameter giving an estimation of secondary cancer risk.
Furthermore, effects of high local doses in unspecified tissue are relevant to assess for dose
escalation treatment schedules. Such high dose effects can be ulceration, interstitial bleeding
and necrosis (Boersma et al. 1998; Madani et al. 2011). However, dose-effect relationships are
difficult to determine since they cannot be based on a specific organ. In the presented treatment
planning study high local doses are planned in close proximity to the SIB volume due to the dose
escalation schedule. As parameter for non-organ specific complications due to high doses, the
volume exceeding 107 % of the prescribed dose (V107) in the target structure were assessed.
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3.3 Results
In Section 3.3.1, the assessment of the treatment plan quality, the fulfilment of the treatment
planning goals and the absolute values of the NTCP and DVH parameters are described. The
detailed analyses of differences in NTCP and DVH parameters for the three examined topics,
dose escalation feasibility, benefit of PT and feasibility of subgrouping, are shown in the Sections
3.3.2 – 3.3.4.
3.3.1 Assessment of treatment plan quality
General For all 45 patients, clinically acceptable treatment plans were generated for all three
treatment series with IMXT and IMPT. The accumulated dose distribution of two representative
patients is visualised for IMXT, IMPT and the additionally generated mixed modality treatment in
Figure 3.5 for the high dose escalation level.
Figure 3.5: Accumulated dose distribution overlaid on a sagittal CT slice of two representative patients
with all three treatment schedules (IMXT, IMPT and mixed modality) planned for the high dose escalation
level of 2.6 Gy(RBE). For the patient of Subgroup A the dose to the larynx area is reduced with IMPT, while
for the patient of Subgroup B the oral mucosa was better spared. A reduction of dose in the neck area
can be seen in both cases. The dose distribution for the mixed modality treatment shows the intermediate
results of this treatment compared to IMXT and IMPT. Delineated organs are described in Figure 3.3.
All plans fulfilled the treatment planning goal of at least 95 % of the target structure receiv-
ing doses higher than 95 % of the prescribed dose, except for the plans of one patient with a
large lymph node included in the GTVSIB which expanded close to the brachial plexus. Boost
coverage in this case was impaired due to the priority of the brachial plexus. No volumes > 2 %
exceeding 107 % of the prescription dose occurred for the GTVSIB, while these volumes were
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constrained to the volume surrounding the GTVSIB for the PTV. The treatment planning goals
for the prioritised OAR spinal cord, brain stem and brachial plexus were fulfilled in all cases,
while these were missed for the subordinated OAR in several patient cases due to the priority
of the target coverage. NTCP values for myelitis and brain stem necrosis were 0 % in all cases,
as targeted. For the other NTCP models, a large spread in NTCP values for the patient cohort
was seen, with high probability of development for larynx oedema (91 % with IMXT) and medium
probability (approx. 50 % with IMXT) for oral mucositis, aspiration and physician-rated swallow-
ing dysfunction. Smaller probabilities were seen for xerostomia, trismus, brachial plexopathy and
patient-rated problems with swallowing solid and liquid food. A correlation between the magni-
tude of the distance of the GTV surface to the center of mass of the OAR and the magnitude
of the respective NTCP value was revealed for mucositis, patient-rated difficulties in swallowing
liquid food and larynx oedema, while the other NTCP models showed no correlation. In order to
maintain a good readability of the results, a shortened table of the NTCP values, Table 3.6, is
shown here, which focuses on the main toxicity domains as described in Section 3.2.6 including
only one of the NTCP models when several models for one toxicity domain exist. Tabular results
of the conformance of the treatment planning goals as well as the complete data of the absolute
NTCP values and DVH parameters are shown in the Appendix A in Tables A.1–A.3. NTCP values
and DVH parameters were similar for the treatment with the high dose escalation level and are
given in detail in the Appendix A, Tables A.4 and A.5.
Table 3.6: Patient cohort and patient subgroup specific values for NTCP (%) of the main toxicities based
on the accumulated dose distributions for treatment with the low dose escalation of 2.3 Gy(RBE), median
(range: P5–P95).
Toxicity
parameter
[No. of patients
all (A, B, C)]
IMXT Mixed modality IMPT
All patients All patients All patients
A B C A B C A B C
Oral 47 (32–57) 46 (30–56) 42 (19–55)
mucositis 54 37 46 54 35 44 53 25 41
[45 (18, 13, 14)] (47–59) (25–42) (37–54) (45–58) (25–40) (36–53) (41–58) (15–34) (29–52)
Xerostomia 17 (8–41) 13 (6–35) 6 (2–15)
(12 months) 20 14 20 14 13 15 7 6 6
[45 (18, 13, 14)] (11–42) (6–22) (12–45) (9–34) (6–17) (9–39) (2–14) (3–7) (3–22)
Physician-rated 50 (28–63) 43 (25–58) 36 (18–56)
swall. dysfunction 50 35 60 42 34 53 36 28 49
[37 (17, 10, 10)] (41–57) (18–50) (40–66) (28–50) (16–49) (36–65) (21–48) (7–46) (31–63)
Ipsil. brachial 22 (0–28) 22 (0–28) 22 (0–28)
plexopathy 17 22 23 10.1 22 23 10.8 22 22
[45 (18, 13, 14)] (0–27) (5–28) (3–29) (0–27) (3–26) (1–30) (0–26) (4–26) (1–28)
Trismus 31 (24–39) 30 (24–38) 25 (23–30)
[45 (18, 13, 14)] 33 28 30 32 28 30 26 25 25
(25–49) (24–32) (24–37) (25–44) (24–32) (24–37) (23–36) (23–28) (23–29)
NTCP values for myelitis and brain stem necrosis were 0 % in all cases.
NTCP values for all evaluated models are given in Appendix A in Table A.2
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Photon plan quality The comparison between step and shoot IMXT plans and rotational VMAT
plans revealed similar target volume coverage and mean target doses for both techniques. All
treatment plans fulfilled the mandatory treatment planning goals. The additional subordinated
treatment planning goals were similarly exceeded if required for target coverage fulfilment. How-
ever, absolute dose differences of > 2 Gy(RBE) in DVH parameters were seen for all OAR in
individual cases reflecting different treatment planning approaches used in the two institutions.
This is in accordance with a study by Tol et al. (2014) revealing the impact of different treat-
ment planning protocols. In case of contradictory dose constraints between targets and OAR,
emphasis was set differently for OAR with the same priority in the treatment planning optimisa-
tion process. The visual comparison between the treatment plans created with IMXT and VMAT
illustrates these differences in the treatment planning approaches, cf. Figure 3.6. For example,
sparing of the spinal cord was achieved by sparing a stripe of the neck with the IMXT plans.
The VMAT plans spared the spinal cord with a margin ring, not emphasizing the neck area. The
results of the DVH parameters with specific treatment planning goals are presented in Table 3.7.
Differences were randomly distributed and did not show a benefit for one of the photon treatment
techniques. This indicates that the seen differences are variations of treatment planning and not
generally technique dependent.
Altogether, the treatment plans were similarly acceptable for the patient treatment. The created
static beam IMXT plans are of good quality and comparable to the second independent institution
which used another intensity-modulated technique, VMAT. Thus, it can be assumed that the
quality of the generated IMXT plans is representative for modern XT treatment. This suggests,
that differences between IMXT and IMPT in the presented treatment planning study will not be
caused by inferior photon plan quality.
Table 3.7: DVH parameters for five patients comparing step and shoot IMXT with VMAT, median (range:
min–max). PTV and GTV parameters are averaged over the separate treatment series, while OAR doses
are calculated on the accumulated dose distributions.
Delineated volume Treatment planning goal IMXT VMAT
Spinal cord Dmax ≤ 45 Gy(RBE) 40.8 (38.3–41.8) 34.2 (31.3 –36.4)
Brain stem Dmax ≤ 54 Gy(RBE) 35.0 (13.7–46.4) 31.0 (12.9–40.3)
Contral. brachial plexus1 Dmax ≤ 72 Gy(RBE) 56.3 (51.1–70.7) 57.6 (49.6–69.9)
Ipsil. brachial plexus1 Dmax ≤ 72 Gy(RBE) 71.0 (51.3–71.8) 67.9 (50.5–70.1)
GTVSIB2 V953 ≥ 95 % 99.6 (97.9 –100.0) 100.0 (99.4 –100.0)
Dmean, rel. = 100 %3 100.0 (99.7 –100.3) 100.9 (100.1 –101.6)
PTV V953 ≥ 95 % 98.3 (96.8–99.5) 98.0 (97.1–99.4)
Dmean, rel. = 100 %3 101.8 (100.4 –104.1) 101.5 (100.8 –104.8)
Contral. parotid gland1 Dmean ≤ 26 Gy(RBE) 23.7 (16.7–34.8) 25.2 (21.6–33.8)
Ipsil. parotid gland1 Dmean ≤ 26 Gy(RBE) 31.7 (24.9–41.9) 35.7 (31.8–48.6)
Glottic larynx D2 ≤ 70 Gy(RBE) 65.5 (44.0–77.1) 63.5 (48.2–76.0)
Supraglottic larynx D2 ≤ 80 Gy(RBE) 73.5 (71.4–78.8) 72.8 (71.4–78.0)
Complete larynx4 Dmean ≤ 45 Gy(RBE) 54.0 (44.2–71.1) 56.2 (47.6–69.4)
Mandible D1ml ≤ 75 Gy(RBE) 74.6 (67.0–75.2) 72.4 (69.0–73.1)
1 Pairwise organs: ipsilateral is organ with higher, contralateral organ with lower dose
2 Evaluation of Series II, III 3 Percentage of prescribed dose 4 Union of glottic and supraglottic larynx
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Figure 3.6: Accumulated dose distribution overlaid on CT slices of two representative patients planned
with step and shoot IMXT (left) and VMAT (right). White lines (a,b,c and d,e,f) indicate the CT layers
where the three axial slides are located. Delineated organs are described in Figure 3.3.
3.3.2 Feasibility of the treatment intensification schedule
Dose differences between the two dose escalation levels for IMXT, IMPT and the mixed modality
treatment are depicted with sagittal CT slices for two representative patients in Figure 3.7, show-
ing that the main dose differences are, as expected, inside the target boost area. Furthermore,
IMXT treatment planning led to more inhomogeneous dose distributions such that dose variations
around ± 2 Gy(RBE) between different treatment plans occur outside the targeted volume.
Target structures Differences in the target parameters caused by the two different dose es-
calation levels can be expected to occur in V95 of the GTVSIB, V107 of the PTVring and Dmean of
both structures. Comparing V95 of the GTVSIB for the high dose escalation to the low dose es-
calation revealed a median decrease of 0.9 % (-2.4 %–0.0 %) and 0.6 % (-2.1 %–0.0 %) for IMXT
and IMPT, respectively. The prescribed value of V95 ≥ 95 % was fulfilled for all but one patient
who had a GTVSIB in close proximity to the brachial plexus. For this patient a V95 of 95 % in
Series III was not achievable for both IMPT and IMXT plans with the high dose escalation level,
due to the priority of the brachial plexus. The targeted V95 was fulfilled for the low dose esca-
lation using IMXT, but slightly missed with IMPT. This difference in coverage between the two
modalities was caused by the larger uncertainty margin required for the brachial plexus for proton
treatment planning compared to photon treatment planning. V107 of the PTVring was increased
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Figure 3.7: Dose differences between the two dose escalation levels of 2.6 Gy(RBE) and 2.3 Gy(RBE)
overlaid on sagittal CT slices for IMXT, mixed modality treatment and IMPT for the two representative
patients of Figure 3.5. The main dose differences are, as expected, inside the target boost area. Further-
more, the higher variability in the dose distribution with photon treatment is visible with the bigger areas of
dose differences around ± 2 Gy(RBE), increased dose is depicted in green and red and reduced dose in
blue and purple. Delineated organs are described in Figure 3.3.
by a median value of 3.5 % (1.1 %–10.9 %) for IMXT, while the value for IMPT did not change
between the two dose escalation levels with 0.1 % (0.0 %–1.8 %). This is caused by the larger
high-dose rim surrounding the GTVSIB as a consequence of the less steep dose gradient with
photons. The relative dose distribution depicted in Figure 3.8 visualise this effect showing doses
exceeding the allowed 107 % of the prescribed dose in an exemplary case. This increase in size
of the high-dose rim is also reflected in the slightly increased relative mean dose in the PTVring
for IMXT of 0.7 % (0.2 %–1.6 %) in contrast to IMPT with 0.1 % (-0.1 %–1.1 %). The relative mean
dose of the GTVSIB was not influenced by the dose escalation level. Other target parameters did
not show any dependence on the dose escalation level, as expected.
NTCP models The evaluation of ∆NTCPDE values revealed only a small increase in toxicity
risk using the higher dose escalation level for most of the evaluated models, with slightly higher
median values for IMXT compared to IMPT. Moderate differences with a median increase of
≥ 5 % in NTCP occurred only for one endpoint, the aspiration model, with 9 % (3 %–16 %) for
IMXT and 5 % (1 %–17 %) for IMPT (p < 0.001). Small differences with median ∆NTCPDE be-
tween 1–2 % (0 %–5 %) were seen in other models of swallowing dysfunctions related toxicities
(physician-rated swallowing dysfunctions and patient-rated difficulties in swallowing solid food,
both p < 0.001). All other NTCP models showed median ∆NTCPDE changes of < 1 % (-3 %–4 %)
with no significance for myelopathy, brain stem necrosis, oral mucositis, xerostomia, brachial
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Figure 3.8: Relative dose distribution of Series II overlaid on axial CT slices of an exemplary patient illus-
trating the increase in the high-dose rim with the high dose escalation level of 2.6 Gy(RBE) resulting in
increased V107 and Dmean values especially for IMXT.
plexopathy and trismus. Substantial disadvantages with ∆NTCPDE ≥ 10 % were seen for the
aspiration model for 14 of 45 patients with IMXT and 8 of 45 patients with IMPT. In all other mod-
els, even moderate disadvantages were found only rarely: with IMXT treatment six patients had
∆NTCPDE ≥ 5 % in single toxicities, all related to swallowing dysfunction. With IMPT no case
occurred above that threshold. Variations in ∆NTCPDE between different individuals were small
for all NTCP models except for aspiration. These variations were smaller for IMPT than for IMXT.
Due to the independent treatment plan creation, an increase in dose escalation led to a reduction
of toxicity risk of up to -2 % for some patients, particularly when the distance between GTVSIB and
impacted OAR was large. Thus, differences of this magnitude can be seen as variations caused
by the treatment planning. Higher toxicity risk reductions for the high dose escalation level oc-
curred only with the model for brachial plexopathy, due to the steep dose-response relationship
around the set dose constraint. In this model, a difference of 0.1 Gy(RBE) already leads to a
NTCP difference of 0.5 %. ∆NTCPDE values for all patients are visualised in Figure 3.9 for IMXT
and IMPT.
DVH parameters of organs at risk All evaluated DVH parameter had median ∆DDE and ∆VDE
below 1 Gy(RBE) and below 1 ml for both modalities. Hence, the biological impact of the dose
escalation is probably small for the evaluated OAR, comparable to the minor impact revealed in
the ∆NTCPDE evaluation of toxicities in OAR with applicable models. The differences of DVH
parameters between the two dose escalation levels for all patients are visualised in Figure 3.10.
3.3.3 Impact of treatment modality
Dose differences between IMXT and the mixed modality treatment as well as between IMXT and
IMPT are depicted with sagittal CT slices for two representative patients in Figure 3.11. The main
dose differences are outside the target volume, with higher dose differences for the IMXT versus
the IMPT treatment than with the IMXT versus the mixed modality treatment. The dose escalation
level had almost no impact on the NTCP and DVH parameter differences of OAR, as it has been
shown in Section 3.3.2. Thus the modality evaluation mainly focuses on the results of the low
dose escalation level of 2.3 Gy(RBE).
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Figure 3.9: Individual NTCP differences between the two dose escalation levels (∆NTCPDE) for the eval-
uated toxicity models for the whole patient cohort illustrated with boxplots including mean values (small
square). ∆NTCPDE for the IMXT treatment is shown in dark grey, ∆NTCPDE for the IMPT treatment in
light grey. Values above 0 (black dotted line) indicate an increased risk with the higher dose escalation.
Figure 3.10: Individual differences of DVH parameters between the two dose escalation levels (∆DDE and
∆VDE) for the OAR without adequate toxicity modelling for the whole patient cohort illustrated with boxplots
including mean values (small square). DVH differences for the IMXT treatment are shown in dark grey,
DVH differences for the IMPT treatment in light grey. Values above 0 (black dotted line) indicate increased
dose parameter values with the higher dose escalation.
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Figure 3.11: Dose differences between IMXT and mixed modality treatment (left) as well as between IMXT
and IMPT (right) with the low dose escalation level of 2.3 Gy(RBE) overlaid on sagittal CT slices for the two
representative patients of Figure 3.5. The main dose differences are outside the target volume, with higher
dose differences for the IMPT versus IMXT treatment than with the mixed modality treatment. Delineated
organs are described in Figure 3.3.
Target structures The dose distributions in terms of target coverage in the PTV and the GTVSIB
were similar for IMXT and IMPT with both dose escalation levels. Differences in V95 were -0.9 %
(-2.1 %–0.3 %) and -1.0 % (-2.0 %–0.1 %) in median for the PTV with the low dose escalation level
of 2.3 Gy(RBE) and the high dose escalation level of 2.6 Gy(RBE), respectively, mainly caused
by the build-up effect of photons. For GTVSIB median differences were 0.0 % (-1.1 %–0.9 %) and
-0.3 % (-2.2 %–1.6 %). Differences of volumes with high doses in terms of V107 of the PTVring
were 0.1 % (0.0 %–1.9 %) for the low dose escalation level, while larger differences of 3.6 %
(1.0 %–10.8 %) occurred for the high dose escalation level, revealing the effect of the less steep
dose gradient of photons. For the GTVSIB differences in V107 were negligible (0 % in all cases
but one). Relative mean doses in the target volumes were almost the same for the GTVSIB with
median differences of -0.1 % (-0.6 %–0.2 %) for both dose escalation levels, while higher mean
doses in the PTVring occurred for IMXT with 0.7 % (-0.3 %–1.6 %) and 1.3 % (-0.3 %–2.8 %) for
the two dose escalation levels, again showing the impact of the less steep dose gradient. The
effect of the increase in high dose areas (V107) on the mean dose is partially compensated by the
reduced V95 in the PTV achieved with IMXT compared to IMPT. The treatment with IMXT resulted
in higher dose inhomogeneities in the target volumes, although the specified range according to
the ICRU of 95 % and 107 % of the prescribed dose were still met. This is shown by the relative
dose distribution in Figure 3.12. The integral dose in the patient body represented by the patient
body contour in the CT image series was doubled using IMXT.
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Figure 3.12: Relative dose distribution of Series II overlaid on axial CT slices of an exemplary patient
illustrating the higher dose inhomogeneity in the IMXT treatment compared to IMPT.
NTCP models Independent of the dose escalation level, the evaluation of ∆NTCPMod values
revealed equal or less toxicity risk for all considered models using IMPT (p < 0.001 for all mod-
els), cf. Figure 3.13. A substantial benefit from IMPT with a median ∆NTCPMod ≥ 10 % was
revealed for 4 of 12 considered toxicities with the low dose escalation level: xerostomia as-
sessed 6 and 12 months after treatment), aspiration and physician-rated swallowing dysfunction
with 19 % (8 %–32 %), 12 % (5 %–28 %), 20 % (3 %–38 %) and 10 % (3 %–19 %), respectively.
Moderate differences (∆NTCPMod ≥ 5 %) occurred in 4 of 12 evaluated endpoints: oral mucosi-
tis, patient-rated difficulties in swallowing solid food, larynx oedema and trismus with 5 % (1 %–
13 %), 9 % (3 %–15 %), 6 % (0 %–40 %) and 5 % (1 %–11 %), respectively. Median ∆NTCPMod
for brachial plexopathy were small with 1 % (-4 %–8 %). However, for this toxicity the use of IMPT
led to increasing NTCP values for individual patients with close proximity between target area
and brachial plexus. In such cases, doses to the brachial plexus were at the allowed limit for both
IMXT and IMPT, leading to NTCP values which vary similarly around the same values due to
the steep dose-response relationship, without a clear benefit for one treatment modality. All other
considered endpoints (myelopathy, brain stem necrosis and patient-rated difficulties in swallowing
liquids) had median ∆NTCPMod < 1 % (0 %–3 %).
The mixed modality treatment, i.e. the use of IMPT for the sequential boost in Series III only,
revealed significant (p < 0.001 for all models) but lower ∆NTCPMixMod values in all NTCP models
compared to ∆NTCPMod, cf. Figure 3.13. Only the toxicity model for aspiration still showed
substantial benefit with median ∆NTCPMixMod of 12 % (1 %–27 %). Moderate benefit was also
seen in only one toxicity, the physician-rated swallowing dysfunction with median ∆NTCPMixMod
of 6 % (0 %–11 %). All other NTCP models had ∆NTCPMixMod < 5 %, including seven models with
median ∆NTCPMixMod < 2 %. For some patients even small increases in NTCP with the mixed
modality treatment in comparison to the IMXT treatment were revealed. This demonstrates the
impact of the target volume reduction in sequential boost treatment allowing in a few cases for
favourable dose distributions for some OAR with IMXT compared to IMPT.
Large variations in ∆NTCPMod were identified for the patient cohort, indicating large differ-
ences in the benefit for individual patients. ∆NTCPMod ranges of ≥ 10 % were seen in most
of the evaluated toxicities, except for myelopathy, brain stem necrosis, patient-rated difficulties
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Figure 3.13: Individual NTCP differences between IMXT and IMPT (∆NTCPMod, dark grey boxes), as well
as between IMXT and mixed modality treatment (∆NTCPMixMod, light grey boxes) for the treatment with
the low dose escalation level of 2.3 Gy(RBE) for the evaluated toxicity models for the whole patient cohort
illustrated with boxplots including mean values (small square). Values above 0 (black dotted line) indicate
beneficial results for IMPT and the mixed modality treatment, respectively.
with swallowing liquids and choking when swallowing. Such ranges for the mixed modality treat-
ment were only seen for toxicities evaluating swallowing dysfunctions, but individual outliers in
xerostomia and brachial plexopathy showed large differences as well. Of the seven different tox-
icity domains in patients’ quality of life, cf. Section 3.2.6, five had modelled NTCP values above
0 % (all except for myelitis and brain stem necrosis). Focusing on one NTCP model for each of
these five domains, i.e. choosing one swallowing dysfunction related model and one xerostomia
model as representative for their respective domain, the number of patients with substantial ben-
efit (∆NTCPMod ≥ 10 %) were 6, 28, 19, 4 and 1 for oral mucositis, xerostomia 12 months after
treatment, physician-rated swallowing dysfunction, trismus and brachial plexopathy, respectively.
With the mixed modality treatment the patient number with substantial benefit was reduced to
0, 2, 6, 0 and 1, cf. Table 3.8. A patient-wise evaluation determining the number of the above
described five toxicities with ∆NTCP≥ 10 % per patient reflected as well the small effect of using
PT for the sequential boost only compared to the complete treatment with IMPT. Using the proton
boost, only 1 of 45 patients had a ∆NTCP≥ 10 % in at least two toxicities, 7 patients in one and
37 patients in none of the toxicities. In contrast, such a NTCP reduction was possible with pure
IMPT for 19, 17 and 9 patients, respectively. ∆NTCPMod and ∆NTCPMixMod values were only
slightly different between the low and the high dose escalation level leading to similar results with
the same general tendency, cf. Table 3.8.
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Table 3.8: Individual NTCP differences (%) between different modalities based on accumulated dose
distributions for complete patient cohort of 45 patients, median (range: P5–P95). Number of patients with
substantial NTCP benefit (∆NTCP≥ 10 %).
Toxicity
parameter1
2.3 Gy(RBE) 2.6 Gy(RBE)
∆NTCPMod / % ∆NTCPMixMod / % ∆NTCPMod / % ∆NTCPMixMod / %
Number of patients with substantial benefit (∆NTCP≥ 10 %)
Oral 5 (1–13) 1 (0–3) 5 (1–12) 1 (0–3)
Mucositis 6 0 7 0
Xerostomia 19 (8–32) 5 (1–9) 19 (9–32) 5 (0–9)
(6 months) 41 2 41 1
Xerostomia 12 (5–28) 4 (0–9) 12 (5–30) 4 (0–10)
(12 months) 28 2 29 2
Aspiration 20 (3–38) 12 (1–27) 23 (3–42) 11 (0–30)
35 25 35 23
Physician-rated 10 (3–19) 6 (0–11) 11 (5–20) 6 (0–12)
swall. dysfunction 19 6 24 6
Problems 9 (3–15) 5 (0–9) 11 (5–16) 5 (0–10)
swallowing solids 14 2 19 2
Problems 1 (0–3) 1 (0–2) 2 (1–3) 1 (0–2)
swallowing liquids 0 0 0 0
Larynx 6 (0–40) 2 (0–16) 7 (0–42) 1 (0–19)
oedema 19 7 19 7
Ipsil. brachial 1 (-4–8) 1 (-2–5) 1 (-3–8) 1 (-2–8)
plexopathy 1 1 1 1
Trismus 5 (1–11) 0 (0–2) 5 (1–11) 0 (0–2)
4 0 4 0
1NTCP values for myelitis and brain stem necrosis are not listed (0 % in all cases)
DVH parameters of organs at risk All evaluated DVH parameters were significantly increased
(p < 0.001) using IMPT except for skin doses, where IMXT allowed for a significant reduction
(p < 0.001). ∆DMod ≥ 5 Gy(RBE) was seen in Dmean for the contralateral submandibular gland
with 5.5 Gy(RBE) (1.0 Gy(RBE)–11.8 Gy(RBE)) and both sublingual glands with 5.6 Gy(RBE)
(0.2 Gy(RBE)–17.6 Gy(RBE)). Such an increased dose in the small salivary glands with IMXT
may contribute to an additional increase in xerostomia risk, not included in the used xerosto-
mia model (Jellema et al. 2005; Murdoch-Kinch et al. 2008). Dcirc of the oesophagus showed a
median increase of 24.3 Gy(RBE) (0.4 Gy(RBE)–33.4 Gy(RBE)). This may lead to an increased
risk of oesophageal strictures, due to the loss of elasticity of the whole transverse section of the
oesophagus. Furthermore, the median ∆VMod of V50 Gy(RBE) for the mandible was 4.9 ml (0.2 ml–
12.7 ml) which may increase the risk of osteoradionecrosis slightly. For the D25cm2 of the skin,
median ∆DMod was -4.8 Gy(RBE) (-14.4 Gy(RBE)–2.8 Gy(RBE)), indicating a better skin sparing
with IMXT due to the build-up effect. Hence, the use of IMPT may lead to a higher incidence
of side effects in the skin such as moist desquamation or necrosis, comparably to the use of
orthovolt RT. All other evaluated DVH parameters showed rather small changes for the patient
cohort with median ∆DMod < 2 Gy(RBE) or ∆VMod < 2 ml.
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The use of the mixed modality treatment revealed smaller differences in DVH parameters com-
pared to the differences between IMXT and IMPT. The median ∆DMixMod of the contralateral
submandibular gland, the sublingual glands and the skin were below 5 Gy(RBE) and the median
∆VMixMod of the mandible below 5 %, although the differences were still significant (p < 0.001). For
all other organs the median DVH parameter differences were smaller with ∆DMixMod < 0.5 Gy(RBE)
and ∆VMixMod< 0.5 ml.
The DVH parameter differences are illustrated in Figure 3.14 for the low dose escalation level
of 2.3 Gy(RBE). The use of the high dose escalation schedule led, as expected, to an only small
increase in the DVH parameter differences compared to the low dose escalation, without influ-
encing the general tendency.
Figure 3.14: Individual differences of DVH parameters between IMXT and IMPT (∆DMod and ∆VMod, dark
grey boxes), as well as between IMXT and mixed modality treatment (∆DMixMod and ∆VMixMod, light grey
boxes) for the treatment with the low dose escalation level of 2.3 Gy(RBE) for OAR without adequate tox-
icity modelling for the whole patient cohort illustrated with boxplots including mean values (small square).
Values above 0 (black dotted line) indicate beneficial results for IMPT and the mixed modality treatment,
respectively.
3.3.4 Evaluation of subgroup assignment
A large spread in toxicity, estimated in terms of NTCP and DVH differences, for the whole patient
cohort may be caused by several homogeneous subgroups of patients defined by an additional
clinical parameter, which could be used for patient selection in PT. The presented treatment
planning study focused on the evaluation of the primary tumour location as clinical parameter, as
this information is routinely assessed before treatment. The subgroup influence was evaluated if
NTCP and DVH differences were in a relevant magnitude indicating an at least moderate NTCP
benefit with the 95 % percentile of ∆NTCP values ≥ 5 % and of ∆D values exceeding 3 Gy(RBE)
or ∆V ≥ 2 ml, respectively. Furthermore, the evaluation was limited to parameters where a
relevant spread in NTCP and DVH differences for the whole patient cohort could be identified.
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Impact of dose escalation level With the described requirements, subgroup evaluation of
∆NTCPDE was limited to two toxicities, aspiration and patient-rated difficulties in swallowing solid
food. The subgroup evaluation of DVH differences between the dose escalation levels focused
on five parameters, Dmean of the contra-lateral small salivary glands, D2 of the carotid sinus, D1ml
of the mandible and D25cm2 of the skin. Significant differences between the subgroups were iden-
tified for only two parameters: first, for patient-rated difficulties in swallowing solid food for IMXT,
indicating a larger effect of the dose escalation for Subgroup A compared to Subgroup C with me-
dian 1 % (0 %–3 %) for Subgroup A versus 3 % (1 %–5 %) for Subgroup C (p = 0.004). Second, a
significant difference was found for D1ml of the mandible for both modalities, revealing a higher
impact of the dose escalation for Subgroup A compared to the other two subgroups with median
3.8 Gy(RBE) (0.5 Gy(RBE)–5.3 Gy(RBE)) for Subgroup A versus 0.0 Gy(RBE) (-0.4 Gy(RBE)–
0.3 Gy(RBE)) and 0.4 Gy(RBE) (-0.5 Gy(RBE)–2.5 Gy(RBE)) for Subgroup B and C (p < 0.001 for
both subgroups for both modalities). All other parameters showed no subgroup dependence and
were increased by the higher dose escalation level similarly for all patients of the three subgroups.
Impact of treatment modality Considering the described requirements, the subgroup evalu-
ation excluded only myelitis, brain stem necrosis and patient-rated difficulties in swallowing liq-
uids as well as Dmean of the ipsi-lateral submandibular gland, V60 Gy(RBE) of the oesophagus and
V70 Gy(RBE) of the skin. For the remaining toxicities, statistically significant differences between
∆NTCPMod values of the three subgroups were found for oral mucositis, both xerostomia mod-
els, aspiration, physician-rated swallowing dysfunction, patient-rated difficulties with swallowing
solid food, larynx oedema, trismus and V50 Gy(RBE) of the mandible. These results are illustrated
in Figure 3.15 for the low dose escalation level and are further described below. The use of the
high dose escalation level led, as expected, to similar results.
The benefit of IMPT for mucositis was significantly different for all three subgroups, favouring
Subgroup B (p < 0.001 for Subgroup B versus Subgroup A and C, p = 0.005 for Subgroup A ver-
sus Subgroup C). As a consequence, only patients of Subgroup B had ∆NTCPMod ≥ 10 %. In
contrast, patients of Subgroup B had significantly less benefit from IMPT for xerostomia 6 and 12
months after treatment than patients of Subgroup A (p = 0.001 and p = 0.017) and C (p = 0.003
and p = 0.030). The threshold of ∆NTCPMod ≥ 10 % was more frequently fulfilled for patients of
Subgroup A and C with about three quarters of these patients having values above the threshold
for xerostomia 12 months after treatment while less than one quarter of the patients of Sub-
group B reached that value. An increased benefit for Subgroup A compared to the other two
subgroups was also found for dysphagia related toxicities like aspiration, patient-rated difficulties
with swallowing solid food, larynx oedema (p < 0.001 for Subgroup A versus Subgroup B and
C in all three cases) and physician-rated swallowing dysfunction (p = 0.003 for Subgroup A ver-
sus Subgroup B, p = 0.001 for Subgroup A versus Subgroup C). This was again reflected in the
number of patients eligible for PT according to a threshold of ∆NTCPMod ≥ 10 %: on average
more than three quarters of patients of Subgroup A had values above that threshold while this
was the case for only one quarter of Subgroup B or C. For trismus, a larger benefit was de-
termined for Subgroup A compared to Subgroup B (p < 0.006), with three of four patients who
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Figure 3.15: Subgroup-dependent evaluation of individual NTCP and DVH parameter differences
(∆NTCPMod and ∆VMod) between IMXT and IMPT for treatment with the low dose escalation level of
2.3 Gy(RBE) illustrated with boxplots including mean values (small square). The separation of the individ-
ual patient differences between the subgroups indicates the potential of subgrouping for identification of
patients with higher benefit.
had ∆NTCPMod ≥ 10 % originating of Subgroup A. The patient-wise evaluation of the number
of toxicities with ∆NTCPMod ≥ 10 % for the seven different toxicity domains impacting on the
patients’ quality of life emphasised this subgroup dependence, cf. Figure 3.16: for 14 patients
of Subgroup A the risk of at least two toxicities could be reduced by the designated threshold,
while this was valid only for 3 and 2 patients of Subgroup B and C, respectively. For DVH pa-
rameter differences, only V50 Gy(RBE) of the mandible showed significant subgroup differences,
with less benefit for Subgroup B (p = 0.032 and p = 0.014 for Subgroup B versus Subgroup A
and C, respectively). Using the mixed modality treatment, i.e. PT only for the sequential boost,
the number of patients with ∆NTCPMixMod ≥ 10 % was distinctly smaller. However, the same
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tendency in subgroup dependence was still observable with 6 patients of Subgroup A with a re-
duction of at least one toxicity above 10 %, but 0 and 1 patient of Subgroup B and C, respectively.
∆NTCPMod, ∆NTCPMixMod and the number of patients of each subgroup with substantial benefit
(∆NTCP≥ 10 %) are shown in Table 3.9.
Figure 3.16: Number of toxicities per patient with ∆NTCPMod ≥10 % (black) and ∆NTCPMixMod ≥10 %
(grey) for treatment with the low dose escalation level of 2.3 Gy(RBE). Evaluated were seven toxicities rep-
resenting the seven evaluated toxicity domains: myelitis, brain stem necrosis, oral mucositis, xerostomia
12 months after treatment, physician-rated dysphagia, brachial plexopathy and trismus, of which the first
two toxicities were 0 % in all patient cases. Patient subgroups are indicated by the different colours: green
for Subgroup A, pink for Subgroup B and blue for Subgroup C.
3.4 Discussion
The presented comprehensive treatment planning study was conducted to examine the three
following aspects of HNSCC RT treatment in detail:
1. Is the created treatment schedule based on biological imaging and including a dose esca-
lation for treatment intensification feasible and which impact has the dose escalation level?
2. What is the expected benefit of PT over modern XT and is there an advantage of the use
of PT for a sequential boost only?
3. Is it possible to subgroup HNSCC patients according to the primary tumour location for the
identification of patients with a high disadvantage of dose escalation or for the identification
of patients with the most benefit of PT?
All evaluations were based on modern NTCP models and DVH parameters derived from the
dose distributions of the generated treatment plans. The chosen evaluation parameters were de-
fined after discussion with experienced clinicians. The plan quality of the IMXT treatment plans
was evaluated by comparing these plans with VMAT plans generated independently in another
institution. The comparison revealed similar quality of the two treatment planning concepts, al-
though showing differences in the treatment planning approach (cf. Section 3.3.1). IMPT plans
were indirectly quality assured by checking the results of the modality comparison against already
published treatment planning studies (details in Section 3.3.3 and Section 3.4.2). The presented
analysis confirms the results of other treatment planning studies. The strength of the presented
examinations is the large number of patients which allowed for the evaluation of subgroup de-
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Table 3.9: Individual NTCP differences (%) between different modalities for patient subgroups based on
accumulated dose distributions, median (range: P5–P95). Number of patients per subgroup with substan-
tial NTCP benefit based on 18, 13, 14 patients of Subgroup A, B, C, respectively.
Toxicity
parameter1
2.3 Gy(RBE) 2.6 Gy(RBE)
∆NTCPMod / % ∆NTCPMixMod / % ∆NTCPMod / % ∆NTCPMixMod / %
Patient subgroup Patient subgroup Patient subgroup Patient subgroup
A B C A B C A B C A B C
Number of patients with substantial benefit (∆NTCP≥ 10 %)
Oral 2 10 6 1 1 1 3 11 6 1 1 1
Mucositis (1–6) (6–15) (2–9) (0–3) (0–3) (1–3) (1–6) (6–14) (2–9) (0–3) (0–2) (1–3)
0 6 0 0 0 0 0 7 0 0 0 0
Xerostomia 22 14 19 7 2 5 22 14 19 7 2 5
(6 months) (12–34) (8–21) (13–28) (3–11) (0–5) (0–8) (11–35) (8–21) (12–29) (3–10) (0–5) (0–8)
17 10 14 2 0 0 17 10 14 1 0 0
Xerostomia 13 9 14 5 1 3 14 8 13 5 1 3
(12 months) (6–32) (3–15) (7–27) (2–10) (0–4) (0–8) (6–33) (3–15) (7–28) (2–11) (0–4) (0–9)
15 3 10 2 0 0 15 4 10 2 0 0
Aspiration 31 13 17 23 5 8 36 11 20 22 4 6
(19–40) (2–19) (3–26) (13–30) (0–13) (0–14) (21–45) (4–26) (2–27) (10–32) (-1–13) (0–12)
18 8 9 17 2 6 18 9 8 17 2 4
Physician-rated 14 9 9 8 2 4 14 10 10 7 2 4
swallowing (8–21) (3–15) (3–11) (3–14) (0–6) (1–7) (8–22) (4–16) (5–13) (4–15) (-1–6) (1–7)
dysfunction 14 3 2 6 0 0 14 5 5 6 0 0
Problems 11 7 7 7 1 3 12 7 8 6 2 3
swallowing (7–16) (3–11) (3–10) (3–12) (0–5) (1–7) (7–18) (4–13) (5–12) (3–13) (0–6) (1–7)
solids 11 2 1 2 0 0 12 3 4 2 0 0
Problems 2 1 1 1 0 1 2 3 2 1 1 1
swallowing (1–3) (1–2) (0–2) (0–2) (0–2) (0–1) (1–3) (1–4) (0–3) (0–3) (0–2) (0–1)
liquids 0 0 0 0 0 0 0 0 0 0 0 0
Larynx 27 0 1 6 0 1 28 1 1 7 0 0
Oedema (14–40) (0–12) (0–9) (1–18) (0–1) (0–4) (15–43) (0–11) (0–9) (1–22) (0–1) (0–3)
17 1 1 7 0 0 17 1 1 7 0 0
Ipsil. brachial 1 1 0 2 1 0 2 0 2 0 1 1
plexopathy (0–9) (-5–5) (-4–5) (-2–10) (-2–3) (-1–2) (-1–9) (-3–5) (-4–3) (-2–10) (-1–4) (-1–3)
1 0 0 1 0 0 1 0 0 1 0 0
Trismus 6 2 6 1 0 0 6 2 6 1 0 0
(2–11) (0–6) (1–9) (0–3) (0–0) (0–2) (2–12) (0–6) (1–9) (0–4) (0–0) (0–1)
3 0 1 0 0 0 3 0 1 0 0 0
1NTCP values for myelitis and brain stem necrosis are not listed (0 % in all cases)
pendences not yet analysed in literature. Furthermore, a larger number of NTCP models was
used for evaluating the impact of the dose escalation level and the treatment modality differences
compared to similar treatment planning studies, increasing the value of the presented analyses.
Moreover, the designed fractionation schedule with three different treatment series allowed for a
detailed evaluation of the probable effect of using PT only for sequential boost application, which
is unclear so far. Hence, the presented treatment planning study is of high quality regarding the
treatment planning for HNSCC and is eligible for hypothesis generation and validation. Thus, it
is suited for answering the three afore mentioned questions on HNSCC RT treatment.
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3.4.1 Feasibility of the treatment intensification schedule
The use of a treatment intensification schedule via dose escalation applied with the SIB treat-
ment technique allows for an increase in dose which is well conformed to the volume of interest
by maintaining the dose distribution of standard fractionation in the surrounding tissue. The dif-
ference in targeted doses between the SIB and the standard fractionation in the remaining PTV
influences how well the dose conformation can be obtained. The steeper dose gradient of the
IMPT treatment plans generally allowed for a smaller high-dose rim surrounding the SIB volume
compared to IMXT. However, for the small dose escalation level of 2.3 Gy(RBE) no substantial
difference in hot-spots (V 107) could be found between IMXT and IMPT in terms of the dose dis-
tribution in PTVring. This is a consequence of the tolerable variation in dose according to the
pursued ICRU constraints, which target a minimum dose of 95 % of the prescribed dose, equal
to 2.19 Gy(RBE) in the SIB, while allowing for a maximum dose of 2.14 Gy(RBE), which is 107 %
of the prescribed dose in the surrounding PTV. Such a small gradient was achieved with both
modalities. Consequently, the low dose escalation level of 2.3 Gy(RBE) is similarly eligible with
both modalities. The higher dose escalation level of 2.6 Gy(RBE) led to a larger dose rim sur-
rounding the SIB with IMXT compared to IMPT, which applies unwanted high doses to the elective
volume, resulting in increased mean doses of the PTVring. As a consequence, NTCP and DVH
parameter differences were also slightly larger for IMXT. This indicates that in some cases the
use of a high dose escalation level may be better applicable with IMPT.
However, the impact of the dose escalation level on the evaluated toxicities was small for both
modalities for all parameters. Only one model, the risk assessment of aspiration, was effected
by the increase in dose escalation from 2.3 Gy(RBE) to 2.6 Gy(RBE). The larger impact on the
aspiration model can be explained by the modelling approach: high local doses to the pharyngeal
constrictor muscles have more weight due to the parameter n = 0.2 of the LKB-model, treating
the pharyngeal constrictor muscles like a serial organ. Thus, small hot-spots in the pharyngeal
constrictor muscles lead to a substantial increase in NTCP when escalating with 2.6 Gy(RBE)
compared to 2.3 Gy(RBE). In contrast, all other models use dose parameters like mean dose or
n ≈ 1 for parallel organs, such that the impact of high local doses is small. This large difference in
the dose escalation effect depending on the modelling approach indicates that the impact of high
local doses on tissue may be underestimated when solely focusing on the evaluated toxicities,
which all are modelled with mean doses or dose-volume parameters of complete OAR. Other
toxicities may also depend on high local doses, but could not be evaluated due to the lack of
appropriate models. For example, the risk of ulceration in non-specified tissue caused by high
focal doses may increase significantly with a high dose escalation (Madani et al. 2011) but a
proper model is missing. The higher values of DVH parameter differences evaluating high local
doses like D2 for the carotid sinus and D1ml compared to the mean doses emphasise this concern.
An increased risk of side effects needs to be carefully weighed against a probable increase in
loco-regional control due to a higher dose escalation. Lühr et al. (2015) generated a TCP model
based on a separate risk estimation of subvolumes, e.g. defined by biological imaging. With this
modelling approach, the TCP increase for the presented fractionation schedule when increasing
the dose escalation from 2.3 Gy(RBE) to 2.6 Gy(RBE) was evaluated. Three subvolumes were
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defined: the GTVSIB with a high risk of relapse, the CTVbaseline with a medium risk of relapse and
the CTVelective with a low risk of relapse. The estimated increase in loco-regional control for the
presented patient cohort was in median 9 % independent of the treatment modality. With respect
to this increase in loco-regional control and based on the evaluated toxicity parameters showing
mainly small influence of the dose escalation increase from 2.3 Gy(RBE) to 2.6 Gy(RBE) inde-
pendent of the treatment modality, the evaluated high dose escalation level seems to be feasible
for the treatment of HNSCC patients with both treatment modalities, especially considering that
the treatment schedule focuses on patients with increased risk of relapse identified by FMISO
imaging. This result is in accordance with a treatment planning study by Thorwarth et al. (2008)
who assessed the possible magnitude of dose escalation under isotoxic conditions to be even
higher (up to 50 % compared to 30 % in the presented treatment planning study) and a clinical
trial of Leclerc et al. (2013) who demonstrated the clinical applicability of dose escalation via a
SIB with up to 2.5 Gy per fraction, however with reduced total dose. Nevertheless, it might be
an adequate treatment approach to exclude patients for whom an increased toxicity risk with the
higher dose escalation level could be identified from the high dose treatment schedule performing
the standard treatment instead.
In conclusion, the presented treatment planning study shows the feasibility of the fractionation
schedule for the dose escalation with 2.3 Gy(RBE) and 2.6 Gy(RBE) with both, IMXT and IMPT,
although the NTCP level with IMPT is generally lower (cf. Section 3.4.2). Since, this evaluation is
limited to OAR which can be delineated and the risk assessment is limited to available reasonable
NTCP models, the applicability of the dose escalation schedule needs to be investigated carefully
in the setting of a proper prospective clinical trial. Based on the presented results indicating
an only small increase in toxicity incidence, such a patient study can be performed ethically
reasonable.
3.4.2 Impact of treatment modality
The evaluation of the target dose coverage revealed similar results between the IMXT and the
IMPT treatment regarding the DVH parameters which are commonly used for treatment plan qual-
ity evaluation. Differences in the dose homogeneity of the target areas were identified, although
staying within allowed constraints according to the ICRU guidelines. Consequently, both modali-
ties can be rated as equivalent in terms of tumour control. This is supported by the evaluation of
the expected TCP, which is approximately 66 % with both modalities.
IMPT allowed for a reduction of all toxicity risks assessed with the considered NTCP models,
except for myelitis and brain stem necrosis which both are prevented by the treatment planning for
both modalities. Organ doses in terms of DVH parameters were overall reduced with IMPT except
for the skin doses, as expected. These results are in accordance with several other treatment
planning studies showing the capability of PT to reduce dose and thus, probably side effects in
HNSCC RT treatment while maintaining similar target coverage (Cozzi et al. 2001; Lomax et al.
2003; Steneker et al. 2006; Taheri-Kadkhoda et al. 2008; Widesott et al. 2008; van de Water et al.
2011; van der Laan et al. 2013).
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The question, at which magnitude of calculated NTCP reduction a referral to PT with its limited
capacity would be justified, is still unanswered. Langendijk et al. (2013) presented a methodol-
ogy for patient selection based on NTCP models, the model-based approach, proposing a NTCP
value reduction of 10 % as criterion. With this threshold, 70 % of their examined cases would
be selected for PT when considering xerostomia as the relevant toxicity alone. In the presented
treatment planning study two similarly well defined models for xerostomia were examined, differ-
ing only in the time point for xerostomia detection (6 months versus 12 months after treatment),
thus, including different stages of tissue recovery. With these models, a threshold of 10 % NTCP
reduction of xerostomia would lead to a selection of 41 of the 45 examined patients (91 %) using
the model evaluating xerostomia 6 months after treatment, but to a selection of only 28 patients
(62 %) using the second model evaluating xerostomia 12 months after treatment. This exam-
ple illustrates a weak point of the selection approach based on NTCP thresholds calculated in
treatment plan comparisons: the result largely depends on the used NTCP model and may differ
substantially between two models even though both may be reasonably applicable.
In addition to the effect introduced by the model choice, the benefit achievable with PT in
HNSCC is even more ambiguous considering the large number of possible side effects which
may be taken into consideration and for which IMPT offers a range from a large reduction in
toxicity risk to a negligible benefit. As a consequence, an identification of the most important side
effects and the priorities to each other is mandatory for the model-based approach. Xerostomia
and dysphagia are toxicities frequently considered relevant in impairing the patients’ quality of life
after RT (Langendijk et al. 2008). In the presented treatment planning study, the risk of these
two toxicities was substantially reduced using IMPT for treatment in the evaluated patient cohort
with median benefits of close to or higher than 10 %. Rating both toxicities equally important
and thus setting the requirement that the risk of both toxicities must be reduced by 10 %, the
number of selected patients would decrease to 14 patients (31 %) of the presented patient cohort,
using the NTCP models for xerostomia 12 months after treatment and physician-rated swallowing
dysfunction. In contrast, setting the requirement that at least the risk of one of both toxicities must
be reduced by 10 %, the number of selected patients would rise to 33 (73 %). This example clearly
shows that the way of using the model-based approach influences the result as well. The more
toxicity models are required to fulfil a selection criterion simultaneously, the less patients would
be chosen. The more models are included and used as independent criterion, the more patients
will be selected. Furthermore, the threshold value impacts the number of chosen patients, with
a higher threshold value leading to the selection of fewer patients. The presented 10 % absolute
NTCP reduction is rather arbitrarily chosen and may need to be adapted for a specific model-
based scenario.
In summary, independent of the model to be chosen, the use of IMPT has been demonstrated
to reduce toxicity risk in general, and thus may translate into a benefit for a part of the patient
cohort. The magnitude of the benefit depends on the emphasised toxicity in the clinical setting
and may be rated differently in different institutions. Patient selection on such comparisons would
largely depend on the chosen model, threshold and toxicities rated as relevant.
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The use of a mixed modality treatment, i.e. the use of IMPT for the sequential boost treatment
in Series III of the presented fractionation schedule only, revealed a smaller benefit for the patient
cohort in terms of NTCP reduction compared to a full IMPT treatment. Following the described se-
lection approach, only 1 patient would be chosen with a criterion of NTCP reduction of more than
10 % for both xerostomia 12 months after treatment and physician-rated swallowing dysfunction.
This emphasises the small advantage which is to be expected from a mixed modality treatment
for the complete patient cohort using PT only for the sequential boost with a schedule similar to
the presented one, where only one third of the dose is applied with IMPT. An additional reason
for the small benefit is the reduced target size of the sequential boost volume, which allows for
a good sparing of OAR which are distant from the primary tumour volume and involved lymph
nodes also with IMXT. The large "dose bath" for most of the OAR is caused by the treatment of
the elective volume. Different results may be achieved if the treatment splitting is executed within
the elective treatment series. However, this would increase the number of fractions delivered with
PT and thereby rise the question why not the entire treatment is performed with PT. Focusing on
individual patients, the presented treatment planning study revealed that for a small number of
patients a mixed modality treatment may still be beneficial. Hence, a mixed modality treatment
may be a reasonable concept with the presented treatment schedule for such patients, especially
when they present with unacceptable high toxicity risk regarding a specific side effect when using
pure IMXT. Unfortunately, the identification of such patients without extensive treatment planning
comparisons is more than challenging. Furthermore, when already focusing only on patients with
IMXT treatment plans that exceeded acceptable risks, a complete IMPT treatment may be prefer-
ential. Altogether, a mixed modality treatment does not present very beneficial for the majority of
the HNSCC patients of the used patient cohort with the presented treatment schedule and thus
should not be the treatment of choice.
Based on the evaluated results, a prospective clinical trial can be designed to verify the theoret-
ical benefit of IMPT over IMXT in terms of toxicity in a clinical setting. Pursuing the model-based
approach, patients for whom ∆NTCPMod ≥ 10 % can be shown in an individual treatment plan
comparison will be randomised between IMXT and IMPT treatment. Choosing the toxicity inci-
dence of xerostomia 12 months after treatment as primary endpoint, a mean difference in NTCP
of 18 % can be expected. The modelled incidence probabilities are 26 % for IMXT and 8 % for
IMPT. The hypothesis that there is no difference between IMXT and IMPT is tested with a signifi-
cance level of 5 % and a power of 80 % using a two-sample one-sided test of proportions. These
assumptions lead to a number of required patients of 72 per treatment modality including a drop-
out rate of 10 % (Löck 2015). Assuming the same portion of patients with ∆NTCPMod ≥ 10 % as
in the presented treatment planning study (62 %), the number of patients presenting for primary
RT of advanced HNSCC would rise to 116 per treatment modality. Based on an optimistic esti-
mation of eligible patients in terms of general health status as well as capability of giving consent
and willingness to participate in a trial, the recruited patient number per year would be 25 at most
at the UPTD. Hence, the trial would have a too long recruitment period and therefore cannot be
performed as monocentric trial. Including other institutions might be an option to perform such
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a trial in a reasonable time period. As an alternative, a reduction of the required patient number
would be possible when aiming for a comparison to historical data for xerostomia incidence with
IMXT treatment. Assuming 35 % incidence for IMXT, as shown by Jensen et al. (2010) assem-
bling literature reporting xerostomia incidence, and assuming that this incidence can be reduced
by 14 % using IMPT, which is a reasonable assumption based on the presented treatment plan-
ning study and the treatment planning studies by Widesott et al. (2008) and van de Water et al.
(2011), the number of patients to be recruited for IMPT would be 73 (Löck 2015), which is more
feasible. This number is based on a one-sample one-sided test of proportions with a significance
level of 5 % and a power of 80 %. However, such a comparison would need to include all patients
independent of their ∆NTCPMod (as calculated here) to match to the historical patient cohort.
Thus, this could not be straightly transferred for a model-based approach.
3.4.3 Potential of subgrouping
Early patient identification based on simple and robust parameters bears the potential to reduce
resources which are needed for detailed individual treatment plan comparisons. For HNSCC pa-
tients the tumour location is a simple feature assessed routinely before treatment. The presented
analysis revealed that for some of the considered NTCP models and DVH parameters a clear
distinction of the benefit of PT between the subgroups exists, in particular for mucositis and dys-
phagia related toxicities like larynx oedema. These differences can be explained by differently
delineated elective target volumes depending on the extent of the primary tumour volume. Parts
of the OAR relevant for a specific toxicity may thus have a different overlap with the targeted area
depending on the subgroup. In regions with little overlap, the steeper dose gradient of IMPT
leads to a better conformity, inducing less dose to OAR, which reduces the toxicity risk.
Another effect was seen in the risk assessment of xerostomia. The toxicity model is based on
mean doses to the contralateral parotid gland and was significantly less reduced for patients of
Subgroup B. The reason for this originates in the definition of the sequential boost volume, con-
sisting of the primary tumour and involved lymph nodes, being distant in cranio-caudal direction
to the glands for patients of Subgroup B. As a consequence, sparing of the contralateral parotid
gland was well possible in Series III with IMXT and IMPT. Mean doses and the resulting NTCP
values were smaller for Subgroup B compared to the other two subgroups. Additionally, the dif-
ferences in mean doses between the two modalities were smaller for patients of Subgroup B.
This also translated into smaller benefit estimation with NTCP reduction.
Small initial NTCP values were additionally impacted by another factor: the shape of the NTCP
function representing the dose-effect relationship. Due to the sigmoidal shape of the NTCP curve,
cf. Figure 2.8, the same dose differences lead to larger differences in the estimated NTCP values
if the initial NTCP value is around 50 %. This illustrates that a simple dose reduction evaluation
will not give the same results as the biological evaluation with NTCP models. Patients with
small NTCP values, e.g. patients of Subgroup B for xerostomia risk, benefit less from a similar
dose reduction than patients of the other subgroups. Figure 3.17 shows this exemplarily for two
patients: patient 1 from Subgroup A had a decrease in NTCP of about 17 % from 26 % to 9 %
xerostomia risk with 8 Gy(RBE) reduction in mean dose, while for patient 2 from Subgroup B with
the same mean dose reduction the NTCP was only reduced by 12 % from 16 % to 4 %.
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Figure 3.17: The difference in NTCP, ∆NTCP, for identical dose differences ∆D depends on the initial
absolute NTCP value. Values for patient 1 are depicted in green, patient 2 in pink, IMXT treatment in solid
lines, IMPT in dotted lines.
Aiming on a patient selection via subgrouping, two different parameters are relevant: first, the
∆NTCP values in a subgroup must be significantly different from the other subgroups. Second,
the estimated benefit from IMPT must be of a relevant magnitude, e.g. ∆NTCP≥ 10 %. With
these requirements, Subgroup A would be most preferred for referral to PT. A significantly de-
creased risk compared to the other two subgroups were seen for all dysphagia related toxicities at
a relevant magnitude of ∆NTCPMod. Furthermore, xerostomia and trismus were significantly less
reduced for Subgroup B. The only significant subgroup difference favouring Subgroup B occurred
for oral mucositis. Subgroup C was intermediate between the other two subgroups in most cases,
as could be expected from the tumour location extending into areas of both, Subgroup A and B,
and showed no advantage compared to the other two subgroups in any toxicity. Subgroup A has
also been found to be preferable when using a PT selection criterion of ∆NTCPMod ≥ 10 % and
counting patients who fulfil this constraint for both, xerostomia 12 months after treatment and
physician-rated swallowing dysfunction: 12 patients of Subgroup A were eligible for PT (67 % of
Subgroup A), while only 1 patient of Subgroup B and 1 patient of Subgroup C fulfilled both crite-
ria. Furthermore, a higher number of toxicities with ∆NTCPMod ≥ 10 % per patient was seen for
patients of Subgroup A compared to those of Subgroup B and C: 14 with at least two toxicities for
Subgroup A but only 3 and 2 in Subgroup B and C. However, a general bias in the analysis of the
selection concept is the different number of patients in each subgroup, with the largest number of
patients in Subgroup A (18), followed by Subgroup C (14) and B (13). Additionally, the exclusion
of patients from the NTCP calculations due to the infiltration of the OAR relevant for modelling
further increased the discrepancy of patients numbers.
Although differences in median benefit of IMPT were seen between the subgroups, a large
spread of benefit still occurred within a subgroup for some toxicities. This may have several rea-
sons. First, depending on the toxicity to evaluate, subgrouping with respect to tumour location
may not adequately represent patient similarities. Second, defining the correct subgroup of a
patient according to the tumour location, although being conceptual simple to assess, may be
difficult in some cases, especially in advanced tumour stages. Thus, the assignment of a patient
to a subgroup may be controversial in some cases. These uncertainties emphasise that even
though patient selection according to subgroups may be reasonable, an individual treatment plan
comparison between IMXT and IMPT may be required to identify the expected individual benefit.
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Furthermore, advanced tumours may grow into other anatomical areas. Involved lymph nodes
may support such a trespassing tumour growth. In the presented treatment planning study, Sub-
group C was created to contain such cases. With about a third of the examined patient collective,
this subgroup is an essential part of the patient population with advanced HNSCC. Due to the
size and extension of the tumour, patients of this subgroup often have high toxicity risks leading
to similar or higher NTCP values compared to the other two subgroups, without higher NTCP
reductions. Thus, patient selection should not be exclusively restricted to a subgroup, but also
allow for the referral of other patients in special cases, e.g. if no applicable IMXT plan can be
created.
Independent of the question concerning the treatment modality, patient subgrouping was eval-
uated for the purpose of excluding patients with large disadvantage of the higher dose escalation
level of 2.6 Gy(RBE). Based on the evaluated NTCP values and DVH parameters, subgrouping
with this goal does not seem required, since almost no differences between the two dose esca-
lation levels occurred. For this reason, the choice of the dose escalation level used for treatment
intensification can be a decision purely based on medical requirements, e.g. by assessing the
risk of relapse based on the magnitude of FMISO uptake after 20 Gy(RBE) of treatment.
Altogether, subgrouping with respect to tumour location allows for a patient stratification ac-
cording to a probable benefit of PT in HNSCC RT favouring HNSCC patients with tumours in the
upper pharyngeal region, e.g. oropharynx and oral cavity carcinoma. Due to the partially large
variation of benefit within this subgroup, the patient selection should preferentially be followed by
an individual treatment plan comparison to assess the actual benefit for a specific patient. The
subgrouping can thus be used as a pre-selection of patients to keep the workload of individual
treatment plan comparisons within feasible limits (a reduction to 40 % of the patients in a patient
population similar to the presented one), while still recognising the majority of patients with signif-
icant benefit. However, this should not be a strict a-priori limitation, since the individual benefits
differ within the subgroups and individual patients with other primary tumour locations can also
have a considerable benefit from IMPT. Those patients could be referred to PT when a generated
IMXT plan violates specified constraints.
3.4.4 Limitations of the presented treatment planning study
Patient selection, number of patients, tumour location Patient selection and number of
patients was limited to the available datasets acquired in the prospective clinical trial by Zips
et al. (2012). An extension to more patients was not possible due to the required PET/CT im-
ages before and during treatment which are not routinely taken for all patients undergoing RT.
As a consequence, included tumour locations were restricted to four: oropharynx, oral cavity,
hypopharynx and larynx, cf. Table 3.2. Other tumour sites like salivary gland tumours (often
adenocystic carcinoma) or periorbital tumours (rare cancer) were not included since no patient
eligible for the prospective clinical trial presented with such a tumour in the patient recruitment pe-
riod. In general, the inclusion of other tumour sites requiring the same treatment schedule would
most probably not change the presented results. Tumours like salivary gland tumours would be
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assigned to Subgroup A and, considering the spread in the results, would lead to similar results
as the other patients of this subgroup. Tumours like periorbital tumours would need to be grouped
in an additional subgroup not analysed in the presented treatment planning study as additional
OAR would need to be considered, e.g. organs of the optical system. Therefore, such patients
would not invalidate the presented conclusions for the other subgroups.
The frequency of tumours at the considered tumour locations was specific for the considered
patient cohort, including only patients receiving primary radiochemotherapy. A treatment sched-
ule was created which allows for a dose escalation on the whole tumour volume of hypoxic pri-
mary tumours stratifying patients according to the hypoxia level identified in FMISO imaging.
Patients receiving adjuvant RT after surgery would not be eligible for such a fractionation regime.
Still, the results for the benefit of IMPT evaluated with NTCP models can be extended to patients
with adjuvant RT in the same tumour locations, since the form and size of the elective target vol-
ume is the same and a similar boost to the tumour bed is usually applied. The expected workload
reduction, though, may change due to differences in the composition of the patient population.
Lohaus et al. (2014) presented a clinical trial including only patients with adjuvant RT of hypopha-
ryngeal, oropharyngeal or oral cavity tumours, in which patients with oropharyngeal tumours –
who contributed about 50 % to Subgroup A – represented 57 % of the patient cases in contrast to
31 % in the presented treatment planning study.
Treatment planning approach A universal beam set was used for treatment planning. Adap-
tations of the beam angles to the individual patient anatomy were mainly performed in case of
one-sided PTVadapt. The beam number and angles were chosen based on literature for IMPT
and treatment planning experience for IMXT (Cozzi et al. 2001; Steneker et al. 2006; van de
Water et al. 2011; Kraan et al. 2013). Although such a universal approach is frequently used in
treatment planning, an individual beam number and angle selection may lead to beneficial results
for individual patients (van der Laan et al. 2013) and thus may influence the presented results.
Additionally, the treatment planning optimisation of HNSCC patients is largely influenced by the
set constraints. As a consequence, a bias is introduced by ranking the toxicities according to
their supposed importance considering the multitude of toxicities. Myelitis or brain stem necrosis,
which are toxicities whose occurrence is not tolerated in RT, are prevented in all cases due to
their priority in treatment planning over target coverage. Thus, no differences in IMXT and IMPT
arise for these toxicities. Similarly, the risk evaluation of brachial plexopathy showed mixed re-
sults in terms of benefit. Xerostomia is an important toxicity generally acknowledged in RT, such
that widely accepted constraints to the impacted OAR, the parotid glands, exist. As a conse-
quence, these constraints are well pursued during treatment planning, although exceeding doses
are accepted if required for target coverage. Dysphagia, a toxicity influenced by a multitude of
OAR without clear superposition, has only risen into focus over the last years. Dose constraints
for these OAR are ambiguous and not well defined in treatment planning. Other toxicities like tris-
mus or oral mucositis were subordinated. No constraints for affected OAR exist, such that generic
constraints to anatomical regions instead of specific a OAR were set in the treatment planning.
The optimisation of the treatment plans evaluated by a medical physicist is more focused on re-
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ducing the dose to OAR with well defined constraints, leading to a better dose reduction in these
regions. Additional optimisation steps during the treatment planning are more frequently chosen
for such OAR. For this reason, the presented results of the NTCP reduction for toxicities rated as
secondary important may be improved when focusing more on these toxicities during treatment
planning process. However, adding further constraints to the optimisation process which already
includes a large number of constraints bears the risk of loosing the focus on the more relevant
toxicities, which are rated more relevant for clinical reasons. Furthermore, a trade-off between
different toxicities always needs to be performed in the optimisation process as a sparing of all
OAR is impossible in the treatment of HNSCC due to their large number and their distribution
in the treated anatomical region. Since the treatment planning process was based on internal
clinically accepted procedures with priorities in OAR sparing determined by medical needs, the
generated treatment plans are of good quality and the presented results valid for a standard RT
treatment approach.
Modelling of normal tissue complication probability The applied NTCP models were de-
veloped at other institutions. Their applicability is prone to uncertainties, due to the unknown
impact of differences in the patient population, in the used treatment techniques and fractionation
schedule and in the delineation guidelines, to name but a few. Differences in the patient popula-
tion will occur for all models generated for HNSCC, since this tumour site includes many tumour
locations. Differences in the fractionation schedules are likely to occur, as for many tumour en-
tities no global treatment concepts exist and the treatment schedule in the presented treatment
planning study includes a dose escalation not yet approved in clinical trials. Differences in the
treatment techniques are common due to changes in the treatment approaches over the last
decade and the required time to collect a sufficient amount of data for model generation. For
HNSCC such a change is the transition from 3D-conformal XT to IMXT as the standard treat-
ment approach, which was identified to have an impact on some NTCP models (Dijkema et al.
2008; Christianen et al. 2012). NTCP models specific to PT have not been generated so far and
it is unknown whether models derived from XT are applicable for PT (Ramaekers et al. 2013).
Differences in the delineation of OAR as well as target structures are a known problem since no
commonly accepted delineation guidelines exist. Changes in the definition of organ structures
due to a different delineation impact the dose parameters of OAR and thus the resulting NTCP
values (Brouwer et al. 2014).
All these uncertainties may be avoided by generating NTCP models based on the own patient
population, treatment technique, fractionation schedule and delineation guidelines or at least
by the validation of a foreign model with institution specific patient data (van Luijk and Schippers
2012). However, the generation of a model and its validation is a complex problem often impeded
by an imprecise or missing collection of follow-up data, the long time needed for collecting a large
number of follow-up data and changes in internal guidelines over such a large time period due to
new findings. Since NTCP modelling based on the presented data does not exist as the patients
were not treated with the generated treatment plans, the use of NTCP models created at another
institution was the only possibility to get at least an estimation of the probable reduction of side
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effects in the presented treatment plan comparisons. Consequently, the conclusions derived
from the NTCP data need to be evaluated carefully. However, the uncertainty in NTCP model
applicability on the results of the presented treatment planning study was reduced by selecting
only models which were generated from similar patient cohorts and treatment techniques. Since
the determined NTCP values for the models are in the range of other studies using these models,
their use seems to be appropriate (Christianen et al. 2012; Kandula et al. 2013). Furthermore,
mainly differences between NTCP values were examined such that the accuracy of the absolute
NTCP values are subordinate.
Handling of changes in patient anatomy The calculation of the NTCP and DVH parame-
ters were based on nominal dose distributions only. In the view of dose delivery uncertainties
caused by setup uncertainties as well as tissue shrinkage or swelling, a realistic assessment of
the delivered dose requires information about the actual patient anatomy at the time point of the
respective treatment fraction. High quality imaging data which would allow for these specific dose
calculations in PT is usually not acquired in such a frequency, rendering a precise assessment of
the delivered dose impossible. As a consequence, using robust treatment planning to reduce the
effect of uncertainties or at least performing robust analyses to assess the effect of uncertainties
is often recommended for PT. Robust optimisation in treatment planning and robust analyses fo-
cus on setup uncertainties and calculation uncertainties due to CT data to mass stopping power
conversion. Robust treatment planning requires the implementation of an uncertainty penalty in
the optimisation process of the treatment planning system, which was not supported by the used
treatment planning system. If a robust optimisation had been used, nominal dose distributions
of IMPT would be slightly degraded compared to the used treatment plans, with the advantage
of a more reliable dose delivery in terms of setup and calculation uncertainties (Pflugfelder et al.
2008). Consequently, if such robustly optimised treatment plans were used for evaluation, the
benefit of PT identified in the presented treatment planning study may be slightly reduced, but
would most probably not change the results and conclusions significantly. Robust analyses of the
treatment plans would allow for the assessment of the dose degradation of the delivered dose
for the generated IMPT plans and, if similarly performed for IMXT, would allow for comparisons
of dose distributions which are closer to actually delivered ones. However, such robust analyses
only include generic stopping power uncertainties and setup uncertainties based on rigid transla-
tions and rotations of the CT used for treatment planning. In the case of head and neck cancer,
setup uncertainties additionally include deformations which impair the strength of robust analy-
ses. Changes in patient anatomy which may have an even larger impact cannot be modelled
at all with that approach. Thus, the inclusion of CT data acquired during treatment is the best
way and was, limited by the available imaging data, included with a one-step adaptation strategy.
Considering the development of patient anatomy changes during the course of treatment, the
evaluated dose distribution will be more degraded in reality. Such changes will also influence
the XT treatment, however probably with less impact. The evaluation of the effect of anatomy
changes on both modalities and an assessment whether an additional treatment adaptation may
be required, could be performed with the presented fractionation schedule using the CT image
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dataset taken at the time point of relapse risk assessment after 20 Gy(RBE) of treatment. How-
ever, such an extensive analysis was beyond the scope of the presented treatment planning study
but is a topic of ongoing research at the UPTD.
Precision of dose calculation The dose calculations of HNSCC RT treatment plans are sub-
ject to calculation uncertainties due to tissue heterogeneities which are present in the treated
anatomical region. The magnitude of these uncertainties depends on the dose calculation algo-
rithm and the tissue heterogeneities in the beam path. In the presented treatment planning study,
a collapsed cone algorithm was used for IMXT, while the IMPT calculations were based on the
more simple pencil beam algorithm. Both calculation algorithms were default in the treatment
planning system for patient treatment plan calculation and could not be changed. The resulting
dose differences may thus also depend on the two different dose calculation algorithms depend-
ing on the tissue heterogeneities due to tissue interfaces. For HNSCC patients, heterogeneities
in terms of tissue interfaces are present in form of soft tissue to air boundaries in the upper lung
area, the trachea and the nasal and oral cavity. Tissue to bone interfaces are ribs, vertebral
bodies, mandible and skull. The superiority of a collapsed cone algorithm especially in anatomi-
cal situations with air cavities, e.g. lung and breast cancer cases, was shown in several studies
for XT (Gansemer 2006; Knöös et al. 2006). For HNSCC treatment planning, the pencil beam
algorithm was evaluated to give sufficiently accurate results in IMXT and IMPT dose calculations
(Kan et al. 1998; Wang et al. 2002; Grassberger et al. 2015), although dose differences occur in
positions close to air heterogeneities especially present in patients with nasopharynx carcinoma
(Aspradakis et al. 2003). In the presented patient cohort rather small air to soft tissue interfaces
were present. Furthermore, the treatment plans consisted of several beams with different angles
which are differently affected by the tissue interfaces. Thus, the differences in the accumulated
dose distributions were evaluated to be rather small and the use of other dose calculation algo-
rithms would most probably not change the conclusions.
An additional uncertainty in the dose calculation is introduced by using registered dose cubes,
i.e. "deformed dose", for dose accumulation. This is required because of the one-step treatment
adaptation schedule and is a frequently used approach for the dose accumulation between dif-
ferent image datasets (Schaly et al. 2004; Schwartz et al. 2012). However, the applicability of
deformable image registration vector fields on dose distributions is highly controversial especially
in the light of dissolving tissue (Schultheiss et al. 2012; van Rijssel et al. 2014). Mencarelli et al.
(2014) found that the deformable image registration was less accurate for tumours than for nor-
mal tissue. Furthermore, validation concepts for deformable image registration are frequently
discussed and, up to now, no commonly accepted method for the accuracy determination of the
deformable image registration exist (Wang et al. 2005; Salguero et al. 2011; Varadhan et al. 2013;
Hoffmann et al. 2014). For this reason, the used deformable image registrations were validated
with several options presented in literature and rated acceptable. The conformance of the treat-
ment plans with the clinical goals was evaluated separately for the three different series on the
respective CT images prior to the dose accumulation. The evaluations of the target structures
were completely restricted to the respective CT datasets, while the dose accumulation was rele-
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vant for the OAR analyses. The dose distributions for these evaluations were accumulated on the
CTbaseline, such that uncertainties in the deformed dose distributions affected the smaller portion
of the dose. Since all dose accumulations for all analyses in the presented treatment planning
study were based on the same deformable image registration vector fields, uncertainties will
presumably have minor impact on the evaluation of differences.
3.5 Conclusion
The presented treatment planning study evaluated three different aspects in dose-escalated HN-
SCC treatment with PT:
1. The presented treatment schedule including a treatment intensification with a dose escala-
tion was rated feasible for the dose escalation levels of 2.3 Gy(RBE) and 2.6 Gy(RBE) for
both IMXT and IMPT treatment based on NTCP evaluations. The impact of the higher dose
escalation level was rather small, although slightly larger for IMXT than for IMPT. Since
NTCP modelling could not be performed for all possible side effects, the dose escalation
should be carefully validated in a prospective clinical trial. Such a trial is currently prepared
as a multi-center, randomized phase-II-trial (INDIRA-MISO).
2. The use of IMPT significantly reduced the toxicity risk calculated with NTCP models for oral
mucositis, xerostomia, dysphagia and trismus for the presented patient cohort. The mag-
nitude of the benefit depended on the individual patient ranging from small to substantial.
Using a selection criterion of ∆NTCP≥10 %, e.g. for xerostomia risk reduction 12 months
after treatment, 28 of 45 patients of the presented patient cohort would be eligible. The use
of IMPT for sequential boosting only, a mixed modality treatment, had smaller impact on
toxicity reduction and may only be reasonable in rare cases (2 patients for the xerostomia
example).
3. The patient subgroup analysis based on the primary tumour location revealed a higher
benefit from IMPT for patients with tumours in the upper head and neck area for dysphagia
related toxicities and a lower benefit for patients with tumours in the lower head and neck
area for xerostomia and trismus. Respecting the limited resources for patient treatment with
PT, patient selection could focus on the patient subgroup with tumours in the upper head
and neck area. Since the individual benefit varies throughout the subgroup, an individual
treatment modality comparison for selected patients is still recommended.
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Patients with lung cancer have very low 5-year survival rates of approximately 15 % (Goeck-
enjan et al. 2010; Francisci et al. 2015). An approach to improve the control rates might be a
treatment intensification with RT, which is mainly restricted by normal tissue complications, e.g.
pneumonitis (Bradley et al. 2015). Thus, PT may be an approach for RT treatment improvement,
offering more favourable normal tissue sparing with similar tumour coverage than XT (Roelofs
et al. 2012). Dosimetric studies showed that such sparing might allow for the dose escalation
with PT even in cases where a treatment with XT to conventional doses was not possible (Lee
et al. 1999; Chang et al. 2006; Nichols et al. 2011). Zhang et al. (2010) determined in their virtual
study that PBS PT allowed for a better sparing of the OAR than PS PT. However, those stud-
ies did not consider the tumour motion caused by the patients’ breathing. This motion leads to
changes in the tumour location and consequently in the density along the beam path. Therefore,
it can deteriorate RT treatment with protons which is highly sensitive to such changes. Especially
for PBS PT, the similar time scale of the proton spot application and the breathing motion leads
to degradations of the dose distribution caused by the interplay effect (Phillips et al. 1992), cf.
Section 2.2.4. These effects in proton beam RT need to be considered in treatment evaluations.
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Several phantom and patient case studies evaluated the interplay effect for tumours in the
lung and the liver which move due to the patients’ respiration (Phillips et al. 1992; Lambert et al.
2005; Paganetti et al. 2005; Bert et al. 2008; Kraus et al. 2011; Zhang et al. 2012; Dowdell et al.
2013; Grassberger 2014; Li et al. 2014b). Besides individual patient characteristics different
treatment planning approaches and machine characteristics, e.g. different times for energy layer
switching, highly influence the dose degradation pattern. Thus, in their review of motion effects
in particle therapy, Bert and Durante (2011) concluded that interplay evaluations are required for
each facility and treatment protocol individually. For the Ion Beam Applications (IBA) treatment
machine type of the UPTD no evaluations exist so far. Thus, to prepare the implementation
of PBS PT for lung cancer patients at the UPTD, the presented treatment planning study was
designed, which examines the influence of several patient- and machine-dependant factors on
the degradation of the dose distribution on a large scale. In contrast to the mentioned phantom
and patient case studies, the focus was not laid on the identification of worst outcome factors
(e.g. the application of a single beam treatment), but the effect evaluation was performed for a
realistic patient treatment (e.g. the use of multiple beams).
The results described in this chapter have been presented at international conferences. The
treatment planning study was approved by the institutional ethics committee (EK 301082013).
4.1 Lung cancer
4.1.1 Clinical background
Lung cancer is the most common cause of cancer-related deaths worldwide. The mortality to
incidence ratio is approximately 0.87, illustrating the poor probability of survival in this patient
cohort (Jemal et al. 2011). Primary lung carcinoma can be divided into two main types which
are distinguished by histology, course of disease and treatment pattern (Schiller 2001): small cell
lung cancer (SCLC), which accounts for about 15–20 % of lung cancer cases, and non-small cell
lung cancer (NSCLC), which represents the major disease type summarising several subtypes
like squamous cell carcinoma, adenocarcinoma and large cell carcinoma.
The main risk factor for the development of lung cancer is tobacco abuse, accounting for ap-
proximately 75 % of all lung cancers (Lubin and Blot 1984; Ezzati et al. 2005). Other risk factors
include exposure to chemicals like asbestos or radon, outdoor and indoor air pollution, previous
lung disease like tuberculosis, hormonal and genetic factors, poor diet and little physical activity
(Wu et al. 1985; Ezzati et al. 2005; Sun et al. 2007). Even though the treatment options increased
over the last decades, the patient outcome is still poor especially for the advanced stages III and
IV (Baumann et al. 2009). The treatment options and the prognosis depend on the type and
histology of lung cancer (SCLC or subtype of NSCLC) and the tumour stage.
Patients with limited NSCLC (stage I and II), which describes localised tumours without distant
lymph node involvement or metastases, usually undergo surgery removing the lung lobe where
the tumour is seated (lobectomy) or the affected lung completely (pneumonectomy). Since ap-
proximately 70 % of the recurrences are classified as systemic relapse in this patient cohort due
to occult lymph nodes, mediastinal lymph node dissection may be an option in surgery, but its
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efficacy compared to lymph node sampling is largely controversial (Lardinois et al. 2005; Dar-
ling et al. 2011). Another option is the use of adjuvant or neoadjuvant chemotherapy for stages
larger than IA (Reck et al. 2013; Vansteenkiste et al. 2013). If a surgery is not possible due to
the tumour location or patient condition, early stage lung cancer can be treated with stereotactic
body radiotherapy (SBRT) to high doses (Louie et al. 2015). The patient outcome for stage I and
II NSCLC is moderate with 5-year survival rates between 40 % and 70 % (Baumann et al. 2001;
Vansteenkiste et al. 2013). Due to the late diagnosis caused by the mostly unspecific symptoms,
approximately 70 % of the patients present with locally advanced (stage III, distant lymph node
involvement, e.g. in the mediastinum) or metastatic disease (stage IV, only palliative treatment)
(Molina et al. 2008). These patients have a poor prognosis with 5-year survival rates of less than
20 % at best, dropping to less than 5 % for the metastatic disease (Goldstraw et al. 2007). Due
to the systemic involvement, most therapy approaches include chemotherapy. If the tumour is
resectable, surgery with chemotherapy or radiochemotherapy is the treatment of choice. In un-
resectable cases, primary concurrent or sequential radiochemotherapy is given (Vansteenkiste
et al. 2013; Eberhardt et al. 2015). A close follow-up is recommended in all lung cancer therapy
cases since approximately two thirds of the relapses occur in the first three years after treatment.
The treatment approach for SCLC differs from the described approaches for NSCLC. SCLC
grows rapidly and leads quickly to regional and distant metastases. It is mainly divided into
two stages: limited diseases are confined to one lung and represent approximately 30 % of the
cases. In extensive diseases the tumour has spread into both lungs or other organs (Sher et al.
2008). However, presently the use of the Union for International Cancer Control staging ac-
cording to TNM catalogue similar to NSCLC is increasingly recommended (van Meerbeeck et al.
2011; Früh et al. 2013). Patients with limited disease are treated with concurrent of sequential
radiochemotherapy, if patient condition allows for it, with a curative approach achieving 2-year
survival rates of approximately 20–40 %. Due to the systemic nature which develops rapidly in
SCLC, surgery is usually not performed except for very rare cases of node-negative limited dis-
eases (van Meerbeeck et al. 2011). Since patients with SCLC have a high risk of developing
metastases in the nervous system, prophylactic cranial irradiation is recommended for patients
with limited disease who show a treatment response (Früh et al. 2013). Extensive diseases are
usually treated palliatively with chemotherapy achieving 5-year survival rates of less than 5 %.
Due to the poor patient outcome, the main focus for treatment improvements in lung tumour
therapy is the tumour elimination. However, severe side effects, which either endanger the pa-
tients’ life or unacceptably impact their quality of life considering the low median survival time,
can occur and need to be minimised. Chemotherapy treatment causes side effects like fatigue,
diarrhoea, renal dysfunction and nausea, amongst others, which are independent of the targeted
anatomical area (Griffin et al. 1996; Ishikawa et al. 2013). Furthermore, the local treatment with
RT may induce side effects in the healthy tissues in proximity to the tumour location. Main con-
sidered OAR are the spinal cord, the oesophagus, the heart and the healthy lung tissue (Bradley
et al. 2005; De Ruysscher et al. 2010; Kong et al. 2014): spinal cord toxicity like paralysis is
commonly prevented by the treatment planning approach due to the high impact on patients’
quality of life. Oesophagitis and oesophageal dysphagia risk as well as cardiac toxicity compris-
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ing pericarditis, inflammation and fibrosis, are generally subordinate, but increasingly considered
in the last years. Most relevant for the treatment optimisation are pulmonary side effects in the
healthy lung tissue like radiation-induced pneumonitis, which can lead to treatment related death
in the worst case. As a consequence, treatment planning has to reduce the pneumonitis risk,
rendering the lung, besides the spinal cord, the main dose limiting organ in lung cancer RT.
Depending on the location and extent of the tumour and involved lymph nodes, other OAR may
be considered in treatment like plexus brachialis (neuropathy), large vessels (bleeding), trachea
(fistula), bronchus (stenosis), ribs (fracture), liver (dysfunction), kidneys (dysfunction), stomach
(dysfunction) and bowels (stenosis).
4.1.2 Aspects of lung cancer radiotherapy
Rationale for proton therapy in lung cancer Loco-regional recurrence rates in advanced lung
cancer are high despite treatment. Similarly, distant metastases are a frequent cause of treatment
failure (Baumann et al. 2009). Saunders et al. (1999) showed in their study that increased loco-
regional control rates also reduced the incidence of distant metastases. Thus, the reduction of
loco-regional recurrence is a main goal in lung cancer treatment. For early stage lung cancer,
photon SBRT treatments administering high local doses lead to high local control rates (about
80 % at 5 years) with little side effects quite similar to the treatment with surgery (Chang et al.
2008; Zheng et al. 2014). For locally advanced lung tumour stages, however, increased doses as
an option to improve the loco-regional control is currently highly controversial since several recent
trials showed no advantage or even disadvantages for such treatments (Bradley et al. 2005, 2015;
Rodrigues et al. 2015; Sher et al. 2015). Cox (2012) hypothesised that increased pulmonary
or cardiopulmonary toxicities and inaccurate attributions of these causes may be confounding
factors in the evaluation of the trials. Kong et al. (2014) described in their review of lung cancer
RT that a clear dose-effect in NSCLC patients exists, which cannot be exploited in RT treatment
schedules due to the high risk of toxicities which already occur at low doses. A possibility to
reduce the risk of fatal toxicities especially when treating with high irradiation doses may be the
use of PT which minimises the doses to healthy tissues tremendously compared to XT. This was
shown in several treatment planning studies (Lee et al. 1999; Chang et al. 2006; Nichols et al.
2011; Roelofs et al. 2012). Clinically, only a few experiences with PT were published. Oshiro et al.
(2014) reported loco-regional control and survival rates of 51 % and 16 % at 2 years, respectively,
with high-dose irradiation of PT in stage III NSCLC. Hoppe et al. (2012) found acceptable toxicities
in patients treated with PT. Sejpal et al. (2011) determined in a retrospective study comparing
patient outcome and toxicity after treatment for NSCLC with either XT or PT that high grade
pneumonitis and oesophagitis rates in the PT cohort were significantly smaller than in the XT
cohort. Patients were treated with higher doses with PT than with XT (74 Gy(RBE) versus 63 Gy)
which led to a higher median overall survival time for PT treatment (24 months versus 18 months),
although this was not significant. Recently, Nguyen et al. (2015) reported 5-year overall survival
rates of about 28 % for patients with stage II and III NSCLC with acceptable toxicities using PS PT.
Thus, the use of PT for lung cancer especially in advanced stages with unfavourable prognosis
may be an option to improve the patient outcome and to minimise toxicities.
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Challenges in proton therapy of lung cancer RT treatment of lung cancer is a challenge due
to the mobility of the targeted area caused by the breathing of the patient. This motion cannot be
described by simple mathematical functions: tumour motion patterns induced by patient breathing
are usually irregular and vary largely between different patients. However, general similarities
exist: main motion direction is commonly cranio-caudal (CC) while the anterio-posterior (AP) and
medio-lateral (ML) motions are rather small, such that in about 50 % of the patients the motion
is similar to a one-dimensional oscillation (Pepin et al. 2010). Several studies found at least a
tendency for higher motion amplitudes of tumours in the lower lobe compared to tumours in the
upper lobe (Ross et al. 1990; Seppenwoolde et al. 2002; van Sörnsen de Koste et al. 2003).
Furthermore, early stage tumours are often more mobile than advanced stage tumours and thus
may be more difficult to treat with PT (Yu et al. 2012). However, advanced tumour stages present
with lymph node involvement. These lymph nodes may be subject to different motion patterns
than the primary tumour and thus can impede motion management strategies in RT treatment
(Donnelly et al. 2007).
The individual patient motion pattern can be extracted from time-resolved patient imaging, e.g.
with 4D CT or fluoroscopic imaging. Implicitly, the extracted information is correct only for the
time period of imaging but was shown to be a representative snapshot for the motion throughout
the treatment course for most patients (Redmond et al. 2009). However, intra- and interfrac-
tional changes of the tumour motion can occur in some patients (Starkschall et al. 2011; Shah
et al. 2012). Thus, the stability of the tumour motion needs to be verified throughout the treat-
ment course, e.g. by repetitive 4D CT (Ge et al. 2013). Single patients may show significant
variations of the tumour motion (Siochi 2010). Especially patients with poor pulmonary func-
tion and tumours in the lower lobe are sensitive to motion pattern changes (Guckenberger et al.
2007). Pattern changes could lead to shifts in the overall position of the tumour, so-called base-
line shifts. In addition to changes in the tumour motion pattern, the tumour volume can regress
or increase considerably throughout the treatment course especially in advanced lung cancer
cases (Bosmans et al. 2006). Other anatomical changes can additionally occur, e.g. atelectasis
or pleural effusion (Kwint et al. 2014). These can also effect the tumour motion, e.g. by increasing
or decreasing motion peak-to-peak amplitudes, as well as by leading to changes in the overall
tumour position (Britton et al. 2007). The reduction or increase of tissue in the beam paths is
an additional difficulty for PT which is highly sensitive to density changes. This problem may be
addressed by adaptive RT based on regular control imaging throughout the treatment course, but
the optimal frequency and efficiency of this approach is yet not determined and a topic of ongoing
research (Hui et al. 2008; Sonke and Belderbos 2010; Koay et al. 2012; Kwint et al. 2014).
Treatment planning considering tumour motion in lung cancer radiotherapy RT treat-
ment planning is usually based on 3D CT image datasets representing a snapshot of the patient
anatomy. In case of the moving anatomy of the thorax, this strategy leads to an image dataset
which is taken in a random breathing phase and thus cannot ensure a representative patient ge-
ometry. As a consequence, when relevant motion is expected, 4D CT image datasets are usually
taken, acquiring a sequence of anatomical snapshots in dependence of the breathing motion.
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However, treatment planning currently still requires a 3D image dataset. Several approaches are
used for a 3D dataset generation or selection from the 4D CT: the generation of time-averaged
CT datasets based on the 4D CT (Kang et al. 2007), the choice of a single 4D CT phase close
to a time-average like 50 % exhale or 15 % inhale (Seco et al. 2012) or even the selection of the
more stable exhalation phase (Kraus et al. 2011). All these approaches have the intention to
ensure the use of a representative geometric imaging of the patient during treatment. Superiority
of one approach was not yet shown, such that a preferential image stack for treatment planning
does not exist and several approaches like the described ones are used in clinical practice.
Besides the choice of a good representation of the patient anatomy, the definition of the target
volume is also a matter of discussion. With 4D CT imaging, the possible positions of the tumour
can be determined more precisely. A simple approach for ensuring that the tumour volume is
always irradiated independent of its actual position in the breathing cycle, is the generation of an
ITV which encompasses all possible tumour positions identified in the different 4D CT phases.
Based on that ITV, expansions for subclinical spread (internal CTV) and patient-beam alignment
uncertainties (PTV) are performed. However, this target volume concept was introduced by the
ICRU for XT (ICRU 1999). Its use in PT is a topic of controversial discussion as it may not be
simply transferable to PT where geometric shifts will not simply lead to similar shifts of the dose
distribution due to proton range changes. In PS PT for lung cancer, treatment planning was
based on an internal CTV in which the density is set to a fixed value (Kang et al. 2007; Flampouri
et al. 2014). Uncertainties in the patient-beam alignment are then incorporated with "smearing"
the compensator and widening the aperture to maintain the dose distribution in the patient in the
presence of setup and density uncertainties (Moyers et al. 2001; Engelsman and Kooy 2005).
Compensator "smearing" and aperture widening is not applicable for PBS PT since generally no
hardware components are used. Nevertheless, the approach using an ITV with fixed density val-
ues was applied in the clinical setting also for treatment planning in PBS using the standard XT
geometric margin for the generation of a PTV (Li et al. 2014a). A more complicated approach for
the target definition was first suggested by Rietzel and Bert (2010) and since adopted by multiple
authors (Graeff et al. 2012; Park et al. 2012; Knopf et al. 2013; Flampouri et al. 2014). This
approach suggests the creation of a beam-specific PTV for each beam angle, which incorporates
potential changes in the range of protons caused by density variations in the beam path when the
tumour moves or the patient is misaligned. For this purpose, the motion of the tumour needs to be
known. Tumour motion information can be based on a 4D CT dataset which may be more or less
representative for the tumour motion throughout the treatment course. Also based on such mo-
tion information, the use of robust optimisation was proposed (Unkelbach et al. 2007; Pflugfelder
et al. 2008). This approach does not use a geometric PTV contour but includes motion and
setup uncertainties in the generation of the treatment plan based on the CTV alone. In a treat-
ment planning comparison by Li et al. (2015) treatment plans based on robust optimisation were
shown to be superior to simpler target contour based treatment plans. Liu et al. (2015) found in
their treatment planning study that this approach produce motion-resistant treatment plans even
though the optimisation did not explicitly account for respiratory motion. Both approaches, the
generation of beam-specific PTV and the use of robust optimisation treatment planning, require a
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reliable tumour motion characterisation. However, the presently available commercial treatment
planning systems do not support these advanced methods in general. Only very recently, Ray-
Search Laboratories AB (Stockholm, Sweden) introduced robust optimisation in their treatment
planning system (RaySearch 2015). All currently existing studies about the efficiency of the two
approaches were based on in-house developed software which is neither certified for clinical use
nor available outside the institution which developed the software.
Effect of tumour motion on the dose distribution in lung cancer radiotherapy Application
techniques in which the whole target volume is irradiated instantaneously, e.g. 3D-conformal XT
or PS PT, enable the delivery of homogeneous dose distributions throughout the target. The dose
distribution is mainly impacted by dose blurring effects at the target margins due to the motion.
However, in time-dependent application techniques like IMXT or PBS PT, the interplay effect
can occur caused by the similar time scales of target motion and beam application sequence,
cf. Section 2.2.4. The effect on the dose distribution was examined for XT and PT with phantom
studies or patient case evaluations. For example Yu et al. (1998); Bortfeld et al. (2002); Seco et al.
(2007) described effects in XT and Phillips et al. (1992); Lambert et al. (2005); Kraus et al. (2011);
Li et al. (2014b) in PT. While the interplay effect may be significant for the dose degradation of
single fractions, the use of fractionated treatment tends to average out the effect at least partially,
although this may not be sufficient in clinical cases (Seco et al. 2007). The biological effect of
large dose variations per fraction is, however, unclear. Bortfeld and Paganetti (2006) estimated
that the effects are negligible if the standard deviation of the dose variation is less than 10 % of
the fraction dose. Since variations of this magnitude or even higher can occur due to the interplay
effect, an evaluation of this effect is essential before using time-resolved application techniques
in the clinical setting.
Two main parameter spaces influence the interplay effect: 1) the individual machine character-
istics affecting the time scheme of the proton application sequences and 2) the patients’ individual
tumour motion characteristics influencing the time scale of the patient-specific motion. The ma-
chine parameter characteristics are specific for a treatment machine and therefore need to be
evaluated for each machine independently. A prospective estimation of the interplay effect can
be performed using nominal values of timing parameters specific for a treatment machine. Indi-
vidual patient characteristics are more difficult to assess and more prone to changes throughout
the treatment course. Thus, these characteristics are difficult to calculate precisely. Realistic
prospective estimations can be made based on pre-treatment 4D CT data and breathing pattern
recordings. However, the uncertainties and possible variations of the relevant input parameters
cause that comprehensive prospective 4D calculations lead to a multitude of possible 4D dose
distributions. Precise 4D dose calculations for a specific treatment can only be performed retro-
spectively, when all relevant impact parameters were recorded during treatment, e.g. the exact
spot times and the patient motion during the spot application. Based on prospective approaches,
several simulation studies identified general influences on the interplay effect in PBS PT (Phillips
et al. 1992; Bert et al. 2008; Seco et al. 2009; Zenklusen et al. 2010; Knopf et al. 2011; Kraus
et al. 2011; Dowdell et al. 2013; Grassberger et al. 2013; Grassberger 2014; Li et al. 2014b):
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Higher motion peak-to-peak amplitudes lead to higher dose degradations. However, despite this
general tendency, a smaller motion amplitude will not always lead to a smaller interplay effect.
The magnitude and locations of the hot- and coldspots due to the interplay effect largely depend
on the initial breathing phase of the patient which coincides with treatment start. The impact of
the tumour volume on the interplay effect is controversial. A tendency of a smaller effect with in-
creased volume was seen, probably caused by the increased treatment time and the subsequent
spread of the proton spot application to more breathing phases.
A multitude of treatment planning parameters can reduce the magnitude of the dose degrada-
tion caused by the interplay effect: first, the use of large spot sizes. However, this parameter is
often a fixed system value and cannot be adapted. Second, the use of small spot distances: for
a fixed volume the reduction of spot distances leads to a larger number of spots, prolonging the
treatment time and thus spreading the spot application to a larger number of breathing phases.
In the clinical setting, a compromise must be found between the duration of the treatment (longer
treatment times lead to less comfort of the patient and increase the risk of unpredictable patient
motion and treatment interruptions) and the probable reduction of the dose degradation. Third,
the use of multiple fields: With multiple fields the dose application is spread out to a larger number
of breathing phases due to longer treatment times. Furthermore, a random superposition of the
interplay patterns of the different fields might result in beneficial dose distributions. Additionally,
different beam angles are differently sensitive to the motion depending on their relative direction.
Fourth, the use of fractionation: the reduction of the dose degradation with fractionation is also an
effect of the random superposition of different interplay patterns. However, the biological effect of
dose variations inside the single fractions is controversial. Thus, a dose conformity which is only
achieved due to fractionation might not be clinically acceptable. Fifth, the use of motion mitigation
techniques can reduce the dose degradation by either reducing the motion (gating, breath-hold)
or increasing averaging effects (rescanning) or even following the tumour motion with the beam
application (tracking).
4.2 Design of the treatment planning study
The presented treatment planning study was designed to prepare the introduction of PBS PT
for the treatment of lung tumours at the UPTD. The study assesses the effect of several patient
and treatment machine specific characteristics on the dose distribution in the presence of or-
gan motion due to the breathing of the patient. Machine specific characteristics were based on
information provided by IBA (Closset and Duplicy 2012), the vendor of the installed proton ma-
chine. For a realistic assessment of patient-specific characteristics, the evaluations were based
on retrospectively available data of 40 patients treated with photon SBRT between August 2012
and September 2013 at the UKD. Within the study, 4D dose calculations were performed to
evaluate the interplay effect. Such calculations have specific requirements and cannot be easily
performed outside a treatment planning system, since each spot dose needs to be recalculated.
At the UPTD, only the treatment planning system XiO was available during the study time. In this
very restricted system, no 4D dose calculation for PBS PT could be implemented. Therefore, the
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4D dose calculations were carried out at the Paul Scherrer Institute, Villigen, Switzerland, during
a research stay of five months. At the Paul Scherrer Institute, an in-house developed software
is used for the treatment planning of PBS PT, which includes an additional 4D dose calculation
module allowing for the modelling of the interplay effect. During the research stay, changes in
the 4D dose calculation module were implemented enabling automatic calculations of large pa-
tient cohorts and including IBA specific characteristics in the calculation routine. The adjusted
software was then used to carry out the 4D dose calculations for different patient cohorts of the
UKD. The analyses of the generated data were performed at the UKD.
4.2.1 Patient data, volume definition
For a realistic treatment simulation, 4D CT datasets were required including the patients’ indi-
vidual breathing patterns which were used for the reconstruction of the images. At the UKD,
such datasets are routinely taken only for patients treated with SBRT of lung lesions. Complete
datasets of 40 consecutive patients with 41 lesions1 in the lung could be collected between Au-
gust 2012 and September 2013. The used patient cohort consisted of patients with early stage
primary lung tumours or lung metastases of other solid tumours. Patient characteristics are de-
scribed in Table 4.1.
Table 4.1: Patient and tumour characteristics.
Patient characteristics Number
Gender Female 11
Male 29
Tumour location Upper lobe 26
Middle lobe 4
Lower lobe 11
Tumour type Primary lung cancer 25
Metastases 15
Tumour characteristics Median (min – max)
Gross tumour volume Volume / ml 8.1 (0.3 – 37.0)
Peak-to-peak motion amplitude / mm
– cranio-caudal 5.8 (0.6 – 23.3)
– anterio-posterior 3.1 (0.7 – 13.4)
– medio-lateral 1.7 (0.5 – 7.3)
Average breathing period Time / s 3.7 (2.4 – 7.4)
Each 4D CT dataset was acquired with a SOMATOM CT scanner (Siemens Healthcare, Er-
langen, Germany). It consisted of eight reconstructed image series (CT phases) which collected
data starting from a specific amplitude of the breathing pattern based on a relative amplitude sort-
ing. The sample period for each image series was 500 ms (gantry rotation time was 1 s according
to standard protocol). The breathing pattern was recorded with a pressure belt respiratory gating
1For the one patient with two lesions, the motion peak-to-peak amplitude used in the analyses was the average of
the single motion peak-to-peak amplitudes of the two lesions and the tumour volume was the sum of the two lesion
volumes.
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system (Anzai Medical Co., Ltd, Tokyo, Japan). For the relative amplitude sorting the absolute
amplitudes of the recorded breathing pattern were scaled between each minimum and the follow-
ing maximum to be 0 % and 100 % inhale and similarly between the maximum and the following
minimum to be 100 % and 0 % exhale. Reconstruction time-points were set according to a UKD
internal guideline used for SBRT patients with 4D CT imaging: the reconstruction start time-point
of the eight CT phases was nominally set to 0 % inhale, 15 % inhale, 50 % inhale, 90 % inhale,
100 % exhale, 70 % exhale, 50 % exhale and 10 % exhale, but adapted individually according to
the breathing pattern. Most frequently, manual adaptations were made for 0 % inhale and 90 %
inhale such that the reconstruction period was symmetrical around the exhalation and inhalation
peak plateaus, respectively. Figure 4.1 shows the positions and periods taken for the reconstruc-
tion in an idealised breathing pattern represented by the cos2 function and how this translates to
the real breathing motion of an exemplary patient with a similar breathing period of approximately
4 s.
Figure 4.1: Breathing patterns illustrating the nominal time segments which where used for the reconstruc-
tion of the 4D CT datasets. An idealised breathing pattern is shown on the left, a real patient breathing
pattern on the right. The different coloured bars and arrows indicate the time for reconstructing one CT
phase. Green: 0 % inhale, cyan: 15 % inhale, blue: 50 % inhale, purple: 90 % inhale, pink: 100 % exhale,
red: 70 % exhale, orange: 50 % exhale, yellow: 10 % exhale.
The structure sets delineated for the clinical SBRT treatment were used for the treatment plan-
ning in the presented treatment planning study. As a consequence, the number of contoured OAR
varied because the required OAR in routine clinical work are individually selected depending on
the location of the tumour. Both lungs and the spinal cord were always delineated. Additional
OAR such as the oesophagus, large vessels, the heart, the trachea, bronchial tubes, the ribs, the
kidneys, the colon, the liver, the stomach and the brachial plexus were contoured for individual
patients only. All OAR were delineated on the 15 % inhale CT phase which is close to an aver-
age CT and is standardly used for treatment planning in SBRT treatments at the UKD. The GTV
was delineated on all eight CT image series separately (GTVPhaseX) and then transferred to the
planning CT. The ITV was constructed via the union of the eight GTVPhaseX contours. To each
GTVPhaseX a uniform margin of 4 mm was added for construction of the respective PTVPhaseX.
The PTVtotal used as target for treatment planning was the union of all eight PTVPhaseX. No CTV
margin was used for the SBRT patients and thus was also not applied in the presented treatment
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planning study. The tumour volume was defined as average volume of all eight GTV. Tumour
motion peak-to-peak amplitude of each patient was determined as the maximum displacement
between the centre of mass of the eight GTVPhaseX. The GTV motion was identified in CC, AP
and ML direction. Patients with a small tumour mobility in CC direction had, with a few excep-
tions, a small mobility in AP and ML direction as well, while a large CC motion was frequently
accompanied by an also larger mobility in the other two directions.
For the case studies of the interplay dependences, two subpopulations of the complete patient
cohort were used. These two different subpopulations exist as the 4D CT simulations were
performed at the Paul Scherrer Institute at two limited time periods. Subpopulation 1 contained
the datasets of the first ten consecutive patients, which were available when the first investigations
were performed. Further studies were conducted when the datasets of the complete patient
cohort were available. Patients of Subpopulation 2 were then specifically chosen among the 40
patients to obtain a large mix of possible motion peak-to-peak amplitudes and tumour volumes.
Only nine patients were analysed for some sub-studies due to data file transfer errors between
the two sites, the Paul Scherrer Institute and the UPTD. In Table B.6, all patients including their
individual motion peak-to-peak amplitudes, breathing periods and tumour volumes as well as the
patient’s affiliation to the respective subpopulations and the associated analyses are given.
4.2.2 3D treatment planning
The 3D treatment planning was performed with the treatment planning system PSIplan, an in-
house software developed at the Paul Scherrer Institute. The treatment schedule was chosen
to be a conventionally fractionated treatment with 2 Gy(RBE) per fraction, 5 fractions per week
and 66 Gy(RBE) total dose, which is a commonly used fractionation scheme (Vansteenkiste et al.
2013). The treatment plans consisted of three coplanar beams for which the beam angles were
individually selected to avoid a beam exit into nearby critical structures, e.g. the spinal cord,
except for the ipsilateral lung. Each beam was planned to deliver a homogeneous dose dis-
tribution to the target volume via a single-field optimisation, generating a so-called single field,
uniform dose treatment plan. All beams contributed equally to the fraction dose of 2 Gy(RBE).
The treatment plans were optimised on the 15 % inhale CT phase, assuming its similarity to a
time-averaged CT. Original CT resolution was 2.0×1.0×1.0 mm3, but was re-sampled due to re-
quirements of the treatment planning system to a resolution of 2.0×2.0×2.0 mm3 for treatment
planning. The target strategy for treatment planning was chosen according to Li et al. (2014a) for
PBS PT, to ensure the calculation of the correct maximum required ranges independent of the
tumour position during a breathing cycle. With this method, the density in the ITV was replaced by
a fixed value of 50 HU for optimisation, which was rated similar to the average CT value of a solid
lung tumour (Kang et al. 2007; Grassberger et al. 2013). The target volume was the PTVtotal,
the geometric extension of the ITV. The single-field optimisation technique in PSIplan focuses
on the application of a homogeneous dose distribution in the target volume for each beam as
single treatment planning goal. Additional constraints cannot be provided. The gaussian spot
size had a nominal sigma of 4 mm in air at isocentre for the highest proton energy of 230 MeV.
Spot spacing was set to one sigma on a regular spot grid in all directions. The air gap between
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the nozzle exit and the patient surface was set to 5 cm. The dose calculation grid was set to
2×2×2 mm3. The dose calculation algorithm was a proton pencil beam algorithm which is stan-
dard in PSIplan. The optimisation procedure was based on the characteristics of Gantry 1 of the
PT site at the Paul Scherrer Institute, e.g. in terms of beam divergence and spot shape. The 3D
dose distribution representing the static case was the recalculation of the created treatment plan
on the 15 % inhale CT phase without artificial density changes.
4.2.3 4D dose calculation
The 3D calculated dose distribution is not representative for the dose which is applied to the pa-
tient when motion is present. For realistic dose assessment the motion needs to be incorporated
into a 4D dose calculation. This section describes, how the the in-house software developed
at the Paul Scherrer Institute performs the 4D dose calculations. More details can be found in
Boye et al. (2013). A schematic of the 4D dose calculation procedure is given in Figure 4.2. The
input data for the 4D dose calculation software are a generated 3D treatment plan, containing
the characteristics of the proton spots (location, proton number, application sequence) delivered
by PSIplan, the treatment machine characteristics (energy layer switching time, magnet timings,
proton dose rate), information about the anatomical changes of the patient (e.g. based on 4D CT
data) and information about the temporal sequence of the anatomical changes (e.g. the breath-
ing pattern recorded for the 4D CT reconstruction). The software was adapted to base the 4D
calculation on characteristics specific for the IBA treatment machine at the UPTD. With the spot
information from the 3D treatment plan and the information about the machine-specific timing
parameters, a "time stamp map" was generated describing the temporal space of the beam ap-
plication. The motion and density information of the patient geometry was extracted from the
4D CT dataset. All 4D CT phases were registered to the treatment planning CT phase with a
deformable image registration using a B-Spline algorithm implemented in the free software Plas-
timatch (Shackleford et al. 2010). Based on that information, "displacement vector maps" were
created giving information about the spatial motion in the patient geometry. With these maps, the
pencil beam spot path was corrected perpendicular to the beam direction. Furthermore, density
changes impacting the proton range were identified based on the 4D CT dataset generating "den-
sity variation maps" correcting the spot path in beam direction. Finally, the individual breathing
pattern was used to identify the 4D CT phase of the patient geometry for a specific time stamp
of a specific pencil beam spot. For this purpose, the time points of the start of reconstruction for
the eight 4D CT phases were extracted from the individual breathing patterns. The most recent
breathing phase with a reconstruction starting point before the actual time stamp was taken as the
current patient geometry. The individual breathing pattern was recorded for about 100 seconds
for each patient and was tailored and repeated such that the whole treatment time was covered
smoothly, if longer. The initial patient geometry, which coincides with the treatment start, usually
is random as it is not influenced by the therapist. To include this effect, the 4D dose calculations
were performed for four possible initial breathing phases at treatment start for each field: 0 %
inhale, 50 % inhale, 100 % exhale and 50 % exhale. A more precise estimation might be pos-
sible using all eight phases. As trade-off between efficiency and precision of the calculations,
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the restriction to four phases was performed, representing a uniform sampling of the theoretical
breathing pattern. Consequently, for each of the three fields per plan, four 4D dose distributions
were calculated. For a single fraction, all 64 possible field and initial breathing phase combina-
tions were generated with Plastimatch independent of their occurrence probabilities. The dose
distribution of the fractionated treatment was created by sampling the probabilities of the four
4D CT phases according to the individual breathing pattern independently for each field and frac-
tion. Sampling was done 100 times for each patient, generating a space of possible total dose
distributions.
Figure 4.2: Schematic display of the 4D dose calculation.
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4.2.4 Assessed impact factors
In addition to the assessment of the effect of the breathing motion on the dose distribution for the
complete patient cohort with the used "standard treatment plan" parameters, for the two subpopu-
lations of the patient cohort, alterations of several parameters were performed and their influence
on the dose degradation compared to the original one was assessed. Standard parameters and
alterations are described in Table 4.2.
Table 4.2: Parameter values of the standard 4D plan and additional values evaluated for the appointed
subpopulations (detailed patient assignment is given in Table B.6).
Plan parameter Value in standard plan Additional examined values
Deformable image registration B-Spline algorithm Demon algorithm1
B-Spline algorithm followed by
Demon algorithm1
Beam angle selection Choice based on clinical Comparison of the three beam
requirements angles chosen for a patient2
Dataset for treatment planning 15 % inhale phase of 4D CT 10 % exhale phase of 4D CT3
Target configuration ITV with artificial density (50 HU) PTV with artificial density (50 HU)3
Beam-specific PTV3
Optimisation approach Single-field optimisation Multi-field optimisation4
Energy layer switching time 2 s 3 s2, 4 s1, 5 s1
Breathing pattern Patient’s own pattern taken Patient specific pattern from the
from the 4D CT acquisition 4D CT acquisition of another patient3
Patient’s moving anatomy 4D CT before treatment start Sequential 4D CT5
Fractionation Standard fractionation 33×2 Gy(RBE) Hypofractionation 3×18 Gy(RBE)1
Motion mitigation technique None Gating1
Layered rescanning1
1 Subpopulation 1 2 Complete patient cohort 3 Subpopulation 2
4 5 patients of subpopulation 1 5 2 patients of subpopulation 2
4D dose calculation – Deformable image registration algorithm The dose accumulation of
all spots in the 4D dose calculation on the planning CT requires a deformable image registration
for voxel assignment between the different phases. Thus, different deformable image registra-
tions, e.g. based on different algorithms, will lead to different 4D dose distributions even if the
deformable image registrations perform similarly in validation studies, e.g. determined by check-
ing landmarks (Zhang et al. 2012). Therefore, for subpopulation 1, the 4D calculation was per-
formed with three different deformable image registrations: one based on a B-Spline algorithm,
the second based on a Demon algorithm and the third based on a B-Spline algorithm followed
by a Demon algorithm. All deformable image registrations were performed with the software
Plastimatch (Sharp et al. 2007; Shackleford et al. 2010). For an exemplary patient, a validation
between the 100 % exhale and the 15 % inhale phase with 20 anatomical landmarks determined
by an experienced physician was performed, revealing mean registration uncertainties with one
standard deviation of (3.1±2.1) mm, (4.1±2.8) mm and (3.6±2.5) mm for the three registration al-
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gorithms, respectively. The three vector fields for this patient are visualised in Figure 4.3, showing
the differently determined vector lengths and directions.
Figure 4.3: Sagittal view of vector fields generated by three different registration algorithms for an exem-
plary lung cancer patient shown on the CT image of the 15 % inhale phase (magenta) overlaid on the
100 % exhale phase (green). Regions with the same HU are grey. Magenta contour: GTV in 15 % inhale
CT dataset, green contour: GTV in 100 % exhale CT dataset.
Treatment planning – Beam angle selection The beam angle influences the dose degrada-
tion in two different ways: first, the angle relative to the main motion direction of the tumour
determines whether the tumour volume is (partially) leaving the irradiated area, due to motion
perpendicular to beam direction, or whether the tumour is shifted in depth, due to motion in beam
direction (Knopf et al. 2011). Second, the spot scan direction relative to the motion direction de-
pends on the beam angle and influences the degree of the interplay effect (Lambert et al. 2005).
In clinical practice, the choice of the beam angle is driven by anatomical needs and technical
capabilities. Thus the "perfect" beam angle in the view of probable dose degradations may dif-
fer from the applicable ones. In the presented treatment planning study, the beam angles were
selected such that a beam exit into a critical structure was avoided. Furthermore, only coplanar
beam angles were chosen. The influence of the beam angles was analysed via the individual
dose degradation for the single fields of the treatment plan for the whole patient cohort.
Treatment planning – 4D CT phase Treatment planning was performed on one single 3D CT
image stack, the 15 % inhale CT phase which is a close approximation to the time-averaged CT.
The average CT phase was identified by Kang et al. (2007) to be best for treatment planning
of PS PT compared to the free-breathing or the maximum intensity projection CT. However, of
the eight 4D CT phases, the patients spend comparably long time in the late exhalation phases.
Consequently, there is a high probability that a multitude of the PBS proton spots will be applied in
these phases. As a consequence, for PBS PT another phase close to the exhalation state might
be better suitable, e.g. Kraus et al. (2011) used the exhalation phase for treatment planning. For
evaluation of the impact of the CT choice, the treatment planning was additionally performed
on the 10 % exhale CT for the ten patients of subpopulation 2, followed by the 4D calculation
accumulating the dose also on the 10 % exhale CT. The dose evaluation was then performed
on the 15 % inhale CT applying the deformable image registration to the dose cube, since the
contours for the OAR were only delineated on that CT.
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Treatment planning – Target volume construction The treatment planning approach using
an ITV with artificial density change tries to ensure the target coverage for all possible tumour
positions although these are not visible in the planning CT. A geometric margin for the PTV
construction was added to include further uncertainties, e.g. caused by the setup (Li et al. 2014a).
However, this concept may be insufficient for density changes in the beam path. Thus, two other
target concepts were tested for subpopulation 2: first, a similar approach but with overwriting the
density inside the PTV instead of the ITV to a specific HU value of 50. Second, an approach with
a beam-specific PTV was evaluated. The beam-specific PTV was generated based on potential
range changes caused by the motion identified in the 4D CT with a software described by Knopf
et al. (2013). Changes in the water equivalent path length along the beam axis were identified
between the 4D CT phases and the original PTV contour was then adapted accordingly to ensure
the irradiation of the PTV contour despite the motion. Treatment planning was performed on the
15 % inhale CT phase without any density changes using the respective beam-specific PTV for
each beam. The three different PTV concepts are visualised in Figure 4.4.
Figure 4.4: Three different PTV concepts compared in the treatment planning study for lung cancer PBS
PT. Left: ITV (inner green contour) with an artificial density change to 50 HU, the treatment planning is
then focused on the PTV (outer green contour). Middle: PTV contour (blue contour) as target for treatment
planning with an artificial density change to 50 HU. Right: beam-specific PTVs for the three fields with
beam angles 147◦ (light orange), 190◦ (red) and 328◦ (coral), indicated by the coloured arrows.
Treatment planning – Multi-field optimisation PBS PT can be applied with single-field opti-
mised treatment fields, where each field delivers a homogeneous dose distribution. An alternative
to this technique is the multi-field optimisation in which only all fields together add up to a homo-
geneous dose distribution in the target volume, cf. Figure 4.5. This second method allows for
steeper dose gradients and may be able to spare close-by OAR better than the single-field op-
timisation (Stuschke et al. 2012). However, the dose gradients are also generated within the
single fields (within the target volume). These in-field gradients cause that multi-field optimisation
is more sensitive to anatomical uncertainties (Albertini et al. 2011). To evaluate the impact of this
technique compared to the single-field optimisation, multi-field optimised PT plans were created
for five patients of subpopulation 1 (cf. Table B.6). Since the best target concept for the multi-field
optimisation has not been identified yet, two approaches were simulated: first, the same target
concept as used for the single-field optimisation with changed density in the ITV (MFO1). Sec-
ond, the treatment planning was performed for the CT without artificial density changes with the
88
4.2 Design of the treatment planning study
PTVtotal as target (MFO2). The second approach, although it does not include any approach to
increase the robustness to motion, was chosen, since the inner-target dose gradients are highly
sensitive to "wrong" density values leading to non-matching gradients when the original density
values are restored. For MFO1, this could lead to unacceptable dose distributions even in the
static case, rendering this treatment planning concept inadequate. The beam-specific PTV con-
cept used for the single-field optimisation without artificial density changes cannot be used for the
multi-field optimisation as this technique requires the same target volume for all beams. However,
treatment planning on an original CT dataset without artificial density changes might be required
to match the dose gradients in the multi-field optimisation and thus could be a beneficial approach
despite the missing additional margins.
Figure 4.5: Dose distribution per field using single-field optimisation or multi-field optimisation (example for
MFO2) showing the higher degree of allowed dose heterogeneity per field with the multi-field optimisation.
For both techniques, the sum of the single fields doses give a homogeneous dose distribution in the target.
Magenta contour: GTV15%inhale, blue contour PTV15%inhale. The larger high dose overshoot of the single-
field optimised plans is caused by the treatment planning concept based on ITV with artificial density
values.
Treatment delivery – Machine parameters The machine parameters comprise the energy
layer switching time, the sweeper magnet switching time, the dose rate and the minimum irradia-
tion time per spot. The former three have nominal values, around which the actual applied values
fluctuate. The last value is a threshold value and fixed. For prospective evaluations, the values for
the switching times and the dose rate can only be estimated with the nominal values. Vendors of
PT machines intend to reduce the energy layer switching time, i.e. the time the treatment machine
needs to change the energy, beyond the currently achievable timings. As a consequence, this
parameter is not clear yet and will likely change in the future by a larger degree than the other two,
both only underlying small fluctuations. Therefore, the energy layer switching time was tested for
its impact on the 4D dose distribution. IBA specified the energy layer switching time between 4 s
and 5 s in 2012 aiming at a reduction to less than 2 s (Closset and Duplicy 2012). For the ten
patients of subpopulation 1, the energy layer switching time was thus varied in 1 s steps between
2 s and 5 s. For the subsequent 30 patients, an energy layer of 2 s and 3 s was simulated. The
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presently achievable energy layer switching time for the IBA machine at the UPTD was about 2 s
in an experimental setup (Priegnitz 2014) and in references measurements performed by IBA for
the irradiation of a 1 l dose cube.
Treatment delivery – Individual breathing pattern Patients’ breathing patterns may vary dur-
ing the course of the RT treatment, due to an acclimatisation of the patient to the treatment situ-
ation or simply the daily changing patients’ condition (Hugo et al. 2006). In Figure 4.6, breathing
patterns of two different patients of the presented patient cohort are shown illustrating possible
interfractional variations. The breathing patterns were recorded with the pressure-belt system
at two different time points (pre-treatment 4D CT and sequential 4D CT) which were three to
four weeks apart. Since the 4D dose calculation is based on the time structure of the breathing
pattern, defining the patient geometry at a specific time point, a change in the pattern will influ-
ence the interplay effect. To evaluate the effect of pattern changes independent of anatomical
changes, the breathing patterns used for the time stamp creation were replaced for the patients
of subpopulation 2 by breathing patterns from other patients, thus preserving realistic pattern ir-
regularity. For the two patients with existing sequential 4D CT (cf. Figure 4.6), the own sequential
breathing patterns were used.
Figure 4.6: Variations of breathing patterns recorded at two different time points three to four weeks apart
(upper and lower row). Patient 27 (a) has a large change in the breathing pattern and also in the breathing
period (4.7 s and 6.1 s), while for patient 38 (b) only small variations occur with a stable breathing period
(7.4 s and 7.2 s). For both patients the breathing patterns show a regular intrafractional structure despite
the interfractional changes.
Treatment delivery – Changes in patient anatomy Changes in the patient anatomy can occur
during the treatment of lung cancer, e.g. tumour growth/shrinkage, pleural effusion or motion pat-
tern changes like peak-to-peak amplitude increase/decrease or baseline shifts (Kwint et al. 2014).
For two of the 40 patients, sequential 4D CT data was available, which was taken three to four
weeks after the original dataset used for treatment planning. The sequential datasets were rigidly
registered based on the bony anatomy with three degrees of freedom (only translations allowed)
to the pre-treatment 4D CT which was used for treatment planning, simulating an image-guided
patient positioning procedure. The rigidly registered datasets were then taken as anatomical
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states of the patient during treatment. A deformable image registration of the rigidly registered
4D CT phases to the original treatment planning 4D CT phase was performed, allowing for a
complete 4D dose calculation. Thus, this evaluation represents the possible dose distribution for
a single fraction during patient treatment including setup uncertainties comparable to a treatment
based on an image-guided setup. Figure 4.7 illustrates the anatomical changes between the
treatment planning CT and the corresponding sequential CT phase for the two patients.
Figure 4.7: Changes of the patient anatomy visualised with the overlay of the rigidly registered in-treatment
CT (green) corresponding to the planning CT (magenta) for the two patient cases (a) and (b) of Figure 4.6.
Magenta contours represent the GTV in the planning CT.
Treatment delivery – Hypofractionated treatment In lung cancer treatment, the hypofrac-
tionated treatment with SBRT was shown to be efficient for increasing loco-regional control and
survival rates for early tumour stages (Louie et al. 2015). Thus, it may be reasonable to use
hypofractionation for PT as well in such cases. Seco et al. (2012) evaluated the use of hypofrac-
tionated treatment with protons and concluded that PT might be a feasible treatment option for
peripheral tumours. However, their evaluation did not consider tumour motion. Case studies
with PS PT showed the practical applicability of hypofractionation with promising patient outcome
(Hata et al. 2007; Nakayama et al. 2010; Westover et al. 2012). Hypofractionated PBS PT re-
quires further evaluation with respect to the interplay effect. Thus, to evaluate the impact of the
prolonged treatment time per field in hypofractionated treatment, which may decrease the inter-
play effect, and the reduced number of fractions, which may decrease the efficiency of averaging
out degraded dose distributions (Dowdell et al. 2013), a SBRT treatment was simulated for the
patients of subpopulation 1 using a fractionation schedule of 3×18 Gy(RBE).
Motion mitigation – Gating Reducing the tumour motion during treatment application is an
effective strategy to reduce its impact on the dose distribution (Engelsman et al. 2013). This is
possible by limiting the irradiation of the patient to only a part of the breathing cycle, so-called gat-
ing. However, this strategy prolongs the treatment per fraction and thus influences patient comfort
and patient throughput. Furthermore, depending on the size of the "gating window", residual mo-
tion will still impact the dose distribution. For an evaluation, how much the dose degradation
may be reduced, an amplitude-based gating window, which stops the irradiation when the rel-
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ative breathing amplitude is above 50 %, was simulated for the patients of subpopulation 2. A
50 % gating window was taken as it may represent an acceptable trade-off between prolonga-
tion of treatment time and motion mitigation. Since the gating time structure could not easily
be implemented in the 4D dose calculation procedure, a rough approximation was performed by
assigning complement breathing phases included in the gating window to the breathing phases
that should be omitted by gating, i.e. 50 % inhale geometry was exchanged by a 50 % exhale
geometry, 90 % inhale by 10 % exhale, 100 % exhale by 0 % inhale and 70 % exhale by 15 %
inhale. The treatment planning target and the CT phase for treatment planning were not adapted.
Motion mitigation – Rescanning Rescanning, i.e. the multiple application of the proton spots
during one treatment fraction, is a method which can be applied to spread the proton spot ap-
plication throughout the breathing cycle and thus to reduce the interplay effect. The best way of
applying those rescans is a topic of current research and may depend on the treatment machine
and plan characteristics. Knopf et al. (2011) determined that the highest effect occurs for plans
with few fields and field directions different from the main motion direction. Bernatowicz et al.
(2013) and Grassberger (2014) found that systems with slow energy switching times (above 1 s)
benefit most from layered rescanning, i.e. from a multiple spot application within one energy layer
before moving to the next energy, in contrast to volumetric rescanning where the spot application
is repeated after the complete volumes was scanned. Kraus et al. (2011) found in their lung can-
cer case study, that ten times layered rescanning improved the dose distribution remarkably but
might not be sufficient as sole motion mitigation technique. In the presented treatment planning
study, the efficiency of ten times layered rescanning was tested for the patients of subpopula-
tion 1.
4.2.5 Evaluation parameters
All evaluations were based on the DVH of the dose distributions for the respective volumes which
were generated with the software Plastimatch. The static case was set as the reference dose
distribution. Differences between the static case and the 4D dose distributions were assessed by
∆Parameter = Parameter4D − ParameterStatic. (4.1)
The fractionated treatment was analysed based on the assumption that the examined parameter
changed between the time of treatment planning and the first treatment. The fractionated treat-
ment consisted completely of single fractions which were simulated with the changed parameter.
Target volume The evaluated target volume was the PTV15%inhale, in the following simply re-
ferred to as PTVeval. Main focus in the target evaluation was laid on the PTVeval since the dose
degradation calculations only considered the impact of the breathing motion but no dose changes
due CT calibration and setup uncertainties. Thus, the goal was to maintain the planned dose
distribution in the PTVeval completely such that this contour might still be a useful structure for
covering the additional uncertainties. Used DVH parameters were V80, V90, V95, V98 and D98
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for the evaluation of the target coverage and low dose volumes ("cold spots") as well as V107,
V110, V120 and D2 for the evaluation of high dose volumes ("hot spots"). For the evaluations of
the influences of changes in the impact parameters described in Section 4.2.4, main focus was
set to the ICRU recommendations for treatment planning with V95 and V107. The homogeneity of
the dose in the target volume was evaluated with the Homogeneity Index (HI). The ideal value is
0, increasing with decreasing homogeneity. The HI was calculated according to Wu et al. (2003)
with
HI =
D2 − D98
Dprescribed
. (4.2)
with the near maximum dose D2, i.e. the dose to 2 % of the target volume, the near minimum
dose D98, i.e. the dose to 98 % of the target and the prescribed target dose Dprescribed.
Furthermore, TCP calculations were carried out for the PTVeval. TCP modelling has been
performed by several groups developing models with differently complex approaches, from a
simple single-hit model up to the inclusion of biological variables like cell density, cell sensitivity or
(accelerated) proliferation, to name but a few (Källman et al. 1992; Deasy 1996). Guckenberger
et al. (2011) have shown that the used model type and complexity significantly influence the
absolute TCP values, e.g. by addressing volume effects or the cell sensitivity inside the tumour
volume differently. The evaluation of TCP differences between two treatment techniques without
changes in the biology of the target, similarly to the presented analyses, was robust to model
differences, though. Therefore, a simple TCP model based on a Poisson model for voxel-wise
calculation described by Källman et al. (1992) was deemed sufficient. Parameters for the model
were based on a study of Willner et al. (2002) calculating the local tumour control probability of
patients with lung cancer 24 months after treatment. The parameter values were similar to the
ones determined by Martel et al. (1999) and thus seem reasonably applicable for the estimation
of the TCP of lung tumours. All lung lesions in the presented patient cohort were evaluated as
lung tumours, independent of their actual tumour type (lung tumour or metastasis). A correction
of the voxel dose to the 2 Gy(RBE) fractionation dose equivalent, EQD2, was performed for each
voxel according to Equation (2.3) with α/β = 10. Based on the fraction-corrected dose, the TCP
per voxel was calculated by
TCPvoxel = 2
− exp
[
2
ln(2)
γ50
(
1−
EQD2, voxel
D50
)
+ln(v)
]
(4.3)
with the parameters γ50 = 3.52, D50 = 74.5 Gy(RBE) and the fractional volume v of each voxel
of the target volume. The total TCP was then calculated as the product of the voxel-wise TCP
values:
TCPtotal =
∏
TCPvoxel. (4.4)
The TCP estimations for the 64 dose distributions of a single fraction were carried out as "worst-
case" evaluations based on the assumption that all 33 delivered fractions would be the one of the
single fraction, preventing any averaging effects of the fractionated treatment, i.e. by multiplying
the dose distributions of the single fractions with 33 fractions. In the fractionated treatment, the
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single fractions had different spatial dose distributions. However, since only DVH files were used
for data analysis, the spatial dose distribution was unknown. For this reason, the TCP of the
fractionated treatment was approximated assuming that the complete treatment was delivered in
33 fractions with equal dose distributions, thus neglecting the different dose per voxel applied
with the different single fractions.
Organs at risk Evaluated OAR were the ipsi- and contralateral lung with Dmean, V20Gy(RBE) and
V5Gy(RBE) and the spinal cord with Dmax, being the most important OAR which were delineated in
all patient datasets. Furthermore, subgroups were assembled for the evaluation of the oesopha-
gus dose (Dmean, V60Gy(RBE), 9 patients) and the heart dose (V60Gy(RBE), V40Gy(RBE), 10 patients)
for patients with tumours in close proximity to these OAR, cf. Table B.6 for specific patient in-
formation. The evaluated dose parameters for OAR were taken from the recommendations of
the RTOG 0617 trial (RTOG 2014) for conventional XT. These recommendations were comple-
mented with additional parameters (Dmean, Dmax) if the tolerance doses were likely not reached
with the expected reduced doses in PT. Doses of the single fractions were scaled to a fraction-
ated treatment with 33 fractions for the OAR, again generating "worst-case" scenarios were no
averaging could occur, similar to the TCP evaluation. An overview of the parameters is given in
Table 4.3.
For the whole patient cohort, the dose parameters are described by their median values and
the ranges determined by the 5th and 95th percentiles (P5 and P95), if not stated differently.
The 4D dose distributions were examined for possible dependences, e.g. on tumour motion or
volume. If dependences could be found, subgroups were assembled and independent two-sided
two-sample t-tests were performed between the subgroups based on the median values of the
patients’ 4D dose distributions. For OAR, mean changes of ±0.5 Gy(RBE) for Dmean and Dmax
and of ±1 % for the volume parameters of the complete treatment were rated as clinically relevant
and set as threshold for the identification of significant changes between the static dose and the
4D dose distributions (one-sided superiority t-test). Changes between the median values of the
4D dose distribution parameters generated with different impact factor values were compared
with two-sided paired t-tests. The significance level was set to 0.05.
4.3 Results and Discussion
4.3.1 Dose degradation of standard treatment plans
Before analysing dependences of the interplay effect on several treatment planning and treatment
delivery characteristics, an evaluation of the static case plan quality and the magnitude of the
dose degradation for the "standard treatment" was required, cf. description in Table 4.2. The
static and 4D dose distributions of an exemplary single fraction and fractionated treatment are
shown in Figure 4.8 for two patient cases, one with small dose changes due to motion and one
with large dose degradation, including the DVH for the PTVeval and the main OAR, the ipsilateral
lung.
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Figure 4.8: Motion induced dose distortion of the standard plan: The static (left), an exemplary single
fraction (middle) and an exemplary fractionated treatment (right) 4D dose distribution overlaid on an axial
CT slice of two representative patients with different motion peak-to-peak amplitudes and the respective
DVH for the PTVeval (continuous lines) and the main OAR, the ipsilateral lung (dotted lines). The GTV
and the PTVeval are depicted in red and blue. The DVH show the static case (black), the pictured 4D
dose distributions (red) and the calculated 64 single fraction and 100 fractionated treatment 4D dose
distributions (grey). Patient 10 had a small tumour motion and therefore showed small dose degradations,
while for patient 37 with a large tumour motion the dose degradation was profound. The fractionation
reduced the dose degradation and the variations of the possible dose distributions. 100 % relative dose
corresponds to 2 Gy(RBE) for a single fraction and 66 Gy(RBE) for the fractionated treatment.
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Static case treatment plan quality The quality of the static case dose distribution was evalu-
ated on the planning CT dataset without artificial density changes. The tolerances, median and
range values for the PTVeval and the evaluated OAR are given in Table 4.3. The median PTVeval
coverage in terms of V95 was 99.7 % (97.3 %–100.0 %). V90 of the PTVeval was above 99 % for
all patients. Hotspots determined by V107 in the PTVeval were in median 1.3 % (0.0 %–11.0 %)
with noticeably higher values for tumours with less tumour motion peak-to-peak amplitudes in CC
direction (p < 0.01 between patients with less than 5 mm motion peak-to-peak amplitude versus
patients with higher motion peak-to-peak amplitude), cf. Figure 4.9. This might be caused by
the treatment planning approach using artificial CT values: the ITV for tumours with little motion
are almost identical with the GTV, but treatment planning is performed with "false" CT values.
As a result, dose changes in the static case occur, leading to increased high dose volumes in
the targeted area. For tumours with large motion peak-to-peak amplitudes the target volume is
increased by a larger amount resulting in a smaller portion of the target planned with artificial CT
values. This reduced the impact of the proton spots with ranges calculated for the artificial den-
sity in the CT without density changes. However, no dependence on the volume or the volume
increase was found. A good dose homogeneity could be achieved in the PTVeval with median
HI = 0.096 (0.070–0.146). The HI also showed a trend of increased homogeneity with increasing
motion peak-to-peak amplitude, mainly caused by the smaller high dose values (reduced D2,
similar to V107 values). The estimated TCP was low, as expected, with the targeted total dose of
66 Gy(RBE) leading to a median TCP = 14.7 % (11.4 %–18.3 %) for the patient cohort.
The DVH parameters for the OAR of the static cases were below the tolerances for all patients
with one exception: for a single patient with a large tumour volume (28.6 ml versus median 8.1 ml
of the patient cohort) and a small ipsilateral lung volume (1028 ml versus median 2127 ml) the tol-
erances of the ipsilateral lung were exceeded with Dmean = 21.1 Gy(RBE) and V20Gy(RBE) = 38.4 %.
The treatment plan was accepted despite these values for three reasons: first, the contralateral
lung could be spared completely, second, in clinical decisions the chosen DVH parameters are
usually used as constraints for both lungs together and third, a reduction of the ipsilateral lung
Figure 4.9: Static dose parameters for the PTVeval per patient versus motion peak-to-peak amplitude in
CC direction. Inhomogeneous dose distributions occurred more frequently for patients with small tumour
motion peak-to-peak amplitudes in CC direction, which is related to the larger spread in TCP, HI, V95, V107,
D98 and D2. VD and TCP are given in 1/100 %.
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Table 4.3: Evaluated parameters of the PTV and OAR, tolerance doses and achieved dose parameters
for the static case of the fractionated treatment for the patient cohort.
Target Parameter Static case dose values Planning goal
median (range)
PTV V80 100.0 % (100.0–100.0) % V80 = 100 %
V90 100.0 % (99.9–100.0) % V90 = 100 %
V95 99.7 % (97.3–100.0) % V95 ≥ 95 %
V98 94.8 % (83.5–98.4) % V98 ≥ 90 %
V107 1.3 % (0.0–11.0) % V107 ≤ 2 %
V110 0.0 % (0.0–1.3) % V110 = 0 %
V120 0.0 % (0.0–0.0) % V120 = 0 %
D2 70.4 Gy(RBE) (69.3–72.3) Gy(RBE) D2 ≤ 70.6 Gy(RBE)
D98 64.0 Gy(RBE) (62.6–64.8) Gy(RBE) D98 ≥ 62.7 Gy(RBE)
HI 0.096 (0.070–0.146) minimise
TCP 14.7 % (11.6–18.3) % maximise
Organ at risk Parameter Static case dose values Tolerance dose
median (range)
Spinal cord Dmax 0.0 Gy(RBE) (0.0–1.8) Gy(RBE) Dmax ≤ 50.5 Gy(RBE)
Lungs (both)1 Dmean 6.1 Gy(RBE) (1.8–13.3) Gy(RBE) Dmean ≤ 20.0 Gy(RBE)
V20Gy(RBE) 11.5 % (3.1–26.2) % V20Gy(RBE) ≤ 37.0 %
V5Gy(RBE) 18.3 % (6.4–36.7) % V5Gy(RBE) without specific goal2
Oesophagus3 Dmean 0.0 Gy(RBE) (0.0–0.4) Gy(RBE) Dmean ≤ 34.0 Gy(RBE)
V60Gy(RBE) 0.0 % (0.0–0.0) % V60Gy(RBE) without specific goal
Dmax 0.0 Gy(RBE) (0.0–13.6) Gy(RBE) Dmax without specific goal2
Heart4 V60Gy(RBE) 0.0 % (0.0–0.0) % V60Gy(RBE) < 33 %
V40Gy(RBE) 0.0 % (0.0–0.0) % V40Gy(RBE) < 100 %
Dmean 0.1 Gy(RBE) (0.0–0.4) Gy(RBE) Dmean without specific goal2
Dmax 6.4 Gy(RBE) (0.0–50.5) Gy(RBE) Dmax without specific goal2
1 Ipsilateral and contralateral lungs were evaluated separately, the parameter values are given for the ipsilateral lung,
the contralateral lung was spared completely except for one patient case
2 Additional parameter not taken from the RTOG 0617 trial
3 Evaluated for nine patients with tumours in close proximity to the oesophagus
4 Evaluated for ten patients with tumours in close proximity to the heart
dose could not be achieved by, e.g. changing the beam angles. All other tolerances were fulfilled
with rather wide differences to the tolerances: in only five of forty patients the spinal cord dose
was above zero. Similarly, doses above zero in the oesophagus were found in only two of the
nine evaluated patients. The heart doses were small and did not reach the tolerances recom-
mended by the RTOG for any patient, V40Gy(RBE) = 0 % and V60Gy(RBE) = 0 %, but with values for
the additional parameters with a maximum Dmean = 0.5 Gy(RBE) and highest Dmax = 52 Gy(RBE).
No dose was spread into the contralateral lung for all patients except for one: for this patient the
beam angle selection led to an overshoot of dose into the contralateral lung, which resulted in a
negligible dose deposition of Dmax = 12.5 Gy(RBE) and Dmean = 0.1 Gy(RBE).
4D dose degradation of the standard plan in target volumes The 64 calculated 4D dose
distributions of the possible single fractions revealed that the tumour motion leads to the gener-
ation of cold spots in the tumour volume. Large low dose volumes were revealed by decreasing
values of V80, V90, V95 and V98 and for the near minimum dose evaluated by D98. Hot spots in-
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crease similarly in the 4D dose calculation with increased values for V107, V110, V120 and D2. As
a consequence of the increase in low dose volumes and high dose volumes, the homogeneity of
the target volumes was reduced by the motion, described by increasing HI. Furthermore, mostly
reductions of the TCP occurred, revealing the clinical impact of the dose degradation in terms of
patient outcome. However, in some cases the tumour motion led to a dose distortion which was
evaluated to be beneficial for the patient compared to the planned static case, e.g. by increas-
ing V98 and D98 values and decreasing V107 and D2, leading in some cases to an increased
TCP. The parameter differences ∆V95, ∆V107, ∆HI and ∆TCP between the single fraction 4D
dose distributions and the static case calculated according to Equation (4.1) are shown in Fig-
ure 4.10 (a) for all patients sorted by their tumour motion peak-to-peak amplitudes in CC direction.
The motion amplitudes are indicated by the underlying colours.
The magnitude of the dose degradation was patient specific. A clear dependence on the indi-
vidual tumour motion peak-to-peak amplitude in the direction of the usually largest displacement,
CC, was found. Higher peak-to-peak amplitudes led to a larger spread in parameter values
throughout the 64 calculated single fraction dose distributions and to a larger median difference
between the static and the 4D dose distributions of the individual patients for all evaluated pa-
rameters. A motion peak-to-peak amplitude of 5 mm was found to be a threshold below which
the dose degradation was rather small in a majority of the cases. Dose degradations in the target
occurred increasingly above 5 mm and even stronger above 10 mm. For this reason, a subgroup
evaluation was performed by splitting the patients into three subgroups depending on their tu-
mour motion peak-to-peak amplitude: up to 5 mm (Subgroup A), between 5 mm and 10 mm (Sub-
group B) and above 10 mm (Subgroup C). The parameter differences for the three subgroups
are shown in Figure 4.11 (a) for the single fractions. The median of the parameter differences
between the static and the different 4D dose distributions was calculated for each patient. This
median was compared between the subgroups to evaluate the impact of the motion on the dose
degradation. The dependence of the dose degradation on the motion peak-to-peak amplitude
was statistically significant between all three subgroups for the median differences between the
4D dose distributions and the static of the respective patients for V90, V95, V98 and D98 (p < 0.01).
Hot spots increased similarly in the 4D dose calculation, again with a larger effect with higher mo-
tion peak-to-peak amplitudes (p < 0.01 for V110 and D2 between all subgroups, p < 0.01 for V107
for Subgroup A versus Subgroup B and C and p = 0.02 for Subgroup B versus Subgroup C).
Changes in the HI were significant between all three subgroups (p < 0.01) with larger differences
for increasing motion amplitudes. The impact of the dose degradation on the TCP ranged from
small changes for Subgroup A (median TCP = -0.9 %) to unacceptably large changes for Sub-
group B and C (median TCP = -4.0 % and TCP = -5.7 %, respectively). The TCP reduction was
significantly larger for patients of Subgroup B and C compared to Subgroup A (p < 0.01). Dose
variations in terms of underdosage per fraction for the patients with motion peak-to-peak ampli-
tudes below 5 mm were mainly below 10 % of the targeted dose: ∆V90 were mainly 0 % for these
patients, keeping V90 at 100 %. Such a small dose variation per fraction was estimated by Bort-
feld and Paganetti (2006) to have a negligible biological effect. This patient subgroup might thus
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Figure 4.10: Motion induced dose distortion of the standard plan per patient: Parameter differences
(∆Parameter = Parameter4D − ParameterStatic) between the 4D dose distribution scenarios and the static
case for the PTVeval (boxplots including mean values as squares) for (a) the single fraction (64 scenar-
ios) and (b) the fractionated treatment (100 randomly selected scenarios). The CC motion peak-to-peak
amplitude for each patient is indicated by the differently coloured backgrounds in the graphs. The verti-
cal dashed lines denote the separation of patients into subgroups with CC motion up to 5 mm, between
5 mm and 10 mm and above 10 mm. Note the different scales of the single fractions and the fractionated
treatment.
be of little concern when treated with PBS PT. For patients with motion above 5 mm, the 10 %
maximum dose variation, hypothesised to have a minor biological impact, was mainly exceeded.
The fractionated treatment reduced the dose degradation seen for the single fractions in the
majority of the patients, cf. Figure 4.10 (b). However, for some patients significant mis-dosage
after 33 fractions was still present: the fractionation was not sufficient to yield the desired ho-
mogeneous dose distribution in these cases. The general trend which was observed for single
fractions, that an increase in motion peak-to-peak amplitude in CC direction increased the dose
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Figure 4.11: Motion induced dose distortion of the standard plan per subgroup: Parameter differences
between the patient-specific median 4D dose distribution scenarios and the respective static case (box-
plots including mean values as squares). For the fractionated treatment, D2 and D98 values are scaled
to a single fraction (factor 1/33) for better visibility. VD and TCP are given in 1/100 %. The subgroups are
indicated by the different colours.
degradation, was still present for the fractionated treatment, but the differences between the three
subgroups were much smaller, cf. Figure 4.11 (b). As a consequence, significant differences be-
tween the subgroups were only seen in V98 between all subgroups (p < 0.01 Subgroup A versus
B and C, p = 0.01 Subgroup B versus C) and in V95, D98, HI and TCP between Subgroup A
and Subgroup B and C (p < 0.01). The shown reduction of the dose degradation caused by the
fractionation is influenced by two factors: first, the consideration of the different breathing phase
probabilities at the start of the treatment, which was used for the simulation of the realistic frac-
tionated treatment, while the 64 single fraction dose scenarios did not include this occurrence
probabilities. As a consequence, patients with larger dose degradations in the fractionated treat-
ment might be those patients with higher probabilities of being in breathing phases at the treat-
ment start, which lead to unfavourable dose distributions. Second, the random superposition of
the differently degraded dose distributions per fraction might influence the effect in fractionated
treatment (averaging effect). For example the occurrence of low dose volumes in one fraction
could be balanced by similarly large high dose volumes at the same position in another fraction,
independent of the magnitude of the dose degradations in the single fractions. Thus, fractiona-
tion could lead to acceptable total dose distributions even if all single fraction doses were largely
degraded. However, as long as the biological effect of the dose degradation per fraction and the
impact of smoothing such differences by fractionation over a treatment course of six weeks is
unknown, it remains unclear whether the reduction of the dose degradation in the fractionated
treatment might result in an acceptable clinical outcome. The analysis of the fractionated treat-
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ment showed that the motion peak-to-peak amplitude alone was no certain indicator, whether
the induced dose degradation was of a high magnitude in a complete treatment course. The
limited power of the motion peak-to-peak amplitude as a predictor for the dose degradation was
also described by Grassberger (2014) contrasting the findings of simplified phantom studies.
Nevertheless, for patients with CC motion peak-to-peak amplitudes of less than 5 mm the dose
degradation remained on an acceptable level for the fractionated treatment, which supports the
choice of this subgroup as most relevant for the application of PBS PT.
Altogether, tumour motion peak-to-peak amplitudes of less than 5 mm in the CC direction have
a small impact on the dose distribution generated by PBS PT for both, the single fractions and
the fractionated treatment. Thus, for patients with tumours moving less than 5 mm PBS PT can
be used without additional motion mitigation procedures. A 5 mm motion threshold for patient
selection would allow for a treatment with PBS PT of 19 of 40 patients (47.5 %) of the presented
cohort. The inclusion of additional patients in the motion analysis treated at the UKD with SBRT
in 2012, who had 4D CT datasets, but were excluded from the 4D dose calculation due to missing
breathing patterns, affirmed this result (34 of 75 patients, 45 %). This patient cohort consisted of
patients with rather small tumour volumes which tend to have larger motion peak-to-peak ampli-
tudes compared to large tumour volumes (Yu et al. 2012). Liu et al. (2007) found in their patient
cohort, consisting of 57 % patients with advanced stage NSCLC, that 60 % of the patients had
motion peak-to-peak amplitudes below 5 mm. Thus, by including patients with higher tumour
stages in the patient selection, even more lung cancer patients could probably be included in
PBS PT treatment without motion mitigation. However, a larger dose degradation might occur
for individual patients despite a small tumour motion peak-to-peak amplitude. Consequently, an
individual risk assessment with a 4D dose calculation should still be performed before treatment
start to identify these patients. Furthermore, the acquisition of 4D CT datasets during the treat-
ment is recommended to determine the stability of the motion amplitudes and patterns and react
to changes which may impact the dose distribution, if necessary.
For patients with tumour motion peak-to-peak amplitudes above 5 mm, the dose degradation
was much larger and mainly remained unacceptable even with fractionation. For these patients,
additional motion mitigation techniques should be considered, even more so since the biological
impact of dose variations in a single fraction is unknown. This is in accordance with the rec-
ommendation of the Task Group 76 of the American Association of Physicists in Medicine, who
advised for the use of motion mitigation techniques when treating tumours with motion peak-to-
peak amplitudes above 5 mm with RT (Keall et al. 2006). As first center, the M.D. Anderson
Cancer Center introduced treatment of lung tumours with PBS PT in their clinical practice with
the restriction to patients with tumour motion peak-to-peak amplitudes below 5 mm (Chang et al.
2014). This patient restriction is used as well in the clinical trial assessing dose-escalation capa-
bilities using PBS PT (ClinicalTrials.gov Identifier: NCT01629498) by the M.D. Anderson Cancer
Center and the Massachusetts General Hospital: patients with motion peak-to-peak amplitudes
above 5 mm are excluded, if the motion cannot be reduced to below 5 mm with a motion mitigation
technique like gating or breath-hold (Liao 2012).
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4D dose degradation of the standard plan in organs at risk The effects of the patient breath-
ing motion on the evaluated dose parameters of the OAR was rather negligible in all cases. The
motion led to only small variations for most of the parameters in most of the patients. Figure 4.12
shows the static case and the single fraction and fractionated treatment 4D dose distribution DVH
parameters of OAR for the patient cohort. Dmean in the ipsilateral lung was changed relevantly
(±0.5 Gy(RBE), cf. Section 4.2.5) only for two patients: for these two patients, the single frac-
tion dose scenarios scaled to 33 fractions showed a maximum increase in Dmean of 0.6 Gy(RBE)
and a maximum decrease of -1 Gy(RBE). Maximum changes of the volume parameters V5Gy(RBE)
and V20Gy(RBE) (relevant changes: ±1 %, cf. Section 4.2.5) were below 3 % with median values
of 0 %, rated relevant in only 8 and 3 patients, respectively. None of these relevant changes
concerned a patient with motion peak-to-peak amplitudes below 5 mm. Significant changes be-
tween the subgroups were seen for the volume parameters of the ipsilateral lung for Subgroup A
versus subgroup C (p < 0.01 for V5Gy(RBE) and p = 0.015 for V20Gy(RBE)) and Subgroup B versus
Subgroup C (p < 0.01 for V5Gy(RBE) and p = 0.01 for V20Gy(RBE)). No dose parameter changes
occurred between the 4D dose distributions and the static case dose of the contralateral lung.
The spinal cord maximum dose, which was 0 Gy(RBE) for the majority of the patients in the static
case, was increased in only four patients for whom the dose in the static case was also different
from 0 Gy(RBE). Relevant changes were seen in one patient only, but did not exceed the dose
constraint of 45 Gy(RBE) due to the low dose level in the static case. Differences in the oesoph-
agus dose occurred only for the two patients who had static case doses above 0 Gy(RBE), cf.
patient 6 and 27 in Figure 4.12. The majority of the 64 calculated 4D dose distribution scenar-
ios per patient led to dose decreases with Dmax up to -2.9 Gy(RBE) and a maximum increase
of 1.2 Gy(RBE). The changes in Dmean were also mainly dose decreases below 0.1 Gy(RBE).
V60Gy(RBE) was 0 % for the static case and remained at that level for the motion scenarios. The
heart dose parameters were also only influenced by the motion for the six patients with dose
values above 0 Gy(RBE) in the static case. The worst case increase in Dmax of the 64 dose distri-
bution scenarios for each of the six patients was 17.0 Gy(RBE) and the maximum decrease was
-7.5 Gy(RBE). Dmean changes were below 0.2 Gy(RBE), being dose decreases in the majority of
the scenarios. The volume parameters V60Gy(RBE) and V40Gy(RBE) were not changed, remaining
at 0 %. The already small dose parameter variations in OAR of the single fraction dose scenarios
were further reduced for the heart and the oesophagus considering a realistic fractionated treat-
ment. Due to almost no variation of the dose parameter differences in the single fraction dose
scenarios for the ipsilateral lung and the spinal cord, parameter differences remained almost the
same for the realistically simulated fractionated treatment.
For all evaluated patient cases, the effect of the motion on the dose in surrounding normal
tissue, mainly the ipsilateral lung, was negligible. The static case dose parameters for the OAR
were good estimators for the deliverable doses. This might be different for patients with advanced
tumours, which are larger than the tumours in the examined patient cohort. For example the
patient with one of the largest tumour volumes (patient 28) also showed the largest deviations in
OAR dose parameters from the static case. Furthermore, for patients with large target volumes,
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Figure 4.12: Motion induced dose distortions of the standard plan per patient: DVH parameters for OAR
of the static dose distribution (red dots) and the 4D dose distribution scenarios (boxplots including mean
values as squares) for (a) the single fractions (64 scenarios) and (b) the fractionated treatment (100 ran-
domly selected scenarios). The CC motion peak-to-peak amplitude for each patient is indicated by the
differently coloured backgrounds.
the dose to OAR might already be close to the tolerance dose, such that dose deterioration might
lead to unacceptable treatment plans. However, in the present study the dose degradation mainly
led to reduced dose values compared to the static case. Thus, the dose degradation might be of
less concern for the OAR compared to the degraded target coverage.
A relevant question might be, whether the used dose parameters for OAR are sufficient to
estimate treatment-related toxicities like radiation-induced pneumonitis. Several studies found a
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clear dependence of pneumonitis on the mean lung dose or on volume parameters like the used
V20Gy(RBE) and V5Gy(RBE) (Kwa et al. 1998; Graham et al. 1999; Seppenwoolde et al. 2003;
Claude et al. 2004; Yorke et al. 2005; Kong et al. 2006; Guckenberger et al. 2010). However,
Rancati et al. (2003) pointed out, that other factors like a chronic obstructive pulmonary disease
or the use of mitomycin are indicators for pneumonitis development and might be confounding
factors if not included in risk evaluations. In their study, they could show only a trend for cor-
relation between the mean lung dose and the development of a pneumonitis when corrected
for the other factors. Similarly, Rodrigues et al. (2004) found in their review of studies evaluat-
ing prediction parameters for pneumonitis that no ideal dose parameter has been identified yet
and that probably several factors need to be considered. This is supported by recent studies
which indicate that localised high doses increase the probability of developing radiation-induced
lung diseases like pneumonitis (Willner et al. 2003; Tucker et al. 2013; Pham et al. 2014). Such
changes are rather unlikely to be found evaluating the mean lung dose, V20Gy(RBE) or V5Gy(RBE),
especially in patients with small tumours. However, such regions of localised high dose deposi-
tion increase using PT despite reduced mean lung doses due to the overshoot volumes which are
required for the mitigation of range uncertainties (Seco et al. 2012). For other OAR like the heart,
the recommended dose parameters based on XT treatments are insufficient in most cases, as
the dose could be reduced so much that the parameters were all 0. For this reason, these pa-
rameters were supplemented by other parameters in the presented study, cf. Table 4.3. However,
the biologic impact of these parameters is uncertain.
In general, the dose degradation due to the tumour motion was only relevant if the considered
OAR was very close to the tumour and consequently to the beam or in the beam path. This was
almost never the case for the evaluated patient cohort. Consequently, the effect of the motion on
the dose distribution of these OAR was difficult to evaluate in the presented treatment planning
study. The effects might be more severe especially for patients with larger tumours which are
closer to the OAR.
Dependence on deformable image registration algorithm The result of the 4D dose cal-
culation depend on the vector fields generated by the deformable image registration. Different
deformable image registration algorithms lead to different vector fields, even if they perform simi-
larly in validation using landmarks. Exemplary, the deformable image registration performance of
the three tested algorithms was validated for one patient, revealing similarly rated uncertainties,
cf. Section 4.2.4. Despite that, the estimated 4D dose degradations were different. Figure 4.13
shows exemplarily a single fraction 4D dose distribution of patient 24 calculated with all three
deformable image registration algorithms and the respective DVH. The deformable image regis-
tration vector fields assigned the voxels differently between the single CT phases. As a conse-
quence, the deformable image registration algorithm changed the position and the magnitude of
the dose degradations in the target volume. This also influenced the resulting dose parameters.
The fractionation reduced the dose degradation and the variability of the dose distributions, but
still differences between the 4D dose calculations of the different deformable image registration
algorithms occurred.
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Figure 4.13: Dose distortion depending on the deformable image registration: (a) an exemplary single
fraction 4D dose distribution overlaid on an axial treatment planning CT slice of patient 24. The GTV is
depicted as red contour and the PTVeval as blue contour. The respective DVH are shown for the PTVeval
(red line), the 64 single fraction 4D dose distribution scenarios (grey) and the static case (black). (b) The
PTVeval DVH of patient 24 for the fractionated treatment are illustrated. The 4D dose distribution with the
same field combination are shown in red, all simulated 4D dose distribution scenarios of the fractionated
treatment in grey and the static case in black.
Thus, an implicit uncertainty in all 4D dose calculations is the required deformable image regis-
tration for the voxel mapping between the different 4D CT phases. The 4D dose differences might
increase with larger motion and with increasing tumour volumes. Larger motion might increase
the effect of differences between the deformable image registration algorithms for two reasons:
first, the effect of the uncertainty of a deformable image registration vector field increases with
increasing motion amplitudes, resulting in larger vector lengths. As a consequence, differences
between the deformable image registrations might result in larger dose variations (Yeo et al.
2012). Second, with increasing peak-to-peak tumour motion amplitudes, the interplay effect gets
more pronounced, i.e. the 4D dose distribution has larger deviations from a homogeneous dose
and the individual voxel doses differ more. Only when dose distribution inhomogeneities are of
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a relevant magnitude, the different voxel shifts of the three deformable image registration algo-
rithms can result in visible location changes of those inhomogeneities. This is not only the case
for dose degradations induced by the tumour motion, but also occurs when the original dose
distribution already included inhomogeneities. Such inhomogeneities might be especially rele-
vant for close-by OAR lying in dose gradient areas. Furthermore, larger tumour volumes might
increase the differences between the deformable image registrations since algorithms usually
perform worse in low-contrast regions, which are larger for big tumours (Rohlfing 2006).
Overall, the used deformable image registration has a relevant impact on the 4D dose dis-
tribution, the evaluated dose parameters and therefore also on the evaluation of the 4D dose
calculations. As a consequence, even with perfect input parameters without any uncertainties,
the lack of a "perfect" deformable image registration will result in 4D dose distributions which are
only estimates for the real dose distribution. However, the actual deformable image registration
might be of minor importance if relative comparisons of several 4D dose distributions are per-
formed which were generated with the same deformable image registration but differ by other
parameters, e.g. the evaluation of input parameters used in treatment planning.
4.3.2 Impact of treatment planning approach
Evaluated treatment planning parameters comprised the selection of beam angles, the anatom-
ical representation of the patient (4D CT phase), the target structure and the choice of a PBS
optimisation technique. All these factors might influence the robustness of the treatment plan
against motion but can be modified by treatment planning. Thus, to achieve the best possible
treatment, independent of further motion mitigation techniques, a careful evaluation and conse-
quent choice of these values is fundamental.
The results of the subanalyses showed that the parameter impact on the dose degradation
was patient specific. For one patient the change of an impact factor could lead to improved
DVH parameters, while for a patient with similar motion amplitude the same factor change led
to declined parameter values. To visualise these individual impacts, the results are shown in
Sections 4.3.2–4.3.4 for each patient of the subpopulations in two ways: first, for exemplary
patients, DVH are shown illustrating the static case DVH and the DVH of the 4D dose distribution
scenarios, i.e. the 64 possibilities for the single fraction doses and the 100 possibilities for the
fractionated treatment. Second, the DVH parameter differences, cf. Equation (4.1), between the
4D cases and the static case are given for the complete subpopulation in the form of boxplots.
These graphics show the dose parameter differences between the 4D dose calculations with the
standard plan parameters and the static case as well as the parameter differences between the
plan with the changed impact factor and the static case in different grey shades next to each other
for each patient. The patients are ordered according to their motion peak-to-peak amplitude in CC
direction. This motion amplitude is further illustrated by the coloured background in the boxplot
graphics. First example of this data presentation is Figure 4.15. For a general overview of the
impact factors, the median parameter differences between the 4D cases and the static cases
were summarised for patients with motion amplitudes above 5 mm. These results are described
in detail in Section 4.3.5.
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Beam angle selection The beam angle selection might influence the interplay effect by impact-
ing the spot sequence in relation to the tumour motion and, furthermore, might have a general
effect depending on the relative density change in the beam path (parallel versus perpendicular
motion). The main motion direction was CC in 25 patients, which is perpendicular to any coplanar
beam angle, but ML for 4 patients and AP for 11 patients, where the beam angles might have a
larger impact. For the patients with small motion peak-to-peak amplitudes (mainly patients 1-20),
only small dose degradations caused by motion were found per plan, cf. Section 4.3.1. For these
patients, the analysis of the single fields also showed minor dose degradations and thus only
very small differences between the three fields. Motion peak-to-peak amplitudes above 5 mm in
the main motion direction different from the CC direction occurred only for three of the patients
in the AP (patient 12, 24 and 29) and for none in the ML direction. For these three patients, the
dose degradation between the three beam angles chosen in the treatment planning was further
analysed. The magnitude of the dose degradation differed between the three fields of different di-
rections. However, no explicit relationship between the field direction and the motion in the ML or
AP direction as impact on the dose deterioration could be identified. The initial breathing phase,
which changes the spot application sequence relative to the patient anatomy, impacted the inter-
play pattern for all fields independent of the beam direction. Hence, for each field direction, four
DVH of possible dose distributions exist. Figure 4.14 (a) shows the dose degradation per field in
dependence of the initial breathing phase for patient 24 with the main motion in the AP direction.
The parallel beam direction (F 0, 0◦) was slightly less sensitive to the different initial breathing
phases than the other two beams (F 1, 45◦ and F 2, 90◦), indicated by the smaller differences
between the possible 4D dose distributions. Figure 4.14 (b) presents the dose distribution per
initial breathing phase for the three fields. None of the fields was superior to another. This would
be the case if one field would always have the smallest dose degradation for all initial breathing
phases. The interplay pattern was the main reason for the dose degradation. Any effects of
relative density changes in the beam path which would be a reason for the superiority of a beam
angle were superimposed by that. Similar to patient 24, no field direction superiority could be
shown for the other two patients.
As all three considered patients had also large motion amplitudes (comparable to the AP mo-
tion) in the CC direction, the expected beam angle effect might be superimposed by that perpen-
dicular motion. Thus, for a patient cohort with large motion amplitudes in the CC direction, either
as the main motion direction or accompanying a larger motion in the AP or ML direction, and
a coplanar beam angle selection in treatment planning, the magnitude of the motion in the AP
and ML direction is not a good indicator for the dose degradation of different field directions and
cannot facilitate the field direction choice. The beam direction effect could be larger for patients
with more pronounced motion in the AP or ML direction and a small motion in the CC direc-
tion. However, estimated on the analysed patient cohort and based on literature analyses, e.g.
(Seppenwoolde et al. 2002), this constellation is uncommon. The strong dependence of the dose
degradation on the initial breathing phase independent of the field direction indicates that, as long
as the initial breathing phase is not influenced during treatment, the choice of the beam angles
based on the dose degradation probability might be of minor interest and should be neglected in
favour of choosing reasonable beam angles based on OAR avoidance.
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Figure 4.14: Dose distortion depending on the field direction: PTVeval DVH of patient 24 with the main
motion in the AP direction showing the static case (dashed lines) and the 4D dose distributions (a) per
field for the four initial breathing phases and (b) per initial breathing phase for the three fields.
Selection of treatment planning phase The 3D image dataset used for the treatment planning
influences the proton energies of the spots chosen in the optimisation process. Selecting the 10 %
exhale 4D CT phase instead of the 15 % inhale 4D CT phase for the treatment planning resulted
in static dose distributions of similar quality, cf. Figure 4.15 (a). Only minor changes occurred in
the dose degradations for a single fraction between the two treatment planning approaches: the
parameter spread for the 64 calculated 4D dose distributions was similar for both scenarios. This
might be caused by the otherwise identical treatment planning approach: the target was the same
with the same artificial density changes. Therefore, the main changes for the single fraction 4D
dose calculations were differences between the the normal tissue density values in the beam path
of the two planning phases, which were of minor effect. The fractionated treatment considered
the probabilities of the patient’s presence in the respective breathing phases in its field sampling
process. With fractionation, the dose degradation was reduced, but also more distinct differences
between the two treatment planning approaches were revealed for some patients, especially in
terms of the tumour coverage evaluated by V95, cf. Figure 4.15 (c). Patients for whom the static
V95 could be better preserved in the 4D calculation with treatment planning on the 10 % exhale
compared to the 15 % inhale phase (patients 23, 38 and 39) had higher probabilities to be within
the 10 % exhale and the 0 % inhale breathing phase (median 38 % versus 30 % for other patients).
Consequently, for the majority of the patients the use of the 15 % inhale CT phase as a good
representation of the average patient geometry, seems to be justified as a standard treatment
planing approach. For specific patients, however, who reside comparably long in the exhalation
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Figure 4.15: Dose distortion depending on the treatment planning CT choice (15 % inhale CT in light grey,
10 % exhale CT in dark grey): (a) DVH of the PTVeval showing the similar static case dose distributions.
(b) DVH of the PTVeval for three exemplary patients (upper row: single fraction scenarios, lower row:
fractionated treatment scenarios). The static case is shown as black line. (c) Parameter differences
between the 4D cases and the static case (∆VD=VD,4D-VD,static) for the single fraction scenarios (left) and
the fractionated treatment scenarios (right) of the PTVeval. The colours indicate the tumour motion peak-
to-peak amplitude in CC direction. Note the different scales of the single fractions and the fractionated
treatment.
phases, changing this standard CT choice for the treatment planning might be beneficial. A
selection criterion could be the individual breathing pattern with which the duration of the specific
breathing phases of the the patient can be determined. Similarly, another 4D CT phase for
treatment planning might be required if a motion mitigation technique is used, since the time-
averaged representation of the patient geometry would also be changed by such an approach.
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The uncertainty which 4D CT phase might be the best representation of the patient anatomy
could be reduced using a time-averaged CT dataset. This is however not a standard option in the
software of the used Siemens CT and would need the development of an in-house solution.
Target volume construction No commonly accepted target volume concept for the treatment
planning of PBS PT of moving targets exists. Therefore, three different concepts were evaluated
in the presented study. The quality of the static case dose distribution was influenced by the target
volume construction, cf. Figure 4.16 (a). Using the beam-specific PTV led to higher doses to the
lung in terms of Dmean and V20Gy(RBE) for patients with large tumour motion above 5 mm caused
by the increasingly larger target volumes. On the other hand, the beam-specific PTV approach
resulted in more favourable values of V95 and V107 than the other two approaches. Highest TCP
were achieved with the standard plan target volume construction with artificial density values
in the ITV, but similar results were obtained with the beam-specific PTV. Only the treatment
planning concept with artificial density values in the PTV led to slightly smaller TCP. Altogether,
despite these differences between the static cases for the three treatment planning approaches,
all concepts yielded treatment plans with acceptable static dose distributions.
The dose degradation per individual fraction was similarly spread for all three treatment plan-
ning approaches, cf. Figure 4.16 (b). The target sizes were not very different between the three
examined concepts. For this reason, the relative motion between the tumour and the beam spot
application remained the same. This implies, that the interplay effect, which is a consequence
of the proton spot motion relative to the tumour motion, is the main cause for the dose distortion
in the single fractions. The target volume construction has only little influence on the relation
between the spot application and the tumour motion and thus is of minor relevance for the single
fractions. This was not the case for the fractionated treatment where the interplay was reduced
by random averaging and spots with different positions from the planned positions (e.g. caused
by artificial densities in the treatment planning) gained more weight: in most patient cases the
beam-specific PTV had the smallest deviations from the static case in terms of V95 and V107
and could preserve higher TCP compared to the other treatment planning approaches, cf. the
fractionated treatment parameters shown in Figure 4.16 (c). This was also shown by Knopf et al.
(2013), who found that a beam-specific ITV incorporating range uncertainties was superior to
a pure geometric ITV in terms of the target coverage at the cost of an increased irradiation of
healthy tissue. Thus, this more complicated target construction approach, which is highly rec-
ommended by several studies for PBS PT (Rietzel and Bert 2010; Park et al. 2012; Knopf et al.
2013; Flampouri et al. 2014), outperforms the simpler approaches if the healthy tissue is not at
critical doses. Up to now, however, this target concept is not implemented in clinical treatment
planning systems. The presented results underline the requirement to develop such a tool for
the clinical practice. Nevertheless, for small tumour motion the use of the simpler approach with
changed density values inside the ITV will be sufficient.
Multi-field optimisation Besides the single-field optimisation, PBS PT can be applied with
treatment plans based on the multi-field optimisation, which can lead to better sparing of close-
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Figure 4.16: Dose distortion depending on the target concept (ITV with density change in light grey,
PTV with density change in medium grey, beam-specific PTV in dark grey): (a) DVH of the static dose
distributions (upper row: PTVeval, lower row: ipsilateral lung). (b) DVH of the PTVeval for three exem-
plary patients (upper row: single fraction scenarios, lower row: fractionated treatment scenarios). The
static case is shown as black line. (c) Parameter differences between the 4D cases and the static case
(∆VD=VD,4D-VD,static) for the single fraction scenarios (left) and the fractionated treatment scenarios (right)
of the PTVeval. The colours indicate the tumour motion peak-to-peak amplitude in the CC direction. Note
the different scales of the single fractions and the fractionated treatment.
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by OAR. With the multi-field optimised treatment fields, a homogeneous dose distribution can
only be achieved, if the dose distributions of the fields fit to each other considering the inhomo-
geneities as planned. As a consequence, the treatment planning approach MFO1 (cf. description
in Section 4.2.4) using density changes led to unacceptable static dose distributions in which the
artificial density changes were not used. All treatment plans showed high volumes of hot-spots
(V107) and, especially for patients with larger tumour volumes, low target coverages (V95), re-
sulting in high inhomogeneity (high HI). In contrast, the MFO2 approach allowed for acceptable
treatment plans in the static case comparable to the static single-field optimised plans, except for
the patient with the smallest tumour volume. In this case, the target volume was so small compris-
ing only a small dense volume and a relatively large volume with a density close to air that setting
PBS spots into the target volume was difficult in the optimisation process. The dose distributions
and relevant dose parameters of the ipsilateral lung (Dmean, V5Gy(RBE), V20Gy(RBE)) were similar for
all three treatment planning approaches. Generally, the highest lung doses occurred for the treat-
ment plans optimised with the MFO1 approach, i.e. with artificial density changes. Figure 4.17 (a)
shows the static case DVH of the PTVeval for the single-field optimisation and the two different
multi-field optimisation treatment planning approaches for the five evaluated patients ordered ac-
cording to their GTV volume. The 4D calculations for these cases showed a similar spread in
the dose degradations with all three treatment planning approaches, cf. Figure 4.17 (b). The
dose degradation was smaller or similar with the single-field optimisation technique compared to
both multi-field optimisation techniques allowing for a better tumour coverage and less hot spots
indicating its superiority for PBS PT. Parameter differences between the 4D dose distributions
and the respective static cases as shown in Figure 4.17 (c) were larger with the MFO2 technique,
especially in terms of the target coverage and volumes of high local doses. The dose differences
to the static case were smaller for MFO1, but this was caused by the inferior static case and thus
not acceptable either. The fractionated treatment reduced the spread of the parameter values,
but could not average out the disadvantages of the multi-field optimisation treatment plans.
Thus, for the presented five patients, the multi-field optimisation was inferior in terms of keeping
the targeted tumour dose coverage (MFO2) or already in the generation of acceptable static treat-
ment plans (MFO1). The generation of a reasonable treatment planning concept is required for
the use of multi-field optimisation PBS PT. No disadvantages could be found for the single-field
optimisation treatment planning. This optimisation approach allowed for good tumour coverage
without worse dose distributions in the OAR and better maintenance of the targeted dose con-
sidering the tumour motion compared to both multi-field optimisation approaches. This result
might be biased by the patient cohort, where mainly no OAR were close to the tumours except
for the ipsilateral lung. The advantage of the multi-field optimisation compared to the single-field
optimisation, i.e. achieving steeper dose gradients and such tailoring the dose more precisely to
the target volume (Albertini 2011), was not required. For patients with target volumes close to
an OAR, however, multi-field optimised treatment plans might be the only possibility to generate
acceptable treatment plans sparing the OAR sufficiently. In the case of multi-field optimised treat-
ment plans, even larger focus needs to be put on possibly required motion mitigation to ensure
the target coverage and the normal tissue sparing in the presence of motion, due to their higher
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Figure 4.17: Dose distortions depending on the field optimisation approach (single-field optimisation in
light grey, multi-field optimisation 1 in medium grey, multi-field optimisation 2 in dark grey): (a) DVH of
the static dose distributions (upper row: PTVeval, lower row: ipsilateral lung). The use of MFO1 led to
inferior static dose distributions for large tumour volumes. (b) DVH of the PTVeval for three exemplary
patients (upper row: single fraction scenarios, lower row: fractionated treatment scenarios). The static
case is shown as black line. (c) Parameter differences between the 4D cases and the respective static
case (∆VD=VD,4D-VD,static) for the single fraction scenarios (left) and the fractionated treatment scenarios
(right) of the PTVeval for the five evaluated patients sorted according to the tumour volume. Small parameter
differences for MFO1 are caused by its inferior static case. The colours indicate the tumour motion in CC
direction. Note the different scales of the single fractions and the fractionated treatment.
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motion sensitivity. Altogether, if there is no special requirement demanding for the multi-field
optimisation, the use of the single-field optimisation should be preferred at the present state of
knowledge.
4.3.3 Impact factors during treatment delivery
Treatment delivery factors, such as the machine-specific time parameters, patient-specific motion
changes and the fractionation schedule, cannot be simply modified by treatment planning. To
which amount the dose degradation depends on these parameters is important for evaluating
how precisely these data need to be determined for a realistic 4D dose estimation. Similar to the
evaluated impact of the treatment planning parameters, the treatment delivery parameters led to
patient-specific changes. For this reason, the results are presented for all patients as described
in Section 4.3.2.
Machine parameters The machine parameters influence the time coincidences of the tumour
position and the proton spot position. For most patients, the interplay pattern of the dose degra-
dation for a single fraction with the same initial breathing phase was changed to a large degree
when the energy layer switching time was modified, although the variation of possible dose degra-
dations was less influenced. Figure 4.18 (a) shows the resulting parameter differences of V95
and V107 for the patients with motion peak-to-peak amplitudes above 5 mm for the energy layer
switching times of 2 s and 3 s and (b) for the subgroup of patients for which additional energy
layer switching times (4 s and 5 s) were analysed. The tested machine parameter variations had
little relevance for patients with a CC motion below 5 mm, not changing the already very small
dose degradation in these cases.
Considering a fractionated treatment of 33 fractions, the effect of the energy layer switching
time on the dose degradation was reduced in most patient cases. However, exceptions were
identified. For example, patient 33 had similar variations between the 64 single fraction dose
degradations of the scenarios calculated with 2 s and the 3 s energy layer switching times, but
the individual dose degradation patterns were different. For the fractionated treatment, this differ-
ence translated into a very large persisting dose degradation with an energy layer switching time
of 3 s, whereas the dose degradation was small for 2 s, cf. Figure 4.19 (a). Such different effects
on the fractionated treatment might result from the different synergistic effects of cold and hot
spots of the individual fractions. Consequently, a fractionated dose distribution, although having a
reduced interplay effect in general, cannot be estimated based on the possible dose degradation
of the single fractions. The same space of possible single fraction doses might lead to completely
different fractionated treatment dose distributions. The subgroup analysis of ten patients with en-
ergy layer shifting times of 2 s, 3 s, 4 s and 5 s gave the same results: patient-specific, the energy
layer switching time may impact the dose degradation massively for the fractionated treatment.
The patient with the largest impact is shown in Figure 4.19 (b): while the energy layer switching
times of 2 s and 3 s lead to similar results, a much higher dose degradation was found for the
energy layer switching times of 4 s and 5 s, emphasising that an incorrect dose degradation could
be assumed when wrong timings are simulated.
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Figure 4.18: Dose distortion depending on the energy layer switching time: 4D dose parameter differences
between the 4D cases and the static case (∆VD=VD,4D-VD,static) depending on the energy layer switching
time (a) for the patients with motion above 5 mm (2 s in light grey, 3 s in dark grey) and (b) the subgroup of
patients for which additional energy layer switching times (from lightest grey to darkest grey: 2 s, 3 s, 4 s,
5 s) were analysed. The colours indicate the tumour motion peak-to-peak amplitude in CC direction. Note
the different scales of the single fractions and the fractionated treatment.
Machine parameter timings are rather stable parameters which underlie mainly small varia-
tions. Due to this stability, a synchronisation between the energy layer switching time and the
tumour motion period might occur which would lead to more pronounced interplay patterns (Bert
et al. 2008). In the presented patient cohort, the mean breathing period of a patient coincided only
rarely with the energy layer switching time or a multitude of it. This was the case for patient 25
shown in Figure 4.19 (c). In this case, the arising dose degradations showed larger variations
between the 64 scenarios compared to the degradation occurring in the situation where the en-
ergy layer switching time was different from the breathing period, indicating a synchronisation
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Figure 4.19: Dose distortion depending on the energy layer switching time (depending on analysis - from
light grey to dark grey: 2 s, 3 s, 4 s, 5 s): (a) PTVeval DVH of the calculated 4D dose distributions and the
static case (black line) for patient 33 including the dose overlay on an axial CT slice for the same arbitrary
field combination / fractionation combination regarding the initial breathing phases. The associated DVH is
shown in red. The different dose distortion patterns of the single fractions lead to different fractionated dose
distributions, although the single fraction dose variations are similar. (b) PTVeval DVH of the calculated 4D
dose distributions and the static case (black line) for the patient with the largest impact of the energy layer
switching time of the patient subgroup for which the 4D dose degradation was analysed depending on four
different energy layer switching times. (c) PTVeval DVH of the calculated 4D dose distributions and the
static case (black line) for two patients showing the possible impact of synchronisation effects.
effect. For patient 39, cf. Figure 4.19 (c), for whom the mean breathing period was 4 s, i.e. twice
the energy layer switching time of 2 s, less dose degradation and a smaller dose degradation
variation was found for the 2 s scenario, although this would be more prone to synchronisation
effects than an energy layer switching time of 3 s. For all other patients, the mean breathing pe-
riod was distinctly different from the energy layer switching time and no dependence of a reduced
or increased dose degradation on the relation between the breathing period and the duration of
the energy layer switching time could be identified. This implies that in patient treatment syn-
chronisation effects as described by Bert et al. (2008) are rather unlikely due to two reasons:
first, the probability that the motion period is identical to the energy layer switching time is small.
This will be even more unlikely, when the energy layer switching times can be reduced further,
as targeted by IBA. Breathing periods being a multiple of the energy layer switching time seemed
to be less impacted in the presented study. Second, the variability of the breathing motion of the
patient prevents a continuous synchronisation between the tumour motion and the beam spot
application sequence.
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The 4D dose evaluation was based on nominal energy layer switching times (as well as mag-
net shifting times) to include these data in the prospective evaluation. However, this needs to be
viewed critically, since the real treatment includes variations of these timings as well as interrup-
tions caused by interlocks. These changes might lead to non-foreseeable effects on the dose
distribution. Thus, the prospective estimation of the motion effect could lead to wrong conclu-
sions, e.g. in the worst case a false sense of security about negligible motion effects, at least for
single patients. A retrospective calculation of the 4D dose distribution based on machine log files
giving the true timings, as reported by Richter et al. (2014) for liver irradiation with carbon ions,
may support an early evaluation of the validity of the prospective dose degradation estimation.
Individual breathing pattern The true breathing pattern of the patient during the treatment ap-
plication is likely to vary from the one recorded for the treatment planning 4D CT. In the evaluated
cases, such changes led to a similar variation of the 4D dose distribution scenarios, although
introducing patient-specific changes to the 4D dose distribution pattern. The changed time se-
quence of the breathing pattern impacts the dose degradation in a non-foreseeable way: large
changes in the motion pattern like breathing period changes might lead to less changes than
only small variations. Considering the two patients, where the sequential breathing patterns were
used for recalculation (patient 27 and patient 38), the patient with the larger differences between
the two recorded breathing patterns (patient 27) showed smaller changes in the 4D dose cal-
culation, cf. Figure 4.20. For patient 38 the DVH curves were shifted to higher doses, while for
patient 27 only minor differences occurred. Consequently, the magnitude of differences between
two 4D dose distribution based on two different breathing patterns cannot be concluded from the
discrepancies between the two breathing patterns. However, this result might also be biased by
the different motion peak-to-peak amplitudes of these two patients (8.8 mm of patient 27 versus
19.5 mm of patient 38 in CC direction). The true breathing pattern is very important and needs
to be recorded for each fraction aiming on a realistic retrospective estimation of the applied 4D
dose distribution. Prospective estimations thus can deviate largely from the true dose degrada-
tion and be delusive. However, the changes in the breathing motion pattern might be different
from changes in the tumour motion pattern and thus can only be an orientation if not checked for
correlation, e.g. by repeated 4D CT acquisition.
Changes in patient anatomy Interfractional anatomical changes are likely to occur during the
course of the RT lasting several weeks. Based on a sequential 4D CT dataset, this sub-study
of two patients evaluated two changes from the "standard treatment plan" simultaneously: the
change in the anatomy and the associated change in the breathing pattern. Figure 4.21 shows
the DVH for the PTVeval and an exemplary dose distribution.
The tumour of patient 27 had a relevant baseline shift between the original 4D CT and the
sequential one, cf. Figure 4.7. This led to a stable peak inhalation position, while the peak
exhalation position was largely different. As a consequence, the dose was degraded substantially
compared to the a-priori estimated 4D dose distribution. This large change in the tumour position
could be estimated with the breathing pattern recorded for the two CT datasets: the patient had
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Figure 4.20: Dose distortion depending on the breathing pattern (original breathing pattern in light grey,
alternative breathing pattern in dark grey): (a) DVH of the PTVeval for three exemplary patients (upper row:
single fraction scenarios, lower row: fractionated treatment scenarios). The static case is shown as black
line. (b) Dose parameter differences between the 4D dose and the static case (∆VD=VD,4D-VD,static) for
the original breathing pattern and the alternative breathing pattern. The two patients for whom their own
sequential breathing patterns could be used (Figure 4.6) are marked with an asterisk. The colours indicate
the tumour motion peak-to-peak amplitudes in CC direction. Note the different scales of the single fractions
and the fractionated treatment.
a very high breathing frequency in the pre-treatment CT which led to a rather shallow breathing.
The motion peak-to-peak amplitude in CC direction was 8.8 mm. In contrast, the patient was
rather relaxed for the sequential 4D CT leading to a reduced breathing period. This resulted
in deeper breaths changing the tumour motion peak-to-peak amplitude by 5.0 mm to 13.8 mm.
As a consequence, the ITV generated from the pre-treatment 4D CT and the subsequent PTV
were too small to cover the tumour motion, such that the tumour was partly moving out of the
irradiated area. Additionally, since the exhalation position changed, in which the patient spends
comparably long time, due to the baseline shift, the dose distribution was considerably effected.
This increased effect caused by the baseline shift might be reduced if another approach of patient
alignment was chosen: instead of aligning to the bony anatomy, the patient could be aligned to
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Figure 4.21: Dose distortion in the changed patient geometry: DVH of the PTVeval showing the single
fraction and the fractionated 4D dose distributions calculated for the original 4D CT (light grey), the se-
quential 4D CT (dark grey) and the static case (black) for the two exemplary patients 27 and 38. A dose
overlay on a sagittal slice of the treatment planning CT is shown for the same arbitrary field combination /
fractionation combination regarding the initial breathing phases. The associated DVH is shown in red.
the tumour baseline position. With such an approach, the tumour would not move outside the
irradiated volume for the long exhalation part. However, it remains unclear whether such an
image-guided strategy based on the tumour volume would be actually better, since the bony
structures in the beam path would then change relative to the calculated plan. A comparison
of image-guided patient positioning based on bony structures versus soft tissue structures for
prostate cancer in PT showed a trend towards favourable dosimetric results for the bony anatomy
match (Schneidt 2014). The best patient positioning strategy in PT of patients with lung tumours
still needs to be evaluated.
The second patient showed a more stable motion pattern: changes in the breathing pattern
were rather small and the tumour motion peak-to-peak amplitude changed less from 19.5 mm
to 21.4 mm, such that the PTV could still cover the changed tumour position quite well. As a
consequence, the dose was not degraded much more than estimated by the original 4D CT and
the original breathing pattern. The changed breathing pattern including the associated 4D CT
anatomy led to even less differences to the originally estimated dose degradation as the changed
breathing pattern alone, cf. DVH of patient 38 in Figure 4.20 (a). This implies that, for some
cases, the effect of changes in the patient anatomy, although they should not be underrated as
seen by the results of patient 27 might even lead to improved dose distributions compared to less
comprehensive 4D evaluations.
Altogether, changes in the patient anatomy can lead to very high dose degradations. This high-
lights, that it is essential to identify the patients with large anatomical changes like tumour motion
increase, tumour shrinkage or pleural effusion. Frequency changes in the breathing pattern can
give an implication whether larger changes in terms of tumour motion can be expected, but might
not be sufficient to identify all relevant anatomical changes. Repeated imaging is required to find
such changes during treatment. Large pleural effusion or large motion changes could be found in
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fluoroscopic images. However, repeated acquisitions of 4D CT offer the possibility to recalculate
the dose distribution and thus estimate the dosimetric effect of the anatomical changes. Based
on such calculations, adaptation strategies can be implemented. Since the effect of undetected
changes is serious, repeated imaging seems to be clinically mandatory.
Hypofractionated treatment The application of hypofractionation, which was shown to be ben-
eficial in early stage lung cancer, changes the time sequence of the proton spot application
compared to the standard fractionation. The 64 single fraction doses of the hypofractionated
treatment showed similar dose degradation variations as the single fractions of the standard frac-
tionated treatment, cf. Figure 4.22. The prolongation of the treatment time due to the increased
number of protons to be delivered per fraction did not impact the dose distribution in the evaluated
cases. This may be caused by the small tumour volumes which were irradiated very quickly due
to the small number of required spots per energy layer. Thus, the increase in the treatment time
was also not very large and could not exploit the possibility of an increased dispersal of the spots
per energy layer throughout the breathing cycle. The dose degradation might be smaller using
hypofractionation for large tumour volumes, for which a larger number of spots is required. This
would take a longer time for treatment and hence allow for a better distribution of spots through-
out the breathing cycle. Due to the patient cohort with only small tumour volumes this hypothesis
could not be tested in the present study. However, in the clinical setting, hypofractionation is
the treatment of choice for smaller tumour volumes, as evaluated here, due to the larger risk of
unacceptable side effects when treating large tumour volumes with such a schedule. Consider-
ing the fractionation, the complete hypofractionated treatment had much larger variations of the
possible dose degradations than the standard fractionated treatment as it can be seen by the
size of the boxplots in Figure 4.22 (b). This is caused by the small number of fractions which
lead to a reduced dose averaging effect. Thus, for hypofractionated treatment, a homogeneous
single fraction dose distribution in the target is even more important than in a standard fraction-
ated treatment, as the small number of fractions of the fractionated treatment will not improve the
dose distribution. Altogether, the use of PBS PT is rather contraindicated for a hypofractionated
treatment of small moving tumour volumes.
4.3.4 Impact of motion mitigation
Motion mitigation techniques might be mandatory to improve the dose distribution for the single
fractions in the presence of large tumour motion peak-to-peak amplitudes and further improve
the dose distribution of the fractionated treatment. Their efficiency in restoring the desired dose
distribution needs to be evaluated. Again, the results are presented for the individual patients as
described in Section 4.3.2.
Gating Gating allows for the proton spot application in a patient geometry with reduced mo-
tion. The simulated gating by a 50 % relative amplitude gating window focusing on the exhalation
phases reduced the dose degradation in terms of V95 for the single fractions, but showed similar
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Figure 4.22: Dose distortion depending on the fractionation approach (standard fractionation in light grey,
hypofractionation in dark grey): (a) DVH of the PTVeval for three exemplary patients (upper row: single
fraction scenarios, lower row: fractionated treatment scenarios). The static case is shown as black line.
(b) Dose parameter differences between the 4D dose and the static case (∆VD=VD,4D-VD,static) of the
PTVeval for the standard fractionated, 33×2 Gy(RBE), and the hypofractionated treatment, 3×18 Gy(RBE).
The colours indicate the tumour motion peak-to-peak amplitude in CC direction. Note the different scales
of the single fractions and the fractionated treatment.
dose distributions than non-gated treatment in most cases for V107. For the fractionated treat-
ment, the dose distribution was mainly not improved with gating, cf. Figure 4.23.
A definite trend that the gating approach simulated in the present treatment planning study
reduced the dose degradation could not be found. The tested gating procedure had only a small
positive effect in reducing the dose degradation. This may be caused by several reasons: first,
the threshold of the 50 % relative breathing amplitude is rather large and may not reduce the mo-
tion sufficiently, especially for patients with large tumour motion. Significant dose degradations
were found for tumours with motion above 5 mm, cf. Section 4.3.1. Assuming that the motion is
halved when using the 50 % threshold, the motion of tumours with original peak-to-peak ampli-
tudes above 10 mm will still lead to a substantial dose degradation. Furthermore, hystereses of
the tumour motion relative to the recorded breathing pattern might influence the gating efficiency:
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Figure 4.23: Dose distortion with gating (no gating in light grey, gating with a 50 % amplitude threshold
in dark grey): (a) DVH of the PTVeval for three exemplary patients (upper row: single fraction scenarios,
lower row: fractionated treatment scenarios). The static case is shown as black line. (b) Dose parameter
differences between the 4D dose and the static case (∆VD=VD,4D-VD,static) of the PTVeval for the standard
treatment and the gated treatment with a 50 % relative amplitude threshold. The colours indicate the
tumour motion peak-to-peak amplitude in CC direction. Note the different scales of the single fractions
and the fractionated treatment.
although the maximum positions in terms of the breathing pattern were excluded by gating, this
might not be the case for the actual tumour motion. For example, patient 27 had the maximum tu-
mour motion peak-to-peak amplitude between the 5 % exhalation and the 50 % inhalation phase
so that gating with the chosen threshold would not be very efficient for this patient. Such a re-
duced efficiency of gating in restoring homogeneous dose distributions due to residual motion
was also shown by Schätti et al. (2014) in their phantom experiments analysing gating efficiency
for different gating windows. Larger gating windows were less capable of generating homoge-
neous dose distributions in the target. Even with a very small gating window the homogeneous
dose distribution could not always be restored considering the irregular breathing pattern (which
led to a larger interplay compared to regular breathing patterns) of a patient. They conclude that
gating should be accompanied by rescanning to counteract the effect of residual motion.
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Fractionated treatment based on gating might suffer from a reduced averaging effect: since
the patient anatomies with large breathing motion are excluded, the occurring single fraction 4D
dose distributions might be more similar to each other with cold and hot spots in the same areas.
As a consequence, the synergistic effect of filling cold spots of one fraction with hot spots at
the same location in another fraction might be less probable. Another confounding factor might
be the use of the 15 % inhale phase for treatment planning. This phase may not be a good
representation of the time-averaged patient anatomy in the simulated gated treatment. The CT
phase of choice should be closer to the peak exhalation geometry. As it has been shown in
Section 4.3.2, where the impact of the treatment planning 4D CT phase selection on the dose
degradation was analysed, this would especially hamper the dose distribution of the fractionated
treatment.
The presented simulations of a gated treatment were limited in several aspects: the sampling
of the 4D dose distributions was performed only for the initial breathing phases of 50 % exhalation
and 0 % inhalation, resulting in less simulated scenarios compared to the non-gated treatment for
which four initial breathing phases were simulated. This might artificially reduce the fractionation
effect, especially in cases, where the individual breathing pattern shows a high probability for
the patient to be within the 50 % exhalation phase. For the random sampling then mainly this
initial breathing phase would be chosen, such that one dose distribution would be the main con-
tributor for the fractionated treatment evaluation. Since the impact of the initial breathing phase
was shown to be rather large also for gated treatment (Schätti et al. 2014), this under-sampling
hampers the quality of the fractionated treatment simulation. Furthermore, the resolution of the
4D CT phases might be too coarse for the targeted purpose. As the sampling time is 500 ms, the
data taken for the reconstruction of the 15 % inhale phase might extend into patient anatomical
states where the breathing pattern already exceeded the 50 % inhale time point which would be
excluded by gating. As a consequence, the 4D CT image stack could include contributions of
the anatomical situation which would actually not be irradiated with the chosen gating window.
The frequency of this problem depends on the breathing pattern of the individual patient and is
less relevant for patients with long breathing periods without a very quick inhalation. The simu-
lation quality was further reduced by the approach of exchanging the "forbidden" motion states
with corresponding "allowed" ones, which does not correctly simulate the time sequence. The
"wrong" time sequence will change the actual 4D dose distribution in a non-foreseeable way, cf.
the results for individual breathing patterns in Section 4.3.3. Furthermore, the gated treatment
would actually stop at the "forbidden" states and restart at the first "allowed" one. This could lead
to synchronisation effects, where the majority of the spots is always started in the same breathing
phase at the beginning of the gating window. This problem, however, would lead to a reduced
dispersal of the spots throughout the patient geometry, reducing the efficiency of the averaging of
fractionation, if the motion is still of a relevant magnitude. Thus, the results need to be carefully
interpreted.
Despite the described limitations, the analysis showed that a 50 % relative amplitude threshold
for gating may be too large to effectively reduce the dose degradation caused by the breathing
motion. The size of the gating window must be chosen carefully and is probably different for each
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patient. If the dose degradation is not sufficiently reduced by gating, the effect of reproducing very
similar single fraction 4D dose distributions and thus reducing the effectiveness of the random
averaging over the course of a fractionated treatment might even lead to worse dose distributions
compared to a non-gated treatment.
Rescanning Rescanning allows for spreading the spot application throughout the breathing
cycle by applying the spots multiple times. Ten times layered rescanning prolonged the time
interval, in which the spots per energy layer were applied, for two reasons: first, the magnet
switching time to target a new position is extended by the factor ten (number of rescans) since
the positions have to be targeted ten times. Second, the accumulated irradiation time per spot is
increased. In theory this time should remain the same, as the number of protons is divided by
the number of rescans and thus number of protons remains the same. However, the irradiation
time is increased since a minimum spot application time is required, e.g. 2 ms by the IBA system.
If the irradiation time per spot falls below this threshold, the dose rate is reduced to fulfil the
requirement. As a consequence, the beam-on time per energy layer was extended by about
a factor 7 for the evaluated patient cohort. Originally, the beam-on time per energy layer was
very small with less than half a second for most of the patients. With rescanning, the beam-on
time was extended to mainly less than 4 s, which is in the magnitude of a breathing period. As
a consequence, the dose application is spread over one breathing cycle, which could lead to a
reduction of the interplay effect and a dose distribution which is closer to the static case. For
most patients, this was indeed the case for the single fraction dose distributions, although the
spread was not completely reduced. The fractionated treatment was only slightly improved by
rescanning if at all, which could be expected since both, rescanning and fractionation, exploit the
averaging effect. Figure 4.24 (a) and (b) show that ten times rescanning did not always reduce
the dose degradation sufficiently for the presented patient subpopulation.
This result is different to publications analysing the effectiveness of rescanning. In their case
study of two liver patients, Bernatowicz et al. (2013)found that seven times layered rescanning al-
ready allowed for the application of quite homogeneous dose distributions for a scanning system
with similar time characteristics as the IBA system. Analogue, Kraus et al. (2011) deemed ten
times volumetric rescanning sufficient in their case study of two lung cancer patients. A reason
for the discrepancies in the presented study could be the small target volumes and the resulting
small number of spots per treated energy layer (on average 39 (13-80) spots) with very low treat-
ment times for the evaluated patients. Although rescanning increased the treatment times, these
remained short such that only a small spread of the spot application throughout the breathing cy-
cle was achieved. As a consequence, ten times rescanning might not be effective in such cases.
This theory is supported by the fact that patients with small tumour volumes (15, 16, 24, 36)
seem to benefit less from rescanning than patients with larger volumes (6, 28, 29, 32, 34), cf. the
DVH of patients 32 and 36 in Figure 4.24 (a). This is in accordance with Hild et al. (2013). They
reported in their analysis of scanned carbon ion beam therapy of a small tumour volume of 6.5 ml
that layered rescanning could not average the dose sufficiently in that case, i.e. the spots were
not delivered equally throughout the breathing cycle. Only breath-controlled rescanning, which
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Figure 4.24: Dose distortion with rescanning (no rescanning in light grey, 10 times rescanning in dark
grey): (a) DVH of the PTVeval for three exemplary patients (upper row: single fraction scenarios, lower row:
fractionated treatment scenarios). The static case is shown as black line. (b) Dose parameter differences
between the 4D dose and the static case (∆VD=VD,4D-VD,static) of the PTVeval for one time spot application
and ten times rescanning. The colours indicate the tumour motion peak-to-peak amplitude in CC direction.
Note the different scales of the single fractions and the fractionated treatment.
ensured the dispersal of the spots throughout the whole breathing cycle, restored the targeted
dose distribution. This result is similar to Seco et al. (2009), who found that ten times layered
rescanning was insufficient in their example case since all rescans were nearly instantaneously
delivered without sufficient dispersal throughout the breathing cycle. Breath-controlled rescan-
ning improved the homogeneity. The superiority of this rescanning approach was also shown in
theoretical analyses by Furukawa et al. (2010) and for stage I NSCLC and lung metastases by
Mori et al. (2013) and Takahashi et al. (2014).
The limited efficiency of rescanning contrasts the simplified idea that rescanning has the same
effect as fractionation: the fractionated treatment led to a reduced dose degradation for all patient
cases independent of the tumour size. For the small evaluated treatment times, the fractionation
might benefit more from synergistic effects of the different single dose distributions than it is
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possible for rescanning alone. Altogether, for an efficient use of the rescanning approach, the
dispersal of the spots throughout the breathing cycle needs to be ensured, e.g. with breath-
controlled rescanning.
4.3.5 Comparison of impact factors
As shown in the Sections 4.3.1–4.3.4 the magnitude of the dose degradation caused by the
breathing motion is patient-specific, although larger effects on the dose were revealed for patients
with higher tumour motion peak-to-peak amplitudes. For a general overview, which parameters
are particularly relevant for 4D dose evaluations, the median dose degradation of the respective
patient subpopulations were determined. The analysis was limited to patients with motion am-
plitudes above 5 mm. Table 4.4 gives an overview about the dose degradation for the standard
4D case compared to the static case using the median of the DVH parameters V95 and V107
for each patient. Furthermore, for each subgroup analysis, the median parameter differences
between the standard 4D case and the case where one impact factor differs from the standard
case were determined per patient. The median and ranges of these values are also summarised
in Table 4.4. The values for the additionally assessed dose parameters, V80, V90, V98, D98, V110,
D2, HI and TCP lead to the same conclusions and are given in the Appendix in Tables B.7 and
B.8 for completeness.
Changes in the patient anatomy had the largest impact on the prospectively estimated dose
degradation of the standard 4D plan. This effect mainly occurred in terms of the target coverage
(V95 reduction) and could not be improved by fractionation. This highlights the importance of
closely monitoring the patient anatomy and adapting the treatment plans, if necessary. Further-
more, the applied optimisation procedure in the treatment planning changed the expected dose
degradation to a large degree: the single-field optimisation was superior to the multi-field optimi-
sation especially for the target coverage evaluated with V95. This difference was statistically sig-
nificant for the MFO1 approach (p = 0.03). Again, fractionation did not improve the median dose
degradation. The motion mitigation techniques gating and rescanning also influenced the dose
degradation to a larger degree: gating shifted the dose distributions to higher doses (p = 0.02),
allowing for a better tumour coverage but also increasing high dose volumes. The latter effect
persisted for the fractionated treatment (p = 0.04). Rescanning did not lead to significant changes,
although the median parameter difference of the patient cohort showed an overall improvement
for single fractions. Rescanning was however less relevant for the analysed fractionated treat-
ment. This can be expected, as both, rescanning and fractionation, improve the dose distribution
based on averaging effects. Using different target concepts led to significant changes in the
dose parameters for single fractions and fractionated treatment, favouring the beam-specific tar-
get concept (p < 0.01 for V95). The other factors, the deformable image registration algorithm, the
4D CT phase chosen for treatment planning, the energy layer switching time, breathing pattern
variations and the use of hypofractionation, had comparably small effects on the dose degrada-
tion for single fractions. For the fractionated treatment, however, the differences to the standard
case were in the same magnitude as the standard plan dose degradation compared to the static
case for the two evaluated factors breathing pattern changes and hypofractionation. This empha-
126
4.3 Results and Discussion
Table 4.4: Median 4D dose degradation between the static case and the standard plan, as well as median
dose differences per subpopulation between the standard plan and the 4D plan with one modified impact
factor for patients with motion above 5 mm. The parameter values of the single fraction scenarios are given
in black and for the fractionated scenarios in grey. A positive value of the under-dosage parameter ∆V95
denotes that the impact factor decreased the dose degradation, while a positive value of the over-dosage
parameter ∆V107 denotes that the impact factor increased the dose degradation.
Impact factor ∆ V 95/% ∆ V 107/%
Parameter differences between the median 4D dose degradation and the static case
Standard plan – single fraction -12.8 (-24.0 – -2.1) 8.0 (0.8 – 20.8)
– fractionated treatment -2.7 (-12.7 – 0.0) 0.2 (-1.3 – 8.2)
Parameter differences between the median 4D dose degradation
with the modified impact factor and the standard plan
Demon algorithm -0.4 (-6.4 – 7.7) 0.0 (-3.0 – 8.2)
0.3 (-8.9 – 1.7) 0.1 (-2.0 – 3.7)
B-Spline algorithm followed by Demon -1.4 (-14.2 – 11.0) -0.7 (-8.0 – 4.8)
0.0 (-7.8 – 1.9) -0.4 (-1.8 – 2.9)
CT phase for treatment planning 1.2 (-1.5 – 6.0) 0.5 (-2.8 – 2.8)
0.6 (-2.1 – 7.8) -0.1 (-4.0 – 1.6)
PTV with artificial density change 0.7 (-7.3 – 3.4) -3.3 (-4.5 – 6.4)
1.1 (-10.0 – 4.4) -0.5 (-3.0 – 2.6)
Beam-specific PTV concept 2.9 (1.9 – 6.6) 1.1 (-2.8 – 4.1)
2.4 (0.6 – 4.2) 0.0 (-3.0 – 1.6)
Multi-field optimisation concept 1 -2.7 (-5.5 – -1.7) 8.8 (4.3 – 9.2)
-5.2 (-13.6 – 0.3) 10.8 (0.1 – 13.1)
Multi-field optimisation concept 2 -8.2 (-25.9 – -2.1) -2.4 (-3.4 – 11.3)
-10.2 (-31.4 – -5.4) 1.1 (-0.8 – 9.5)
Energy layer switching time (3 s vs 2 s) 0.9 (-7.9 – 8.1) -2.0 (-11.4 – 11.9)
0.0 (-13.0 – 7.8) 0.0 (-6.3 – 26.3)
Breathing pattern changes 2.7 (-0.8 – 12.1) 4.0 (-2.8 – 14.7)
2.4 (-1.5 – 7.5) 0.7 (-2.5 – 10.5)
Sequential CT Patient 1 -14.8 0.7
-13.5 -0.4
Sequential CT Patient 2 -9.5 5.8
-5.6 1.0
Hypofractionation -1.4 (-3.9 – 5.1) -0.2 (-1.7 – 5.4)
-2.8 (-6.2 – 0.3) 1.1 (-0.2 – 3.9)
Gating 3.9 (1.6 – 11.1) 3.9 (-7.4 – 15.8)
-0.4 (-4.2 – 3.6) 6.6 (-0.1 – 18.6)
Rescanning 4.8 (-6.6 – 14.1) -2.9 (-10.0 – 2.2)
0.3 (-1.1 – 3.7) 0.0 (-1.6 – 1.1)
sises that an impact factor which seems of minor importance in the single fraction case might be
important for the fractionated treatment. However, as it has been shown in the Sections 4.3.2 –
4.3.4, in specific patient cases single factors might have a large influence despite these overall
results. This is also shown by the ranges given in Table 4.4.
4.3.6 Limitations of the presented treatment planning study
A major limitation of the presented treatment planning study is the composition of the patient
cohort, which consisted of consecutive patients with lung lesions who underwent 4D CT imaging
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for treatment planning. At the UKD, 4D CT imaging is only standardly done for patients receiving
SBRT treatment. As a consequence, all tumours were rather small and no lymph nodes were
involved. For this patient cohort, a good outcome is already achieved with photon SBRT treat-
ments and the use of the limited PT resources for these indications is unlikely. The application of
PT is more probable for patients with lung tumours in advanced stages. Advanced tumour stages
present additional difficulties: They often present with involved lymph nodes, which might move
differently than the primary tumour, and have an increased probability of prominent tumour shrink-
age throughout the treatment course (Weiss et al. 2012; Jan et al. 2014). Such changes could
further impact the dose distribution in lung cancer patients treated with PBS PT. However, the
presented treatment planning study revealed, that the main impact on the dose degradation was
the individual tumour motion peak-to-peak amplitude, which is a patient-specific characteristic.
This was described similarly by Bert et al. (2008). Accordingly, the results presented here might
be transferable to advanced tumour stages as well. Furthermore, the results of the treatment
planning study suggests that prospective estimations of the 4D dose distributions are warranted
for all patients treated with PBS PT of moving tumours in the lung. Such calculations should
also precede any treatment with PBS PT of advanced stage lung cancer. Thus, the validity of
the presented results for other tumour stages could be shown when patients with advanced tu-
mour stages are actually treated with PBS PT. However, especially for advanced tumour stages,
repeated 4D CT imaging during treatment is essential to determine patient anatomy and motion
changes and are a requirement of the treatment. These datasets can also be used for retrospec-
tive 4D dose calculations, which are reasonable in the view of the high sensitivity of the 4D dose
distributions to small changes.
The presented effect analyses of several parameter changes was limited by the small patient
number in the used subpopulations. Due to the high complexity and the restricted time for the
4D dose calculations, an extension of the analyses to the whole patient cohort was impossible.
The results for the standard plan dose degradation showed the large influence of the individual
patient. Thus, general conclusions drawn from the sub-studies need to be handled with care due
to the small number of patients which might superimpose general trends.
Most evaluations were performed assuming a stable 4D dose distortion throughout the treat-
ment, which is only impacted by a single additional factor. This factor was also kept constant
throughout the simulation. Many of the changed single factors had the same effect on the 4D
dose degradation as the originally used factor in the standard plan. Thus, their impact was well
estimated by the standard plan 4D dose for the majority of the patients. However, the influence
of factor changes was larger in single patients for specific parameters. For example, this was
the case for the changes of the machine parameters for patient 29, for whom 4 s energy layer
switching time largely degraded the dose, while 2 s had a small effect, cf. Figure 4.19. Thus,
the motion effect for a complete treatment might be misinterpreted, e.g. underestimated, when
differences to the parameters used for the 4D dose calculations occur. Furthermore, changes in
parameters like machine timings during treatment and patient breathing will often occur simul-
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taneously during treatment and needs to be evaluated in combination. The separate evaluation
of different impact factors, although allowing for the evaluation of their specific impact, neglects
the possibility of synergies between several factors occurring together. This was seen in the
case study for patient 38, calculating the 4D dose distribution on a sequential CT including the
sequential breathing pattern, which was less impacted than the calculated 4D dose distribution
for the sequential breathing pattern alone, cf. Section 4.3.3. In addition, variations of the param-
eters which are different for the different single fractions increase the number of possible dose
distribution scenarios for the single fractions. This could decrease the dose degradation of the
fractionated treatment to a higher degree as estimated in the presented analyses.
All calculations were based on a 4D CT assuming that this image dataset is representative for
the patient anatomy and the motion. However, the generation of a 4D CT presumes a stability
of the patients’ breathing motion for retrospective image sorting which is a simplification that can
lead to artefacts in the image data (von Siebenthal et al. 2007). Such artefacts reduce the validity
of the dataset to be a representation of the patient. This effect might be increased in patients
with small breathing periods where the fixed reconstruction time of 500 ms covers a large amount
of different breathing states. Furthermore, the 4D CT image reconstruction was based on an
external one-dimensional surrogate signal which might lead to non-representative reconstruction
time points in terms of the internal tumour motion (Ozhasoglu and Murphy 2002; McClelland et al.
2013). The generation of more reliable 4D image datasets including motion prediction models
is currently under investigation and could provide more precise data for 4D dose calculations
(Ehrhardt et al. 2007; Zhang et al. 2013; Hong and Bukhari 2014). However, up to now, the use
of 4D CT imaging data is the standard for breathing induced motion estimation without an estab-
lished alternative.
Although the 4D calculations were performed for the IBA treatment machine characteristics, the
3D treatment plan generation was based on data from the Gantry 1 system at the Paul Scherrer
Institute (e.g. spot shape, divergence of the beam). This might impact the 4D dose calculation
as the original 3D treatment plan would not have been generated identically for the IBA machine.
Nevertheless, this effect might be negligible for the overall results.
Dose calculations in the lung are limited by the capabilities of the dose calculation algorithm to
model the dose at intersections of tissues with different densities. The used pencil beam algo-
rithm has been shown to give inferior results compared to Monte-Carlo algorithms (Grassberger
et al. 2014). However, in their patient case studies evaluating the efficiency of motion mitigation
techniques in PBS PT for the lung, Grassberger (2014) came to similar conclusions as presented
in this thesis using a Monte Carlo algorithm for dose calculation. Thus, the presented results,
although hampered by the reduced accuracy of the pencil beam algorithm, can be used to draw
the described general conclusions.
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4.4 Conclusion
The presented treatment planning study was conducted to examine the effect of different treat-
ment planning and delivery parameters on dose distortions caused by the breathing motion in
the irradiation of lung cancer patients with PBS PT. The evaluations were based on simulations
performed at the Paul Scherrer Institute with their in-house developed software PSIplan. The
treatment planning study was specifically designed for the evaluation of the PT machine of IBA in-
stalled at the UPTD. For realistic simulations, 4D CT datasets and the associated patient-specific
breathing patterns were used. The treatment plan quality was evaluated based on requirements
defined by the ICRU, a study protocol and internal guidelines (ICRU 1999, 2007; RTOG 2014).
Compared to the existing phantom and patient case studies which mainly focus on the evalua-
tion of single parameters (Phillips et al. 1992; Lambert et al. 2005; Paganetti et al. 2005; Bert
et al. 2008; Kraus et al. 2011; Zhang et al. 2012; Dowdell et al. 2013; Grassberger 2014; Li et al.
2014b), the presented study evaluated a multitude of possible impact factors in realistic patient
case studies for a comparably large number of patients. For this reason, the presented results
are of major interest for the implementation of PBS PT in a clinical setting.
The results of the parameter evaluations led to the following conclusions:
1. The tumour motion peak-to-peak amplitude is a factor hinting at the expectable dose degra-
dation caused by the patients’ breathing motion. Tumour motion peak-to-peak amplitudes
below 5 mm were found to be of minor impact. However, the amplitude alone is not a
perfect predictor for the severity of the dose degradation, since the degradation is further
influenced by other factors like synergies between under- and overdosage and probabilities
of the different breathing phases according to the individual breathing pattern. Since the
single fraction dose is generally largely degraded for patients with tumour motion peak-to-
peak amplitudes above 5 mm and the biological efficiency of fractionation to counteract the
single dose degradation is unknown, patients with such a motion should be treated with an
adequate motion mitigation technique.
2. Dose changes in OAR are only of relevance for close-by organs. Except for the ipsilateral
lung, most patients of the presented patient cohort had no relevant OAR in close proximity
to the tumour. Thus, the effect of motion on the dose in OAR could not be properly evalu-
ated. Dose parameters of the ipsilateral lung, however, were not increased in most cases
of the presented patient cohort.
3. The deformable image registration algorithm influences the voxel assignment between dif-
ferent motion phases of the patient anatomy and thus has a direct influence on the calcu-
lated dose distribution. Due to uncertainties in the deformable image registration, every 4D
dose distribution can only be an estimation of the reality.
4. The beam angle selection was found to be a minor impact factor in the evaluated patient
cohort. The main motion direction was CC, such that all beam angles in the coplanar
treatment setting were perpendicular to this motion. Thus, no dependences on the other
motion directions could be identified.
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5. The selection of the 4D CT phase used for the treatment planning influenced the dose
degradation, but the effect was patient specific. For most patients, the used general treat-
ment approach was acceptable. The individual breathing pattern could be used to identify
the patients with large exhalation time, for whom the choice of another treatment planning
CT phase would be beneficial.
6. The target construction was a relevant factor in the fractionated treatment evaluation where
the interplay effect was reduced by averaging effects such that spot position uncertainties
could gain weight. The advanced method of generating beam-specific target volumes was
superior to the tested simpler approaches, but may not be required in patients with small
tumour motion.
7. The multi-field optimisation approach led to overall inferior 4D dose distributions compared
to the single-field optimised treatment plans. Single-field optimisation would be the treat-
ment of choice for patients similar to the presented patient cohort, for whom the advantage
of the multi-field optimisation which spares close-by OAR better is not required.
8. Machine parameter variations can have a large impact on the dose degradation for some
patients and thus are important to be assessed during treatment. Synchronisation effects
were found to be unlikely in the clinical setting. Typically, they are prevented by variations
in the patient breathing patterns.
9. Variations in the individual breathing pattern influenced the dose degradation. Thus, the
actual breathing pattern should be assessed during treatment.
10. Patient anatomy changes had the largest influence on the dose distributions. Thus, re-
peated (4D CT) imaging is mandatory to assess such changes quickly, estimate their effect
on the dose distribution and possibly initiate treatment adaptations.
11. Retrospective 4D dose distribution analyses including the real machine timings, the indi-
vidual breathing pattern and preferentially an updated 4D CT are important to assess the
reliability of the prospective 4D dose estimations.
12. Hypofractionation led to inferior dose distributions compared to the standard fractionation
for the presented patient cohort. No benefit was achieved from increased treatment time
and proton spot dispersal throughout the patient motion states for the evaluated patient
cohort with small tumour volumes.
13. Gating can only be efficient if the gating window is chosen restrictive enough to reduce the
residual motion to an acceptable level. Thus, the gating window needs to be determined
individually for each patient. The tested global 50 % relative amplitude as gating threshold
was too large and led, in some cases, to even worse dose distributions in the fractionated
treatment than ungated treatments.
14. Rescanning was more efficient for larger tumour volumes. With small tumour volumes,
rescanning was not able to distribute the proton spots sufficiently throughout the motion
phases of the patient.
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Altogether, the magnitude of the tumour motion caused by the breathing has the main impact on
the dose distribution in lung tumour patients treated with PBS PT. The resulting dose degradation
is further influenced by a multitude of parameters, e.g. treatment planning parameters like the
target volume construction and by treatment application parameters like variations of the spot
application sequence. Prospective estimations of the 4D dose distribution should be done in the
clinical setting for all patients, at best complemented by (daily) retrospective calculations using
actual machine parameter times, breathing patterns and patient anatomy imaging.
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In the future, PT might play a more important role in the treatment of cancer patients due to its
favourable depth dose profile. However, currently, the advantage of PT over conventional XT has
been clinically shown only for rare cases. For more common cancer diseases like HNSCC or
lung cancer the advantage has not yet been clinically proven. For a clinical introduction of PT for
these entities, it is necessary to estimate its expected benefit. Furthermore, the generation of PT
treatment planning concepts is required including a risk assessment of treatment uncertainties.
The presented thesis comprises these aspects for two different cancer types. First, for patients
with HNSCC, an evaluation of PT compared to XT was performed focusing on the toxicity risks.
Second, for patients with lung cancer, an evaluation of the treatment application of PT with the
PBS technique was conducted considering the effect of tumour motion caused by breathing.
The first part of the presented thesis focused on HNSCC, which includes patients with tumours
of different origin in the head and neck region. For a patient cohort of 45 patients, IMXT and IMPT
treatment plans were generated for a biologically-adapted dose escalation fractionation schedule.
The toxicity risk was assessed with modern NTCP models and physical dose parameters when
no models existed. A large number of OAR was included to allow for a comprehensive analysis.
The study was divided into three major topics: first, the feasibility of the biologically-adapted dose
escalation fractionation schedule for IMXT and IMPT was evaluated. The higher dose only led to
a small increase of toxicity risk in terms on NTCP for both modalities. Physical dose parameters
showed similar results. As a consequence, the dose escalation seems to be feasible for both
modalities based on the considered toxicities. However, toxicities like ulcers which are difficult to
asses by dosimetric parameters might be underestimated. The second topic was the compari-
son of toxicity risks of IMXT and IMPT: IMPT was able to reduce the probability of side effects
compared to IMXT for the majority of the patients. The magnitude depended on the proximity be-
tween tumour volume and affected OAR. The integral dose to the patient was halved using IMPT.
Third, the possibility of a patient selection based on the primary tumour location was investigated.
The benefit of IMPT was rated especially relevant for patients with the primary tumour location in
the upper head and neck region, for whom swallowing dysfunctions could be well reduced. To
optimally use the limited PT treatment resources, the selection of patients for PT should focus on
this subpopulation of HNSCC patients. Subsequent to the presented study, the sensitivity of the
generated IMXT and IMPT treatment plans to anatomical changes of the patient will be evaluated,
aiming on the identification of adaptation requirements and frequencies. Furthermore, improved
treatment planning concepts like robust optimisation reducing the impact of uncertainties will be
assessed. The results of the presented treatment planning study require a confirmation in a clin-
ical trial. The execution of such a trial is feasible based on the presented results. A multi-center,
randomized phase-II-trial which focuses on the dose escalation in hypoxic tumours with IMXT or
IMPT (INDIRA-MISO) is planned and will start in 2016.
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The second part of the presented thesis focused on the irradiation of tumour lesions in the
lung using the PBS PT technique. Since this technique is based on active field formation, it is
highly sensitive to anatomical patient changes that occur on the time scale of seconds, which
is the case for patient breathing. For a patient cohort of 40 patients, realistic treatment plans
were generated followed by 4D dose calculations estimating the dosimetric consequences of the
change in patient anatomy caused by breathing. Furthermore, the impact of several treatment-
and patient-related parameters on the dose degradation was assessed. It was shown that tumour
motion peak-to-peak amplitudes which are smaller than 5 mm are of minor concern: the expected
dose degradation caused by the motion was minimal. About 50 % of the examined patients had
tumour motion peak-to-peak amplitudes below this threshold. Thus, PT might be feasible for a
relevant portion of lung cancer patients without additional measures. For patients with motion
amplitudes above 5 mm, the planned dose distributions were degraded to an unacceptable de-
gree. For these patients, the use of motion mitigation techniques might be required to improve
the dose distributions, especially for the single fractions of a fractionated treatment. The tested
approaches, gating with a universal gating window and layered rescanning, were not sufficient for
the examined patient cases. This emphasises the importance to carefully select the motion miti-
gation technique and its details (e.g. gating window size, rescanning approach) on an individual
patient basis. The importance of treatment- and patient-related parameters which might influence
the dose degradation was revealed: the definition of a reasonable treatment planning approach
including a target concept and the choice of an optimisation procedure is mandatory. Breathing
pattern variations or anatomical changes and treatment-related parameters like the energy layer
switching time can largely effect the dose distribution. Those parameters might change in each
treatment fraction. Thus, a retrospective dose evaluation for actually treated patients is recom-
mended, including repeated imaging of the patient during treatment. In future work, the use of
the PBS PT technique needs to be compared to the more robust and already clinically applied
PS PT technique. Since at the UPTD both techniques can be used, the PS PT technique might
be an alternative for patients where the additional motion uncertainties of PBS PT do not allow for
a reliable dose application. Furthermore, to enable calculations of realistic 4D dose distributions
for PBS PT at the UPTD on a regular basis, a respective software needs to be implemented. This
might be possible with the treatment planning system RayStation, which already allows for sim-
ple recalculations, e.g. considering regular motion. Developments for inclusion of realistic timing
patterns are ongoing work.
In summary, the presented thesis represents an important contribution to the implementation
of PT for HNSCC and lung cancer at the UPTD. The results are of scientific interest providing a
comprehensive benefit evaluation for HNSCC including the proposition of a selection criterion for
patient individualised assignment to PT and a large scale technical applicability assessment for
PBS PT of lung cancer. In the thesis, recommendations are given how to proceed with the use of
PT for these two entities.
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Für die Behandlung von Krebserkrankungen bietet die Protonentherapie aufgrund ihrer präzis-
eren Dosisverteilung theoretisch einen Vorteil gegenüber der konventionellen Photonentherapie.
Klinisch konnte dieser Vorteil bislang allerdings nur für seltene Tumorerkrankungen gezeigt wer-
den. Für häufiger auftretende Tumorerkrankungen wie Kopf-Hals- und Lungentumoren steht ein
solcher klinischer Nachweis aus. Die klinische Einführung der Protonentherapie für diese En-
titäten erfordert eine umfassende Abschätzung der zu erwartenden Vor- und Nachteile gegenüber
der Photonentherapie. Des Weiteren wird eine grundlegende Evaluierung der Protonenbestrah-
lungstechnik in Hinblick auf Unsicherheiten, die die Qualität der Behandlung beeinträchtigen kön-
nten, benötigt. Die vorliegende Arbeit umfasst daher zwei Bestrahlungsplanungsstudien, die sich
mit diesen beiden Themenkomplexen auseinandersetzen. Für die Behandlung von Patienten
mit Kopf-Hals-Tumoren wurden die zu erwartenden Nebenwirkungen von Photonen- und Pro-
tonentherapie verglichen. Für die Behandlung von Patienten mit beweglichen Lungenläsionen
wurde eine umfassende Analyse des Einflusses der aktiven Protonenstrahltechnik auf die Do-
sisverteilung durchgeführt.
Der erste Teil der vorliegenden Arbeit beschäftigt sich mit der Behandlung von Kopf-Hals-
Tumoren mit Photonen- oder Protonentherapie. Für eine Patientenkohorte von 45 Patienten mit
verschiedenen Primärtumoren im Kopf-Hals-Bereich wurden intensitäts-modulierte Photonen-
und Protonentherapiepläne erstellt, die auf einem biologisch adaptierten Fraktionierungsschema
inklusive Dosiseskalation basieren. Das Inzidenzrisiko für eine Vielzahl möglicher Nebenwirkun-
gen wurde auf Basis von Wahrscheinlichkeitsmodellen oder durch die Erfassung von physikalis-
chen Dosisparametern evaluiert. Dabei zeigten sich im Allgemeinen nur geringe Auswirkun-
gen der Dosiseskalation auf die Nebenwirkungswahrscheinlichkeiten sowohl für die Photonen-
als auch für die Protonentherapie, sodass diese für beide Modalitäten geeignet erscheint. Die
Evaluierung ist dabei allerdings auf Modelle beschränkt, sodass nicht modellierte Nebenwirkun-
gen unterschätzt werden können. Unabhängig von der Dosiseskalation führte die Verwendung
von Protonen in den meisten Fällen zu verringerten Nebenwirkungswahrscheinlichkeiten. Die
Höhe dieser Reduktion war dabei abhängig vom Abstand zwischen dem Tumor und dem Organ,
das die Nebenwirkung hervorruft. Die größte Reduktion war für Patienten mit einem Primär-
tumor im oberen Kopf-Hals-Bereich gegeben. Für diese Patienten konnte eine deutliche Re-
duktion der Wahrscheinlichkeit von behandlungsbedingten Schluckbeschwerden erzielt werden.
Die Fokussierung der Patientenauswahl auf diese Patientengruppe ermöglicht somit eine klin-
isch begründete gute Nutzung der begrenzten Protonentherapiekapazitäten. Aufbauend auf der
vorliegenden Arbeit werden in zukünftigen Studien die Einflüsse von Veränderungen der Patien-
tenanatomie untersucht, die im Rahmen der mehrwöchigen Strahlentherapie häufig auftreten.
Dabei ist es das Ziel, festzustellen, ob bzw. wie häufig Bestrahlungsplanadaptionen notwendig
sind. Im Rahmen dieser Untersuchungen soll weiterhin der Einfluss von alternativen Bestrahlungs-
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planungsweisen wie die robuste Bestrahlungsplanung analysiert werden. Abschließend erfordern
die Ergebnisse der vorliegenden virtuellen Studie eine Validierung anhand von prospektiven klin-
ischen Daten. Die Anwendbarkeit der Dosiseskalation für Photonen- und Protonentherapie wird
daher in einer multizentrischen, randomisierten Phase II Studie (INDIRA-MISO) ab 2016 unter-
sucht werden.
Im zweiten Teil der vorliegenden Arbeit wurde der Effekt der aktiven Protonenfeldformierung
auf die Dosisverteilung für Tumoren in der Lunge, die aufgrund der Atmung ihre Position verän-
dern, untersucht. Die aktive Protonenfeldformierung ist aufgrund der ähnlichen Zeitskalen von
Strahlapplikation und Tumorbewegung besonders empfindlich. Für eine Patientenkohorte von
40 Patienten wurden Bestrahlungspläne erstellt, deren Dosisverteilungen unter Berücksichtigung
der Atembewegung evaluiert wurden. Des Weiteren wurde der Effekt von Veränderungen in
behandlungs- und patientenbezogenen Faktoren untersucht. Es konnte gezeigt werden, dass
die Tumorbeweglichkeit die Dosisverteilung nicht relevant beeinflusst, wenn die maximale Ver-
schiebung unter 5 mm liegt. Da dies für etwa 50 % der vorliegenden Patientenkohorte der Fall
war, kann die aktive Protonenstrahltherapie für einen relevanten Anteil der Patienten ohne weitere
Maßnahmen eingesetzt werden. Bei Patienten mit Tumorbewegungen über 5 mm wird die Do-
sisverteilung so stark degradiert, dass die Anwendung von Bewegungskompensationstechniken
erforderlich ist. Die fraktionierte Bestrahlung reduziert zwar das Ausmaß der Dosisdegradierung,
allerdings zumeist nicht auf ein akzeptables Maß. Die untersuchten Bewegungskompensa-
tionstechniken Gating und Rescanning waren mit einem universellen Ansatz für alle Patienten
nicht ausreichend, um die Dosisdegradierung zu verringern. Dies zeigt, dass die zu verwen-
dende Bewegungskompensationstechnik patientenindividuell ausgewählt und angepasst werden
muss. Auch hat die Veränderung von behandlungs- und patientenbezogenen Faktoren teilweise
einen starken Einfluss auf die Dosisdegradierung: der Bestrahlungsplanungsansatz inklusive der
Zielvolumendefinition und der Optimierungsweise muss sorgfältig gewählt werden. Variationen
des Bewegungsmusters des Tumors sowie Veränderungen der Patientenanatomie im Verlauf der
mehrwöchigen fraktionierten Bestrahlung als auch Veränderungen im Zeitablauf der Strahlapp-
likation durch das Behandlungsgerät können die Degradierung stark beeinflussen. Da sich diese
Faktoren von Fraktion zu Fraktion verändern können, ist eine retrospektive Analyse der Dosisde-
gradierung auf Basis der aktuellen Parameter (Bewegungsmuster, Patientenanatomie, Strahlap-
plikationszeiten) empfehlenswert. Am Universitätsprotonenzentrum Dresden kann neben der
aktiven Protonenfeldformierung die passive Protonenfeldformierung genutzt werden, welche in-
trinsisch robuster gegenüber Bewegungen im Bestrahlungsfeld ist. Daher werden die in der vor-
liegenden Arbeit bewerteten Dosisdegradierungen in einer zukünftigen Arbeit mit Dosisverteilun-
gen der passiven Protonenfeldformierung verglichen, um patientenindividuell bewerten zu kön-
nen, welche Formierungstechnik klinisch genutzt werden soll. Weiterhin wird an einer Implemen-
tierung der Dosisberechnung, die den Effekt der Bewegung möglichst realitätsnah mit einbezieht,
in einer am Universitätsprotonenzentrum Dresden vorhandenen Software gearbeitet.
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Die vorliegende Arbeit leistet einen wichtigen Beitrag zur Implementierung der Protonenthera-
pie für Kopf-Hals-Tumoren und Lungentumoren am Universitätsprotonenzentrum Dresden. Da-
rüber hinaus sind die Ergebnisse auch wissenschaftlich relevant: Die Individualisierung der
Therapie von Patienten mit Kopf-Hals-Tumoren konnte durch die Identifizierung von Patienten-
subgruppen, die einen höheren Vorteil von der Behandlung mit Protonen zu erwarten haben,
vorangetrieben werden. Für die Behandlung von Patienten mit Lungentumoren wurde eine de-
taillierte Analyse der Dosisdegradierung bei Behandlung mit aktiver Protonenstrahlformierung für
eine große Patientenkohorte durchgeführt. Für beide Entitäten wurden abschließend Empfehlun-
gen für die Therapie ausgesprochen.
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Appendix
A Additional material of the head and neck squamous cell cancer
study
The comprehensive NTCP and DVH parameter tables for the patient population and the sub-
groups are given here to improve the readability of the results section. The complete data are
highly relevant for biometric assessment.
Table A.1: Fulfilment of treatment planning goals of the optimised treatment plans for the complete patient
cohort, median (range: P5–P95). PTV and GTV parameters are averaged over the separate treatment
plans, while OAR doses are calculated on the accumulated dose distributions.
Delineated volume
Treatment
planning goal
2.3 Gy(RBE) 2.6 Gy(RBE)
IMXT IMPT IMXT IMPT
Spinal cord Dmax ≤ 45 Gy(RBE) 40.0 29.6 39.6 29.4
(37.5–42.1) (18.8–32.7) (36.8–42.3) (18.7–33.3)
Brain stem Dmax ≤ 54 Gy(RBE) 33.5 19.7 33.6 19.7
(6.3–46.4) (1.0–33.9) (6.1–46.7) (1.0–34.1)
Contral. brachial plexus1 Dmax ≤ 72 Gy(RBE) 64.0 55.1 64.1 55.5
(51.7–71.1) (49.7–71.5) (51.6–71.1) (49.6–71.5)
Ipsil. brachial plexus1 Dmax ≤ 72 Gy(RBE) 70.9 70.8 70.9 70.8
(53.6–71.9) (50.7–71.7) (53.4–71.9) (50.7–71.6)
GTVSIB2 V1073 < 2 % 0.0 0.0 0.0 0.0
(0.0–0.0) (0.0–0.0) (0.0–0.0) (0.0–0.0)
V95
3
≥ 95 % 99.8 99.9 98.6 99.2
(98.2–100.0) (99.0–100.0) (96.8–100.0) (97.6–99.9)
Dmean, rel. = 100 %3 100.1 100.2 100.1 100.2
(99.7–100.3) (99.8–100.6) (99.6–100.3) (99.9–100.4)
PTV V1073 < 2 % 0.1 0.0 3.9 0.1
(0.0–1.9) (0.0–0.0) (1.2–11.1) (0.0–1.8)
V95
3
≥ 95 % 98.0 99.1 98.1 99.1
(97.0–99.4) (98.3–99.7) (97.1–99.2) (98.5–99.7)
Dmean, rel. = 100 %3 100.8 100.0 101.4 100.2
(100.0–101.5) (99.8–100.8) (100.4–102.6) (99.8–101.5)
Contral. parotid gland1 Dmean ≤ 26 Gy(RBE) 24.6 15.2 24.5 15.0
(16.9–36.4) (7.7–23.5) (16.9–36.7) (7.7–23.5)
Ipsil. parotid gland1 Dmean ≤ 26 Gy(RBE) 36.0 24.6 35.5 24.5
(23.1–45.6) (12.7–37.1) (22.9–46.0) (12.9–37.1)
Glottic larynx D2 ≤ 70 Gy(RBE) 68.6 66.8 69.0 67.0
(44.3–78.1) (31.9–77.0) (44.5–84.9) (31.5–83.0)
Supraglottic larynx D2 ≤ 80 Gy(RBE) 75.6 75.0 79.4 78.3
(70.2–77.8) (67.5–76.8) (70.2–84.3) (67.8–82.7)
Complete larynx4 Dmean ≤ 45 Gy(RBE) 64.1 60.8 64.4 60.9
(45.1–73.9) (36.6–72.7) (45.1–76.8) (36.6–74.4)
Mandible D1ml ≤ 75 Gy(RBE) 72.0 71.7 71.9 71.7
(52.9–75.4) (49.2–74.9) (52.8–80.5) (49.5–78.7)
1 Pairwise organs: ipsilateral is organ with higher, contralateral organ with lower dose
2 Evaluation of Series II, III 3 Percentage of prescribed dose 4 Union of glottic and supraglottic larynx
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Table A.2: Patient cohort and patient subgroup specific values for NTCP (%) based on the accumulated
dose distributions for treatment with the low dose escalation of 2.3 Gy(RBE), median (range: P5–P95).
Toxicity
parameter1
[No. of patients
all (A, B, C)]
IMXT Mixed modality IMPT
All patients All patients All patients
A B C A B C A B C
Oral 47 (32–57) 46 (30–56) 42 (19–55)
mucositis 54 37 46 54 35 44 53 25 41
[45 (18, 13, 14)] (47–59) (25–42) (37–54) (45–58) (25–40) (36–53) (41–58) (15–34) (29–52)
Xerostomia 37 (24–61) 33 (21–56) 21 (12–35)
(6 months) 41 33 41 34 31 35 23 20 20
[45 (18, 13, 14)] (29–61) (21–43) (30–64) (25–54) (20–38) (26–59) (11–33) (13–23) (13–43)
Xerostomia 17 (8–41) 13 (6–35) 6 (2–15)
(12 months) 20 14 20 14 13 15 7 6 6
[45 (18, 13, 14)] (11–42) (6–22) (12–45) (9–34) (6–17) (9–39) (2–14) (3–7) (3–22)
Aspiration 55 (16–94) 37 (14–94) 32 (9–90)
[45 (18, 13, 14)] 55 35 82 33 27 71 25 19 59
(41–71) (4–73) (44–96) (18–55) (3–71) (32–95) (11–48) (2–61) (26–92)
Physician-rated 50 (28–63) 43 (25–58) 36 (18–56)
swall. dysfunction 50 35 60 42 34 53 36 28 49
[37 (17, 10, 10)] (41–57) (18–50) (40–66) (28–50) (16–49) (36–65) (21–48) (7–46) (31–63)
Problems 35 (20–49) 28 (14–45) 25 (10–42)
swall. solids 33 27 46 25 25 41 21 21 37
[37 (17, 10, 10)] (25–44) (14–39) (30–53) (15–37) (12–38) (28–52) (11–35) (6–35) (24–50)
Problems 13 (4–15) 12 (3–15) 12 (2–14)
swall. liquids 5 14 14 4 13 13 4 13 13
[39 (18, 10, 11)] (3–13) (11–15) (12–15) (2–12) (10–15) (12–15) (2–12) (9–14) (12–15)
Larynx 91 (29–99) 89 (25–99) 84 (8–99)
Oedema 50 99 96 43 99 96 17 99 96
[42 (18, 11, 13)] (25–89) (84–99) (89–99) (18–83) (83–99) (86–99) (6–74) (72–99) (83–99)
Ipsil. brachial 22 (0–28) 22 (0–28) 22 (0–28)
plexopathy 17 22 23 10.1 22 23 10.8 22 22
[45 (18, 13, 14)] (0–27) (5–28) (3–29) (0–27) (3–26) (1–30) (0–26) (4–26) (1–28)
Trismus 31 (24–39) 30 (24–38) 25 (23–30)
[45 (18, 13, 14)] 33 28 30 32 28 30 26 25 25
(25–49) (24–32) (24–37) (25–44) (24–32) (24–37) (23–36) (23–28) (23–29)
1NTCP values for myelitis and brain stem necrosis are not listed (0 % in all cases)
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Table A.3: Patient cohort and patient subgroup specific values for evaluated DVH parameters for OAR
without NTCP model based on the accumulated dose distributions for treatment with the low dose escala-
tion of 2.3 Gy(RBE), median (range: P5–P95).
Evaluated
parameter
[No. of patients
all (A, B, C)]
IMXT Mixed modality IMPT
All patients All patients All patients
A B C A B C A B C
Subm. gland1 65.1 (54.9–72.8) 59.0 (48.1–72.1) 58.7 (44.1–71.0)
Dmean, co. / Gy(RBE) 63.7 59.6 68.3 56.8 56.7 63.6 55.6 56.7 63.4
[44 (18, 13, 13)] (56–72) (51–72) (63–73) (51–71) (46–69) (53–72) (50–71) (42–68) (52–71)
Subm. gland1 72.5 (66.2–74.5) 72.2 (67.2–74.3) 71.7 (67.0–73.0)
Dmean, ip. / Gy(RBE) 72.8 71.2 73.2 72.8 70.7 72.8 72.2 70.2 71.8
[43 (18, 13, 12)] (72–75) (60–73) (72–74) (71–75) (61–73) (71–74) (71–73) (60–72) (70–73)
Subl. gland1 57.8 (28.9–72.8) 48.0 (25.9–73.0) 45.9 (14.6–72.0)
Dmean, co. / Gy(RBE) 69.5 35.0 60.2 66.6 32.7 56.5 66.1 23.2 51.2
[41 (14, 13, 14)] (55–73) (27–45) (40–73) (46–73) (24–40) (36–73) (45–72) (12–36) (29–72)
Subl. gland1 58.9 (34.0–74.2) 52.9 (30.8–74.1) 50.1 (19.4–72.9)
Dmean, ip. / Gy(RBE) 72.2 41.2 65.3 71.5 37.2 56.9 70.8 30.8 54.1
[36 (10, 13, 13)] (62–74) (29–46) (45–73) (59–74) (29–44) (39–73) (58–73) (15–41) (31–73)
Carotid sinus 71.8 (61.5–73.8) 71.7 (51.1–73.6) 71.6 (51.0–72.2)
Dcirc / Gy(RBE) 71.7 71.7 72.1 71.3 71.9 72.3 71.1 71.8 71.8
[43 (16, 13, 14)] (66–73) (62–74) (64–74) (60–73) (59–74) (55–74) (60–72) (59–73) (55–72)
Carotid sinus 74.3 (68.4–77.5) 73.9 (63.6–76.9) 72.5 (63.5–76.0)
D2 / Gy(RBE) 73.8 74.5 74.5 73.7 74.3 74.4 72.5 72.7 72.8
[43 (16, 13, 14)] (70–77) (70–77) (70–76) (67–76) (69–77) (64–76) (66–74) (68–76) (63–75)
Mandible 72.0 (52.9–75.4) 71.8 (51.1–75.6) 71.7 (49.2–74.9)
D1 ml / Gy(RBE) 74.6 62.6 72.2 74.3 59.3 71.8 73.3 58.7 71.7
[44 (17, 13, 14)] (70–77) (44–71) (66–75) (69–76) (44–71) (62–74) (68–75) (39–71) (62–73)
Mandible 23.9 (2.0–37.4) 16.9 (1.4–34.0) 16.0 (1.3–30.7)
V50 Gy(RBE) / ml 27.2 8.2 24.9 23.7 6.9 18.9 21.9 6.2 16.9
[44 (17, 13, 14)] (18–45) (1–14) (13–35) (13–41) (01–10) (8–29) (10–36) (0–10) (7–26)
Oesophagus 38.9 (33.7–74.5) 37.9 (33.4–74.1) 12.9 (3.3–72.7)
Dcirc / Gy(RBE) 36.0 70.2 40.8 35.9 70.0 37.8 7.4 69.2 18.1
[45 (18, 13, 14)] (33–46) (35–75) (34–73) (33–45) (35–75) (34–73) (3–27) (11–73) (5–71)
Oesophagus 0.0 (0.0–3.4) 0.0 (0.0–3.1) 0.0 (0.0–3.0)
V60 Gy(RBE) / ml 0.0 1.5 0.0 0.0 1.4 0.0 0.0 1.4 0.0
[45 (18, 13, 14)] (0–0) (0–5) (0–3) (0–0) (0–4) (0–3) (0–0) (0–4) (0–3)
Skin 63.6 (46.8–76.0) 65.5 (50.2–75.6) 69.0 (61.1–74.7)
D25cm2 / Gy(RBE) 64.1 61.8 63.9 65.2 66.1 66.0 68.7 69.0 70.2
[45 (18, 13, 14)] (52–77) (45–78) (54–71) (54–76) (47–78) (57–70) (60–74) (60–75) (64–74)
Skin 0.0 (0.0–15.1) 0.1 (0.0–14.3) 0.3 (0.0–14.3)
V70 Gy(RBE) / ml 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.6
[45 (18, 13, 14)] (0–5) (0–16) (0–6) (0–6) (0–16) (0–7) (0–12) (0–16) (0–13)
1 Pairwise organs: ipsilateral is organ with higher, contralateral organ with lower dose
141
6 Appendix
Table A.4: Patient cohort and patient subgroup specific values for NTCP (%) based on the accumulated
dose distributions for the high dose escalation of 2.6 Gy(RBE), median (range: P5–P95).
Toxicity
parameter1
[No. of patients
all (A, B, C)]
IMXT Mixed modality IMPT
All patients All patients All patients
A B C A B C A B C
Oral 47 (32–58) 46 (30–56) 42 (19–55)
mucositis 55 37 46 54 35 44 53 26 40
[45 (18, 13, 14)] (47–59) (25–42) (37–54) (45–59) (25–40) (36–54) (41–58) (15–33) (29–53)
Xerostomia 37 (23–61) 33 (21–56) 21 (12–35)
(6 months) 41 33 41 34 31 36 23 20 20
[45 (18, 13, 14)] (29–62) (21–43) (30–64) (25–55) (20–38) (26–59) (11–33) (13–23) (13–43)
Xerostomia 17 (7–42) 13 (6–36) 6 (2–15)
(12 months) 20 14 20 14 12 16 7 6 6
[45 (18, 13, 14)] (11–43) (6–22) (12–46) (8–34) (6–17) (9–39) (2–14) (3–7) (3–22)
Aspiration 64 (18–98) 47 (15–97) 37 (10–94)
[45 (18, 13, 14)] 64 43 89 43 38 81 33 30 64
(56–84) (7–86) (51–99) (26–69) (5–86) (40–99) (13–58) (3–79) (30–97)
Physician-rated 52 (30–65) 45 (26–61) 37 (18–57)
swall. dysfunction 52 36 62 43 35 56 37 28 51
[37 (17, 10, 10)] (43–58) (19–55) (41–71) (29–52) (17–54) (38–69) (22–49) (7–48) (33–65)
Problems 36 (21–53) 30 (15–49) 25 (9–43)
swall. solids 35 28 49 27 27 43 21 21 39
[37 (17, 10, 10)] (26–45) (15–44) (32–58) (16–39) (13–43) (29–56) (11–37) (6–38) (25–51)
Problems 13 (4–18) 13 (3–17) 12 (2–15)
swall. liquids 6 15 16 4 15 14 4 14 13
[39 (18, 10, 11)] (3–14) (12–18) (13–17) (2–13) (10–18) (13–17) (1–13) (10–16) (12–16)
Larynx 92 (28–100) 90 (24–100) 85 (9–100)
Oedema 52 100 97 43 100 97 18 99 97
[42 (18, 11, 13)] (25–91) (85–100) (90–100) (18–84) (84–100) (88–100) (6–75) (74–100) (83–99)
Ipsil. brachial 22 (0–28) 21 (0–27) 22 (0–27)
plexopathy 17 22 23 10 21 22 11 23 22
[45 (18, 13, 14)] (0–28) (6–27) (4–26) (0–29) (4–25) (1–26) (0–26) (4–26) (1–27)
Trismus 30 (24–39) 30 (24–38) 25 (23–30)
33 28 30 32 28 30 26 25 25
[45 (18, 13, 14)] (25–49) (24–32) (24–37) (25–44) (24–31) (24–37) (23–36) (23–28) (23–29)
1NTCP values for myelitis and brain stem necrosis are not listed (0 % in all cases)
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Table A.5: Patient cohort and patient subgroup specific values for evaluated DVH parameters for OAR
without NTCP model based on the accumulated dose distributions for the high dose escalation of
2.6 Gy(RBE), median (range: P5–P95).
Evaluated
parameter
[No. of patients
all (A, B, C)]
IMXT Mixed modality IMPT
All patients All patients All patients
A B C A B C A B C
Subm. gland1 64.9 (54.9–73.5) 58.9 (47.9–72.9) 58.7 (44.2–71.2)
Dmean, co. / Gy(RBE) 64.3 59.7 68.9 57.0 56.97 63.9 55.7 56.6 64.0
[44 (18, 13, 13)] (57–72) (51–73) (64–74) (51–72) (46–70) (53–73) (50–71) (42–69) (52–71)
Subm. gland1 72.2 (66.1–78.3) 73.0 (67.3–77.2) 72.0 (67.1–74.5)
Dmean, ip. / Gy(RBE) 73.7 71.5 74.7 73.9 71.1 74.2 72.5 70.4 72.0
[43 (18, 13, 12)] (72–79) (60–75) (72–77) (71–78) (61–74) (72–77) (71–76) (60–72) (71–74)
Subl. gland1 56.9 (29.3–75.9) 48.7 (25.9–75.4) 47.1 (14.6–72.5)
Dmean, co. / Gy(RBE) 70.9 34.9 60.8 67.2 32.5 56.2 66.2 23.7 50.6
[41 (14, 13, 14)] (56–76) (27–44) (40–75) (47–75) (25–41) (37–75) (46–72) (12–36) (30–73)
Subl. gland1 59.2 (34.5–76.3) 52.2 (30.4–75.4) 48.5 (19.4–74.2)
Dmean, ip. / Gy(RBE) 74.4 41.6 65.5 73.8 37.5 57.2 71.1 30.7 54.3
[36 (10, 13, 13)] (61–77) (29–46) (46–75) (58–76) (29–44) (41–75) (59–75) (15–41) (31–75)
Carotid sinus 72.2 (61.2–74.4) 71.8 (51.1–74.5) 71.6 (51.2–72.3)
Dcirc / Gy(RBE) 71.9 72.2 72.6 71.3 72.7 72.3 71.3 71.7 71.9
[43 (16, 13, 14)] (67–74) (63–76) (65–77) (60–74) (59–75) (55–76) (60–72) (59–74) (55–72)
Carotid sinus 75.0 (69.0–83.3) 74.5 (64.5–82.3) 72.7 (63.8–80.4)
D2 / Gy(RBE) 74.3 75.7 76.6 74.1 75.2 76.5 72.5 73.0 73.9
[43 (16, 13, 14)] (70–79) (71–82) (71–82) (67–78) (68–82) (65–80) (66–75) (68–82) (63–78)
Mandible 71.9 (52.8–80.5) 71.8 (50.8–80.0) 71.7 (49.5–78.7)
D1 ml / Gy(RBE) 78.4 63.0 71.8 77.6 59.3 71.4 76.3 58.8 71.7
[44 (17, 13, 14)] (71–81) (44–71) (65–77) (69–80) (43–71) (62–76) (68–79) (39–71) (62–73)
Mandible 24.5 (2.0–38.6) 17.5 (1.4–34.2) 16.3 (1.3–30.8)
V50 Gy(RBE) / ml 27.6 8.3 25.4 23.3 7.0 18.9 22.2 5.9 17.0
[44 (17, 13, 14)] (18–45) (1–14) (13–35) (13–41) (1–10) (8–29) (10–36) (0–10) (7–27)
Oesophagus 39.0 (33.6–76.3) 37.5 (33.1–76.2) 12.9 (3.3–73.9)
Dcirc / Gy(RBE) 36.7 71.3 40.7 35.9 69.5 37.8 7.7 69.3 18.3
[45 (18, 13, 14)] (33–46) (35–77) (34–74) (33–45) (35–77) (34–74) (3–27) (11–75) (5–72)
Oesophagus 0.0 (0.0–3.4) 0.0 (0.0–3.2) 0.0 (0.0–3.0)
V60 Gy(RBE) / ml 0.0 1.5 0.0 0.0 1.3 0.0 0.0 1.4 0.0
[45 (18, 13, 14)] (0–0) (0–5) (0–3) (0–0) (0–4) (0–3) (0–0) (0–4) (0–3)
Skin 64.3 (47.0–79.1) 65.8 (50.5–78.4) 69.0 (61.3–78.3)
D25cm2 / Gy(RBE) 64.4 62.0 65.0 65.7 66.6 65.8 68.6 69.0 70.0
[45 (18, 13, 14)] (53–80) (45–82) (54–71) (54–80) (48–82) (57–72) (60–79) (60–80) (64–74)
Skin 0.0 (0.0–15.9) 0.1 (0.0–15.7) 0.4 (0.0–14.7)
V70 Gy(RBE) / ml 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.3 0.8
[45 (18, 13, 14)] (0–6) (0–17) (0–7) (0–7) (0–17) (0–9) (0–13) (0–16) (0–13)
1 Pairwise organs: ipsilateral is organ with higher, contralateral organ with lower dose
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Details to the individual patients, subpopulations and additional DVH parameters are given.
Table B.6: Individual patient’s tumour motion peak-to-peak amplitudes, mean tumour volume (GTV) and
mean breathing periods. Patient’s affiliation to subpopulations with extra OAR (heart (H), oesophagus (O))
and affiliation to the presented case studies.
Patient ID1 Motion amplitude / mm Volume / ml Breathing OAR Sub-
nominal consecutive ML AP CC GTV period / s population2
1 15 1.9 0.7 0.6 3.8 2.9 2
2 18 0.7 1.7 0.8 0.9 3.4
3 9 2.0 1.2 0.8 5.4 2.4 1∗
4 16 0.6 2.1 0.9 7.3 3.4 O
5 19 0.8 1.0 0.9 5.1 7.0
6 7 2.1 1.9 1.1 30.4 5.1 O 1
7 26 1.1 3.1 1.1 2.2 3.0
8 28 1.0 3.5 1.2 1.9 4.0
9 24 1.8 1.5 1.5 20.1 4.4 2
10 38 0.6 1.0 1.6 17.3 2.7
11 30 3.5 4.1 1.8 10.8 2.8 H
12 12 2.0 6.2 2.2 3.9 3.4 2∗
13 31 1.3 1.4 2.2 8.8 3.6
14 32 2.8 3.7 2.4 18.8 3.9
15 4 0.9 1.0 2.5 0.4 3.1 1, MFO
16 5 1.7 1.5 2.5 3.2 2.9 1
17 20 1.1 2.8 2.6 18.0 3.6 O
18 39 1.4 3.2 4.1 0.3 3.6
19 29 0.5 0.8 4.5 26.3 3.7 2
20 40 2.0 1.8 5.7 13.6 3.8 H, O
21 37 2.7 1.4 5.9 1.4 3.3 H, O
22 23 1.4 1.8 6.1 15.9 4.1 H, O
23 34 1.7 5.1 6.2 6.5 3.3 2
24 10 1.2 8.5 6.8 3.1 4.2 1
25 17 1.2 3.0 6.8 4.0 3.0 H
26 21 1.6 6.0 7.4 36.0 4.4 2
27 25 2.0 3.4 8.8 28.6 4.7 H, O 2, CT2
28 8 1.4 2.0 9.5 28.7 3.8 H 1, MFO
29 1 2.4 10.5 9.9 9.9 6.0 H, O 1, MFO
30 14 1.3 6.0 10.2 6.9 3.4
31 35 2.0 5.9 10.8 3.4 2.6
32 2 0.9 5.3 11.4 18.2 3.6 H 1, MFO
33 11 0.9 4.8 12.9 8.7 2.7
34 3 3.0 4.4 15.3 10.4 5.1 1
35 27 4.7 13.4 15.9 15.8 5.9
36 6 3.9 3.8 17.9 1.1 5.4 H, O 1, MFO
37 33 5.5 8.8 18.3 33.8 3.7 2
38 36 3.4 10.7 19.5 37.0 7.4 2, CT2
39 13 7.3 2.2 22.7 9.2 4.0 2
40 22 2.1 4.2 23.3 11.8 4.6
1 Patient ID: nominal according to CC peak-to-peak tumour motion amplitude (used in the study as identifier),
consecutive according to RT treatment date
2 Subpopulation 1: Deformable image registration, additional machine parameters, rescanning, hypofractionation
Subpopulation 2: Treatment planning phase selection, target concept, breathing pattern, gating
Subpopulation CT2: Sequential 4D CT dataset
Subpopulation MFO: Multi-field optimisation
∗ denotes the two patients of the subpopulations which were excluded from the case studies "rescanning",
"gating", "hypofractionation" and "breathing pattern" due to corrupt data files
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Table B.7: Median single fractions dose differences between median 4D dose parameters for the standard plan and the additionally evaluated impact factors for
patients with motion above 5 mm for the single fractions. For comparisons, the median 4D dose degradation to the static case is given for the standard plan. Increase
in under-dosage parameters (V80, V90, V98, D98) and TCP denotes that the impact factor decreased the dose degradation, while increase in over-dosage parameters
(V110, D2) and HI denotes that the impact factor increased the dose degradation.
Impact factor ∆V 80/% ∆V 90/% ∆V 98/% ∆D98/Gy(RBE) ∆V 110/% ∆D2/Gy(RBE) ∆HI /% ∆TCP/%
Standard plan – Parameter differences of the median 4D dose degradation and the static case
Single fraction 0.0 -1.7 -24.9 -0.1 1.9 0.1 11.1 -4.8
-0.0 – 0.0 -6.5 – 0.0 -39.0 – -10.5 -0.2 – -0.0 0.0 – 11.5 0.0 – 0.2 4.2 – 21.3 -10.6 – -1.3
Parameter differences of the median 4D dose degradation with the impact factor and the standard plan
Demon algorithm 0.0 0.0 0.9 -0.0 -0.4 -0.0 -0.3 0.9
0.0 – 0.0 -0.6 – 1.1 -12.5 – 6.6 -0.0 – 0.0 -2.0 – 3.2 -0.0 – 0.1 -3.4 – 6.0 -6.3 – 2.2
B-Spline algorithm followed by Demon 0.0 -0.0 -3.9 -0.0 -0.2 -0.0 -1.0 -0.5
0.0 – 0.0 -1.1 – 1.2 -24.7 – 25.4 -0.1 – 0.1 -3.3 – 1.6 -0.1 – 0.1 -9.8 – 6.4 -6.7 – 4.0
CT phase for treatment planning 0.0 0.2 1.8 0.0 0.1 -0.0 -0.4 -0.2
0.0 – 0.0 -0.4 – 2.6 -2.2 – 10.5 -0.0 – 0.0 -0.8 – 0.8 -0.0 – 0.0 -2.8 – 0.7 -1.7 – 2.9
PTV with artificial density change 0.0 0.5 4.4 0.0 -1.1 -0.0 -0.9 2.2
0.0 – 0.0 -1.8 – 1.2 -5.5 – 11.2 -0.0 – 0.0 -1.9 – 1.7 -0.0 – 0.1 -3.3 – 3.5 0.7 – 3.1
Beam-specific PTV concept 0.0 1.2 6.3 0.0 -0.5 0.0 0.2 2.2
0.0 – 0.0 0.1 – 2.3 -1.1 – 9.4 0.0 – 0.0 -2.0 – 1.0 -0.0 – 0.1 -1.4 – 1.8 1.5 – 3.6
Multi-field optimisation concept 1 0.0 -0.8 -2.1 -0.0 7.3 0.1 5.4 -0.3
0.0 – 0.0 -2.8 – 0.1 -5.0 – 1.2 -0.0 – 0.0 2.9 – 8.5 0.1 – 0.1 4.1 – 8.6 -0.9 – 0.9
Multi-field optimisation concept 2 -0.2 -4.5 -10.9 -0.1 -0.0 0.0 6.2 -3.6
-1.6 – 0.0 -17.2 – -1.7 -22.6 – 8.5 -0.2 – -0.1 -0.8 – 1.8 -0.0 – 0.0 1.9 – 9.2 -7.1 – 5.0
Energy layer switching time (3 s vs 2 s) 0.0 0.1 0.6 0.0 -1.0 -0.0 -1.5 0.4
-0.0 – 0.1 -4.7 – 5.7 -10.2 – 10.2 -0.1 – 0.1 -8.1 – 8.7 -0.1 – 0.1 -6.8 – 7.8 -3.7 – 3.5
Breathing pattern changes 0.0 0.5 9.6 0.0 1.1 0.0 1.8 2.5
0.0 – 0.0 -2.9 – 2.6 0.9 – 20.9 -0.1 – 0.1 -1.2 – 6.7 -0.0 – 0.1 -3.6 – 8.8 0.8 – 6.4
Sequential CT Pat. 1 -7.5 -12.1 -14.9 -0.6 0.3 0.0 27.8 -10.4
Sequential CT Pat. 2 -1.8 -7.5 -7.5 -0.1 4.3 0.1 9.6 -3.0
Hypofractionation 0.0 -0.1 -2.1 -1.0 0.3 0.7 0.5 *
0.0 – 0.0 -1.6 – 0.3 -6.1 – 9.9 -1.4 – -0.6 0.0 – 2.0 0.3 – 0.9 0.0 – 1.9
Gating 0.0 -0.3 12.2 0.0 1.6 0.0 1.0 2.6
-0.0 – 0.0 -1.7 – 2.5 -5.0 – 18.9 -0.0 – 0.1 -2.4 – 5.5 -0.1 – 0.1 -5.9 – 5.0 -1.6 – 7.2
Rescanning 0.0 0.6 2.1 0.0 -1.3 -0.0 -2.9 0.5
0.0 – 0.0 -0.4 – 1.8 -15.8 – 20.3 -0.0 – 0.1 -3.6 – -0.1 -0.1 – 0.0 -8.2 – 1.4 -2.5 – 5.0
V95 and V107 are given in Table 4.4. V120 values not given since they all were 0 %.
* TCP model for hypofractionation not applicable.
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Table B.8: Median fractionated treatment dose differences between median 4D dose parameters for the standard plan and the additionally evaluated impact factors
for patients with motion above 5 mm for the fractionated treatment. For comparisons, the median 4D dose degradation to the static case is given for the standard plan.
Increase in under-dosage parameters (V80, V90, V98, D98) and TCP denotes that the impact factor decreased the dose degradation, while increase in over-dosage
parameters (V110, D2) and HI denotes that the impact factor increased the dose degradation.
Impact factor ∆V 80/% ∆V 90/% ∆V 98/% ∆D98/Gy(RBE) ∆V 110/% ∆D2/Gy(RBE) ∆HI /% ∆TCP/%
Standard plan – Parameter differences of the median 4D dose degradation and the static case
Fractionated 0.0 -0.0 -14.9 -1.8 0.0 -0.1 3.0 -2.7
treatment 0.0 – 0.0 -1.0 – 0.0 -32.3 – 1.8 -3.9 – 0.0 -0.3 – 1.8 -1.9 – 3.2 -2.3 – 10.9 -7.3 – 0.3
Parameter differences of the median 4D dose degradation with the impact factor and the standard plan
Demon algorithm 0.0 0.0 4.8 0.5 0.0 -0.0 -0.5 1.4
0.0 – 0.0 -0.0 – 0.2 -26.4 – 14.1 -3.6 – 1.0 0.0 – 0.9 -0.6 – 1.5 -2.4 – 7.7 -7.8 – 2.9
B-Spline algorithm followed by Demon 0.0 0.0 0.2 -0.1 0.0 -0.1 -0.4 0.1
0.0 – 0.0 -0.4 – 0.2 -24.1 – 17.9 -2.6 – 1.8 -0.2 – 0.5 -0.7 – 1.8 -2.7 – 6.6 -5.6 – 3.0
CT phase for treatment planning 0.0 0.0 1.2 0.4 0.1 -0.5 -1.0 0.2
0.0 – 0.0 -0.1 – 2.6 -5.1 – 21.5 -1.3 – 2.1 -0.3 – 0.6 -2.9 – 2.2 -6.3 – 3.5 -1.5 – 3.4
PTV with artificial density change 0.0 0.0 3.0 0.2 -0.2 -0.2 -0.6 2.0
0.0 – 0.0 -1.5 – 0.7 -3.4 – 14.1 -1.9 – 1.4 -0.6 – 0.3 -1.4 – 1.8 -4.2 – 4.4 -0.3 – 3.2
Beam-specific PTV concept 0.0 0.0 9.7 0.5 -0.1 0.7 0.5 2.1
0.0 – 0.0 0.0 – 0.9 4.6 – 12.6 0.0 – 2.3 -0.3 – 0.3 -1.0 – 1.6 -3.2 – 1.8 1.3 – 3.4
Multi-field optimisation concept 1 0.0 -0.2 -6.0 -1.4 4.1 3.9 8.7 0.0
0.0 – 0.0 -3.0 – 0.0 -13.6 – -2.6 -3.5 – 0.0 0.0 – 7.0 1.6 – 4.4 2.2 – 10.7 -2.0 – 0.7
Multi-field optimisation concept 2 0.0 -1.4 -21.5 -3.1 0.0 0.7 8.6 -4.2
-0.9 – 0.0 -15.8 – -0.3 -29.9 – -5.9 -6.5 – -2.6 -0.1 – 0.5 -0.5 – 3.5 3.1 – 9.5 -8.4 – 4.2
Energy layer switching time (3 s vs 2 s) 0.0 0.0 0.5 -0.1 0.0 0.1 0.4 -0.4
0.0 – 0.0 -5.4 – 1.6 -14.2 – 12.9 -5.7 – 2.0 -2.0 – 11.6 -1.3 – 4.4 -6.3 – 30.3 -3.1 – 3.7
Breathing pattern changes 0.0 0.0 12.4 0.8 0.0 1.6 2.0 3.5
0.0 – 0.0 -0.7 – 0.8 -1.9 – 19.2 -0.4 – 1.5 -0.3 – 2.8 -1.2 – 2.9 -4.1 – 3.9 0.3 – 6.7
Sequential CT Pat. 1 -6.9 -10.2 -15.8 -18.5 0.0 -0.4 27.6 -12.2
Sequential CT Pat. 2 -0.5 -4.1 -14.7 -2.7 0.0 0.6 5.1 -2.9
Hypofractionation 0.0 0.0 -4.8 -0.4 0.1 1.2 2.7 *
0.0 – 0.0 -0.9 – 0.1 -18.8 – 8.1 -1.8 – 0.7 -0.5 – 0.3 -0.5 – 2.1 1.1 – 5.9
Gating 0.0 -0.4 9.4 -0.5 1.3 2.6 5.2 3.6
0.0 – 0.0 -1.7 – 0.6 -23.7 – 18.2 -1.6 – 0.8 0.0 – 5.7 -0.2 – 4.8 -0.7 – 9.2 -3.9 – 5.9
Rescanning 0.0 0.0 0.7 0.4 0.0 -0.5 -0.6 0.3
0.0 – 0.0 -0.2 – 0.2 -10.9 – 13.6 -0.7 – 0.8 -0.6 – 0.0 -0.8 – 0.7 -2.3 – 1.6 -1.8 – 2.5
V95 and V107 are given in Table 4.4. V120 values are not given since they all were 0 %.
* TCP model for hypofractionation not applicable.
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